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ABSTRACT OF THE DISSERTATION 
Mathematical Models of Innate Immune Cell Signaling Networks Using Protein Phosphorylation 
Patterns 
by 
Allison Anne Throm 
Doctor of Philosophy in Biomedical Engineering 
Washington University in St. Louis, 2018 
Professor Anthony French, Chair 
 
Immune dysregulation has been implicated in pediatric autoimmune disease 
pathogenesis, but the underlying mechanisms still remain poorly understood. We explored 
immune cell signaling dysregulation in two different pediatric autoimmune diseases: 
polyarticular juvenile idiopathic arthritis (JIA), a disease characterized by pain, swelling, and 
limited range of motion in five or more joints and juvenile dermatomyositis (JDM), a disease 
characterized by pathognomonic skin rashes and proximal muscle weakness. Both polyarticular 
JIA and JDM can be controlled with newer biologic medications, but a substantial fraction of 
patients still experiences refractory disease courses. To explore potential immune cell signaling 
dysregulation, mass cytometry was performed on peripheral blood mononuclear cells (PBMCs) 
from treatment-naïve patient, remission patient, and control blood samples. Cryopreserved 
samples were thawed, rested, stimulated with different cytokines (polyarticular JIA) or a cocktail 
of stimuli over a time course (JDM), fixed, barcoded, stained with surface marker antibodies, 
  
     
xiv
methanol permeabilized, stained with antibodies for intracellular molecules, and analyzed on a 
CyTOF2/Helios mass cytometer.  
No differences in immune cell signaling were detected at baseline or after 15 minutes of 
IL-6 stimulation between treatment-naïve polyarticular JIA patients and controls. With IFN 
stimulation, treatment-naïve polyarticular JIA patient classical monocytes and naïve CD4 T cells 
more strongly phosphorylated STAT1 and/or STAT3 than those from controls. These stratifying 
cell populations were heterogeneous. Enhanced IFN responsiveness in naïve CD4 T cells was 
associated with elevated levels of JAK1 and SOCS1.  
Examination of the JDM data set at 0, 3, and 15 minutes with a cocktail of multiple 
stimuli with Significance Analysis of Microarrays (SAM) yielded 292 results with a false 
discovery rate (FDR) of less than 5%. As a large number of results is difficult to manually 
interpret, Citrus paired with LASSO feature selection was also employed to model differences in 
immune cell signaling between treatment-naïve JDM patients and controls over three time 
points. LASSO selected 12 Citrus features (signaling molecule in specific immune cell subset); 
10 out of 12 were in PLC2 phosphorylation with 4 out of 12 in NK cell PLC2 
phosphorylation. NK cell PLC2 phosphorylation was lower in treatment-naïve JDM patients in 
comparison to controls across all analyzed time points. Decreased treatment-naïve JDM patient 
NK cell PLC2 phosphorylation was associated with lower levels of calcium flux in NK cells 
upon receptor crosslinking in comparison to a healthy control.  
While similar analytical approaches were applied to the polyarticular JIA and JDM 
cohorts, different stimulation protocols were utilized. However, quantitative analytical 
techniques revealed previously undescribed signaling abnormalities in both diseases. These 
signaling differences provide a mechanism for tofactinib (a JAK inhibitor) treatment in a clinical 
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trial for polyarticular JIA and a potential new target for therapy in JDM. In addition, these 
signaling differences may be valuable for confirmation of polyarticular JIA and JDM diagnoses, 
as well as biomarkers to predict which treatment-naïve patients may respond to a given therapy 
with expansion of the original models. 
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  Chapter 1: Introduction 
Autoimmune diseases and mass cytometry 
 More than 23.5 million Americans are affected by autoimmune diseases (1). Some 
autoimmune diseases can be life threatening, and most are debilitating, requiring a lifetime of 
treatment. The mechanisms for many pediatric autoimmune diseases are not well understood.  
Autoimmune responses are thought to be due to imbalances between regulatory and effector 
immune responses (2). Certain HLA alleles are associated with greater autoimmune disease risk 
(3). Cytokine antagonists have shown great promise in treating many autoimmune diseases, but 
these treatments target the later stages of inflammation rather than addressing the initiation and 
progression of the diseases (2). Examination of the pathogenesis of autoimmune diseases can aid 
in the development of therapies to reestablish homeostasis in the immune response.  
 Mass cytometry has been employed to describe immune cell signaling abnormalities in 
some autoimmune diseases, but it has not been extensively leveraged to examine immune cell 
signaling phenotype in many pediatric diseases. Since CD4 T cells have been implicated as key 
mediators of autoimmune pathology, one study characterized CD4 T cell phenotype in the 
affected joints of rheumatoid arthritis (RA) patients using mass cytometry and RNA-Seq with a 
panel to assess many T cell markers (4). PD-1hiCXCR5-CD4+ T cells, deemed peripheral T 
helper cells, were detected in the synovium of affected joints in RA patients; despite being PD-
1hi, these cells did not appear to be exhausted, as these cells had higher levels of IL-21, CXCL13, 
IFN, and IL-10 in comparison to PD-1- cells (4). Chikungunya virus (CHIKV) infection often 
leads to the development of arthritic disease and shares clinical features with RA (5). In a study 
examining CHIKV infected patients alongside healthy controls and active, untreated RA 
patients, CHIKV infected patients and RA patients had higher frequencies of activated and 
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effector CD8 and CD4 T cells than healthy controls as determined by mass cytometry (6). 
Elevated levels of MCP-1, MIP1B, and IL-1RA were found in monocytes in lupus patients using 
mass cytometry; this abnormal cytokine expression was abrogated with selective JAK1/JAK2 
inhibition (7). However, many pediatric autoimmune diseases remain unexplored by mass 
cytometry. Further investigation of pediatric autoimmune diseases using the high dimensional 
capabilities of mass cytometry may elucidate potential disease mechanisms. 
High dimensional cytometry and computational methods 
 Fluorescence-activated cell sorting (FACS) is valuable for examining the immune 
system, using antibodies for surface markers conjugated to fluorophores that are detected by 
laser excitation as cells pass through a flow cell single file (8). However, because of spectral 
overlap of these fluorophores, a limited number of parameters (typically 12-18) can be analyzed 
simultaneously in a single cell. In contrast, mass cytometry employs heavy metal conjugated 
antibodies with downstream mass spectrometry, eliminating spectral overlap and allowing for the 
simultaneous analysis of over 40 parameters in a single cell (9). Thus, mass cytometry can 
facilitate phenotyping of immune cell subsets and intracellular signaling simultaneously. 
 The large number of measured parameters in mass cytometry necessitates the use of 
different analysis techniques in comparison to those employed for lower dimensional flow 
cytometry. Traditional flow cytometry analysis methods involve sequential gating of biaxial 
plots for markers of interest (10). The use of heavy metal isotopes conjugated to antibodies in 
mass cytometry eliminates spectral overlap issues associated with fluorophores. As mass 
cytometry has allowed for the analysis of many more parameters than flow cytometry in a single 
cell simultaneously, it is necessary to employ computational methods to gain insights from data 
sets, rather than laborious and user subjective manual gating prevalent with lower dimensional 
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flow cytometry data (11). Furthermore, limiting analyses to pairwise comparisons could lead to 
missing multivariate relationships that could be gleaned from a more high dimensional view of 
the data set (12). 
 Along with new methods for determining cell populations, new analysis methods are 
necessary to statistically explore mass cytometry data sets. Both ANOVA and t-tests are often 
used for analysis of biological data and make the assumption that each analyzed variable has a 
normal distribution and is independent of other observed variables (13, 14). Both of these 
assumptions are often false when analyzing signaling molecules (or other markers) with or 
without stimulations in different cell types between classes. Many markers and signaling 
molecules analyzed via mass cytometry are connected in signaling cascades, and some cell 
subsets likely respond similarly to a given stimulation. Furthermore, within a high dimensional 
data set, many comparisons are often necessary; methods either return too many false positives 
or detect no differences with stringent multiple hypothesis correction (15). Statistical methods 
developed for high dimensional microarray analysis can be useful for finding meaningful 
differences in mass cytometry data exploration while minimizing false positives. One statistical 
method developed for microarrays that has previously been applied to mass cytometry data sets 
is Significance Analysis of Microarrays (SAM) (16). SAM has already been validated for the 
application to high dimensional biological data sets, is non-parametric and makes few 
assumptions about the underlying distribution, and takes into account multiple hypothesis 
correction (15, 16). SAM provides a useful platform for cytometry data exploration while 
minimizing false positives.   
 While insights can be gained from manual gating, manual gating is labor intensive and 
prone to bias. Dimensionality reduction techniques can be valuable tools for visualizing cell 
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populations in cytometry data without employing manual gating. Principal component analysis 
(PCA)  is a linear dimensionality reduction technique that involves transforming the data into a 
new variable space containing linearly uncorrelated variables (17). PCA is a valuable exploratory 
tool for determining relationships of variables in biological data sets (18). However, PCA 
linearly transforms the data set while nonlinear relationships are often present in cytometry data. 
viSNE allows high-dimensional cytometry data to be mapped into two dimensions using the t-
Distributed Stochastic Neighbor Embedding (t-SNE) algorithm, preserving the non-linearity and  
high-dimensional relationships in the data and allowing visualization of single cells rather than 
clusters (12). Color can be overlaid to visualize marker expression in different cell populations, 
allowing for characterization of cell types. viSNE is useful for exploring novel cell populations 
present in different sample conditions, such as health and disease, particularly when sample 
number may be limiting for statistical power. 
 In addition to dimensionality reduction, immune cell populations can be examined with 
clustering techniques specifically developed for high dimensional cytometry data rather than 
relying on manual gating. One clustering based method for the examination of cell populations in 
a cytometry data set is spanning-tree progression analysis of density-normalized events (SPADE) 
(19). In SPADE, data is viewed as a high-dimensional point cloud; SPADE explores the 
geometry of the cloud. SPADE down-samples data to allow for detection of rare cell subsets then 
performs agglomerative clustering on the down-sampled data, constructs a minimum spanning 
tree from the clusters, and then up-samples the data. Populations in the tree can be manually 
defined after looking at marker expression patterns in clusters. SPADE is useful for visualizing a 
continuity of phenotypes in cells in the data set but lacks single cell resolution. While 
populations must be manually annotated after SPADE (19), X-shift arranges populations by 
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marker-based classification (20). X-shift employs k-nearest neighbors (kNN) density estimation 
(kNN-DE) that finds the optimal number of clusters in a data driven manner by finding local 
density maxima in a neighborhood and making them cluster centroids (20). All remaining points 
are then connected to centroids to form clusters. Clusters are binarily split and labelled with the 
marker that drove the split, producing a hierarchy that resembles manual gating hierarchies but 
also allowing for the discrimination of populations that may not have been detected by manual 
gating. 
 Exploratory statistical techniques, such as SAM or t-tests, may yield a large number of 
statistically different features. It is difficult to interpret the biological relevance from an analysis 
yielding a large number of results. To aid in data interpretation, feature selection can be 
performed. Additionally, if features are to be used for downstream modeling, retaining too many 
features may lead to overfitting of the model to the training data set (21). Feature selection can 
be performed separately from downstream classification modeling. However, such methods can 
select radically different feature sets with small fluctuations in the data set (22). Some 
classification methods incorporate feature selection as a part of their algorithms. Classification 
models can be valuable for modeling differences between healthy and diseased samples; 
measured cytometry features (generally population frequency or signaling molecule-or other 
protein-levels within a population) that are retained within the classification model are 
potentially important differences that can be probed for disease mechanisms and treatment 
targets or possible biomarkers.  
One such classification method that incorporates feature selection  is L1- penalized 
regression, or the least absolute shrinkage and selection operator (LASSO) (22).  LASSO 
performs regression on the data set, leading some regression coefficients to shrink to 0 by 
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applying a penalty of the L1 norm of the regression coefficients. Variables with a regression 
coefficient of zero, are not included in the final model, resulting in feature selection. Linear 
combinations of variables retained in the LASSO model are important for distinguishing healthy 
and diseased classes. In contrast, ridge regression, where an L2 norm based penalty is applied to 
the regression rarely shrinks regression coefficients to zero, leading all variables to be included 
in the final model (23). If exploring the biological mechanisms of differences between healthy 
and diseased states rather than merely classifying samples, LASSO regression is a better option 
than ridge regression for high dimensional cytometry data sets as some regression coefficients 
are shrunken to zero with LASSO but not ridge regression. Another classification technique that 
employs feature selection within its algorithm is shrunken centroids. Shrunken centroids 
identifies the centroids of features (for cytometry this could be signaling molecule 
phosphorylation intensity in a given cell population) for each class (i.e. healthy and diseased) 
while shrinking class centroids towards the overall centroid, leading some features to be 
shrunken to zero (24).  Thus, shrunken centroids performs feature selection to determine which 
individual features differ between classes.  
Other classification methods do not employ feature selection in the original data space as 
a part of their algorithms. Thus, features should be selected before classification to prevent 
overfitting. One such method is partial least squares discriminant analysis (PLS-DA) (25). PLS-
DA tests the association of a dependent matrix (i.e. signaling cytometry data with the classes of 
healthy/diseased samples) with a vector of classes in a transformed variable space of orthogonal 
variables and performs feature selection in the transformed variable space rather than original 
variable space. The relationships of the variables to classification can easily be visualized in 
scores and loadings plots, and the biological relevance can be interpreted. This is ideal when the 
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goal of model application is to explore biological mechanisms, rather than merely classifying 
samples. Some other classification techniques, discussed here briefly, may be of value if 
classification but not mechanism exploration is the goal, due to black box mechanisms and 
difficulty interpreting the roles of variables in classifying samples as healthy or diseased. 
Random forest classification techniques combine decision tree predictors where each tree 
depends on a vector of independently selected random vectors, and a sample is classified 
according to the modes of the individual trees (26). Support vector machines separate data (i.e. 
signaling molecule phosphorylation patterns) sets into classes (i.e. healthy/diseased) in space 
using hyperplanes (27). Artificial neural networks are a collection of nodes (artificial neurons) 
that can process signals and transmit to other artificial neurons that are designed to recognize 
patterns and classify samples (28). Gradient boosting methods can improve the performance of 
other classification methods by adaptively reweighting the training set (29).  
 Several computational methods have been developed specifically for the analysis of mass 
cytometry data sets. Citrus is one classification method that leverages variables to determine 
distinguishing differences between healthy and diseased states (or other states of interest) (30). 
The first step in Citrus is clustering cells based on marker expression, generally using the same 
markers that would be used in manual gating. Then either frequency or signaling molecule 
phosphorylation (or other marker intensity) is characterized for each sample for each cluster 
above a user defined size threshold. In the R “citrus” package, three possible models can be used 
for characterizing differences between classes: SAM, LASSO, or shrunken centroids. As 
described above, SAM is a non-parametric statistical technique that employs feature specific t-
tests (15). SAM is a correlative method, while both LASSO (22) and shrunken centroids (24) are 
predictive classification methods that can be applied to predict if new samples belong to healthy 
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or diseased classes. Features (either cluster frequency of molecule intensity within a given 
cluster) that are important for the classification of samples as healthy or diseased, may be 
important differences between cells in a healthy and diseased state and may be valuable to 
exploit for biomarker or treatment development. Density resampled estimate of mutual 
information (DREMI) also allows for the analysis of signaling phenotype in high dimensional 
cytometry data sets (31). DREMI can be used to analyze the effects of one protein in a signaling 
cascade in a particular cell type on another protein in the cascade in the same cell type by 
considering the activity of signaling molecule Y as a stochastic function of the activity or 
abundance of signaling molecule X. In addition to Citrus and DREMI, PhenoGraph can also be 
used to examine signaling in different cell types. PhenoGraph partitions high dimensional 
cytometry data into subpopulations with distinct phenotypes (32). In PhenoGraph, it is assumed 
that intracellular signaling molecules more accurately represent the functional state of a cell than 
surface marker expression. PhenoGraph is valuable for studying diseases, such as cancer, where 
cells often do not fall within classically gated populations. Cells are clustered into a kNN graph 
and connected to a neighborhood of similar cells, leading the graph to be partitioned into 
communities. These communities can be examined as cell populations without the biases of 
manual gating. PhenoGraph can also be applied to classify samples as healthy or diseased. 
 Other computational methods developed for mass cytometry consider the developmental 
trajectory of cell populations in health and disease. Wanderlust can be used to construct the 
potentially non-linear developmental trajectories of different cell types, predicting de novo 
developmental paths and timing of development (33). Cells are considered in an n-dimensional 
space (where n is the number of markers being examined). Data are transformed into an 
ensemble of graphs and orientation trajectory is computed for each graph with the final graph 
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trajectory being the average over all graphs. Similarly, FLOW-MAP can be used to examine 
developmental changes over time in healthy and diseased states (34). In FLOW-MAP cells are 
clustered (using SPADE) with clusters sequentially added at each time point. Clusters are 
connected in a graph with the number of edges determined by local density. The graph is laid out 
using a force directed layout on the weighted graph with all agglomeratively clustered cells. 
Time points are combined into a single graph after independently clustering each time point. 
Leveraging knowledge gained in cytometry to disease treatment 
 Mass cytometry is a valuable tool for the study of autoimmune diseases, allowing the 
analysis of over 40 parameters simultaneously in a single cell. It is a valuable exploratory 
method to generate hypotheses to further explore differences detected with a large panel of 
antibodies. The high dimensional data afforded by mass cytometry can also be used to develop 
classification models to determine if a specimen has a disease of interest. Features retained in 
classification models can provide insight into potential disease mechanisms, providing further 
mechanisms to test. Differences detected between healthy and diseased states in mass cytometry 
can be potential biomarkers for the disease and putative targets for treatment development. The 
goal of the described mass cytometry studies in Chapters 2 and 3 was to determine which 
signaling features were unique to patients. Citrus paired with SAM was employed for analysis of 
the polyarticular JIA set; using this technique, signaling differences were detected in naïve CD4 
T cell and classical monocyte subsets that would not have been detected with a manual gating 
scheme (Chapter 2). Citrus with LASSO regression was employed for the JDM data set, as 
manual interpretation of the large number of results from SAM was difficult. A PLS-DA model 
was constructed from LASSO selected features to classify JDM patient and control samples and 
determine the relationships of the variables to status as a patient or control (Chapter 3). 
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Chapter 2: Differential IFNγ Responsiveness in polyaritcular 
juvenile idiopathic arthritis clasical monocytes and naïve 
CD4 T cells 
Abstract 
Polyarticular juvenile idiopathic arthritis (JIA) is among the most challenging JIA subtypes to 
treat.  Even with current biologic therapies, the disease remains difficult to control in a 
substantial subset of patients, highlighting the need for new therapies. The aim of this study was 
to use the high dimensionality afforded by mass cytometry with phospho-specific antibodies to 
delineate signaling abnormalities in immune cells from treatment-naïve polyarticular JIA 
patients. Peripheral blood mononuclear cells were isolated from 17 treatment-naïve polyarticular 
JIA patients, 10 of the patients after achieving clinical remission, and 19 healthy controls.  
Samples were stimulated for fifteen minutes with IL-6 or IFNγ and analyzed by mass cytometry. 
Following IFNγ stimulation, increased STAT1 and/or STAT3 phosphorylation was observed in 
subsets of CD4 T cells and classical monocytes from treatment-naïve patients. The enhanced 
IFNγ signaling was associated with increased expression of JAK1 and SOCS1 in CD4 T cells.  
Furthermore, substantial heterogeneity in surface marker expression was observed among the 
subsets of CD4 T cells and classical monocytes with increased IFNγ responsiveness.  The 
identification of enhanced IFNγ signaling in CD4 T cells and classical monocytes from 
treatment-naïve polyarticular JIA patients provides mechanistic support for investigations into 
therapies that attenuate IFNγ signaling in this disease. 
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Introduction 
 Polyarticular juvenile idiopathic arthritis (JIA) represents a subset of JIA patients with 
arthritis involving five or more joints beginning before 16 years of age without features of 
psoriatic arthritis or a spondyloarthropathy. It comprises approximately 15-25% of JIA patients 
and can be further subdivided based on the presence or absence of rheumatoid factor (RF) (1, 2).  
The incidence of polyarticular JIA in the US has been reported to be 2 per 100,000 people (3).  
Polyarticular JIA inflicts significant morbidity on children including joint limitation and/or 
destruction. For example, a high percentage of hand and wrist x-rays from polyarticular JIA 
patients identify abnormalities at the time of diagnosis (4), and 50% of patients manifest 
evidence of radiographic progression within 2 years of diagnosis (5).   
Prior to the advent of biologic agents, polyarticular JIA was often refractory to therapy 
with only 6-23% of patients achieving long-term remission at ten years (6, 7) and with RF+ 
polyarticular JIA being the least likely to sustain remission off medications of all JIA subsets (8).  
Even with modern biologic therapies, a significant fraction of polyarticular JIA patients have 
persistent disease activity (9).  RF+ polyarticular JIA patients in particular have lower response 
rates to treatment and longer times to clinical remission with higher rates of disease flare (8, 10, 
11).   Together, these observations suggest mechanistic differences in polyarticular JIA 
compared to other JIA subsets.  
 Overall, the etiology of JIA is not well characterized.  Siblings of patients with JIA are 
over 15-fold more likely to develop JIA than the general population (12) with monozygotic twins 
having an even higher concordance rate of 25-40% for JIA (13), implicating a genetic 
component to the disease.  However, minimal evidence exists for a Mendelian pattern of 
inheritance, suggesting that JIA is a complex disorder associated with multiple genes.  The 
strongest genetic association is with HLA alleles (1, 2), accounting for 13-20% of the sibling 
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concurrence risk in JIA and implicating T cell involvement in disease (12, 14).  Furthermore, 
cellular infiltrates in affected joint synovium are enriched for T cells as well as B cells and 
macrophages (1). There is also accumulating evidence that innate immune responses contribute 
to the onset of polyarticular JIA (15-18).  For example, a study of transcriptional profiles of 
peripheral blood mononuclear cells (PBMCs) from polyarticular JIA patients (prior to therapy 
with methotrexate or biologic agents) identified the upregulation of monocyte-associated and 
plasmacytoid dendritic cell-associated genes in subsets of polyarticular JIA patients (19).  
 The strong upregulation of inflammatory cytokines in polyarticular JIA patients has 
provided additional insight into the pathogenesis of polyarticular JIA.  Interleukin 6 (IL-6) is 
upregulated in the serum and synovial fluid of polyarticular JIA patients and correlates with 
severity of joint involvement and inflammatory markers (20).  A multiplex survey of 30 
cytokines and chemokines in the plasma and synovial fluid of polyarticular JIA patients 
demonstrated that IL-1, IL-6, IFNγ, and to a lesser extent TNFa were strongly upregulated in the 
plasma of polyarticular JIA patients with active compared to quiescent disease (21).  Biologic 
agents specifically targeting IL-1, IL-6, and TNFa have been shown to be efficacious in treating 
polyarticular JIA in randomized controlled trials (22-27), highlighting the importance of 
inflammatory cytokines in the pathogenesis of polyarticular JIA. 
Despite the insights gained in previous studies and the success of a number of biologic 
agents that block proinflammatory cytokines, a subset of polyarticular JIA patients have difficult 
to control, refractory disease.  Therefore, to further investigate potential immune cell signaling 
perturbations in polyarticular JIA patients, we performed mass cytometry on PBMCs from 
treatment-naïve polyarticular JIA patients and controls.  By coupling the deep profiling allowed 
by mass cytometry with multiparameter phospho-specific antibodies, we were able to probe the 
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activation state of 14 signaling molecules in 13 distinct leukocyte subsets within single patient 
samples both at baseline and following perturbations with IFNγ or IL-6.  This approach 
identified enhanced IFNγ responsiveness in subsets of CD4 T cells and monocytes from 
treatment-naïve polyarticular JIA patients.   
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Materials and Methods 
Patient Cohort  
Polyarticular JIA patients diagnosed in our pediatric rheumatology clinics were eligible 
for enrollment if they were new-onset and treatment-naïve. Samples were also collected from ten 
of the patients after achieving clinical remission, as defined by the Wallace criteria (without the 
use ESR or CRP). The Wallace criteria define clinical remission as having no joints with active 
arthritis, physician assessment of disease activity best possible on scale, no active uveitis, no 
fever, splenomegaly, rash, serositis, or generalized lymphadenopathy, and normal ESR or CRP 
(8, 28). Seven out of the 17 treatment-naïve patients had either not achieved clinical remission at 
the time of the study analysis or had no available follow-up samples. PBMCs from treatment-
naïve polyarticular JIA patients and controls were also utilized from the Cincinnati Children’s 
Hospital Medical Center Pediatric Rheumatology Tissue Repository and the Cincinnati Genomic 
Control Cohort. Given the relatively small number of treatment-naïve polyarticular JIA patients 
in this study and recent evidence demonstrating minimal differences in microarray data between 
RF+ and RF- polyarticular JIA PBMCs (29), we did not further subset our polyarticular JIA 
patients into RF+ and RF- patients. 
 
Reagents 
Antibodies conjugated to heavy metals were purchased from Fluidigm (San Francisco, 
CA) with the exception of CD69 (Table S1). Antibodies for flow cytometry were purchased from 
multiple vendors (Table S2).   
 
Sample Preparation and Collection 
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Blood samples were collected from 17 treatment-naïve, new-onset polyarticular JIA 
patients, a follow-up sample when 10 of the 17 JIA patients were in clinical remission on 
medication, and 19 controls (Table 1), and peripheral blood mononuclear cells (PBMCs) were 
isolated using a Ficoll gradient (GE Healthcare, Uppsala, Sweden) and cryopreserved.  
 
Mass Cytometry 
PBMCs were thawed and stained with cisplatin to discriminate dead cells (Fluidigm, San 
Francisco, CA). Cells were aliquoted (1.7-3.3x106 cells/tube) in 1 ml total volume and rested for 
30 minutes at 37°C prior to simulation. Cells were either left unstimulated or were stimulated 
with 50ng/ml IL-6 or 250ng/ml IFNγ (PBL, Piscataway, NJ) for 15 minutes in RPMI1640 
supplemented with 10% fetal calf serum at 37°C, fixed with MaxPar Fix I Buffer, permeabilized 
with MaxPar Barcode Perm Buffer, and barcoded with the Cell-ID 20-Plex Barcoding Kit (Table 
S3; Fluidigm, San Francisco, CA).  Barcoded samples were pooled and stained with antibodies 
for surface markers. After staining for surface markers, the pooled samples were methanol 
permeabilized and stained with antibodies for intracellular markers (Table S1). Samples were 
incubated with Cell-ID Intercalator-Ir (Fluidigm, San Francisco, CA) to detect debris and 
doublets, and run on a CyTOF2/Helios instrument (Fluidigm, San Francisco, CA). Samples were 
debarcoded using the Single Cell Debarcoder, a stand-alone MATLAB application (30).  Data 
was analyzed using Cytobank and R (Santa Clara, CA).  A run control from the same normal 
donor was used in each experiment to normalize the phosphoprotein data as follows: 
 :  ℎ(!"#$%&'/5) − ℎ(!,-. /0.120&/5) 
Citrus 
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Citrus, a computational technique combining hierarchical clustering with an analysis of  
stratifying differences in cluster features (in our case, phosphorylation of a panel of signaling 
proteins within specific immune cells) between two groups of samples, was performed with the 
R “citrus” package on fcs files gated on live immune cells to compare treatment-naïve patients 
with matched controls (or remission samples) under different stimulation conditions (31). 
Surface markers were clustering parameters. Minimum cluster size was set as 2% of the total 
population with 10000 events sampled per file. Cluster characterization features were signaling 
molecules. All clustering and characterization features were arcsinh transformed. Differences in 
cluster features were calculated using significance analysis of microarrays (SAM). A false 
discovery rate (FDR) of 5% was set as a cutoff for significance (q<0.05).  
To delineate which subsets of cells responded differently between treatment-naïve 
patients and controls, deeper analysis of surface markers on stratifying (significantly different 
signaling molecule phosphorylation between patients and controls for a given cluster) versus 
non-stratifying clusters for p-STAT1 and p-STAT3 was performed. All surface markers were 
analyzed. A trio of clusters containing three connected nodes in which two clusters were 
stratifying and one non-stratifying were examined to determine which surface markers contribute 
to a cluster being stratifying or non-stratifying. Surface marker intensity for clusters was also 
visualized as a colored hierarchical clustering tree as well as plots of median surface marker 
intensity for all stratifying and non-stratifying classical monocyte and naïve CD4 T cell clusters. 
 
Flow Cytometry 
To further investigate potential mechanisms causing differences in IFNγ signaling 
potential, flow cytometry experiments were performed with a subset of six treatment-naïve 
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patients (for which there were remaining samples available) and four control samples from the 
samples collected at the host site. Samples (0.5-1x106 cells per sample) were left unstimulated or 
stimulated 15 minutes with 250 ng/ml IFNγ and fixed with BD Cytofix/Cytoperm buffer (San 
Jose, CA). Samples were stained with one of several antibody panels (Table S2).  Flow 
Cytometry was performed on a 12-color LSRFortessa X-20 Flow Cytometer (BD) and analyzed 
with FlowJo (FlowJo, Ashland, OR). Classical monocytes and naïve CD4 T cells were gated and 




 One-way ANOVA with Bonferroni’s multiple comparisons test between all patient and 
control samples was used to test differences in the distribution of immune cell subsets between 
treatment-naïve patients and controls (32). A paired two-tailed Student’s t-test with Benjamini-
Hochberg multiple hypothesis correction was used to analyze paired treatment-naïve and 
remission patient immune cell percentages. SAM was used to explore differences in signaling 
phenotype in various types of PBMCs. Differences detected by SAM were confirmed with 
unpaired two-tailed Student’s t-tests and Benjamini-Hochberg multiple hypothesis correction. To 
determine which PBMC subsets drove differences detected in SAM, live cells were analyzed via 
Citrus with SAM to classify differences distinguishing patients and controls and results 
confirmed using unpaired two-tailed Student’s t-tests with Benjamini-Hochberg multiple 
hypothesis correction.  Differences in surface marker expression between trios of clusters with 
two stratifying and one non-stratifying were analyzed with ANOVA and a Dunnett’s test in 
relation to a singular non-stratifying cluster. Classical monocyte and naïve CD4 T proliferation 
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differences were tested for both gated populations and Citrus clusters with an unpaired two-tailed 
Student’s t-test and Benjamini-Hochberg multiple hypothesis correction. To analyze flow 
cytometry data, two-tailed Student’s t-tests with Benjamini-Hochberg multiple hypothesis 
correction were used to test the hypotheses that there are differences in: STATs (p-STAT1 and p-
STAT3), JAK1, and inhibitory proteins in cells (SOCS1 and PIAS1).  
 
Study Approval 
The work was approved by the institutional review boards at Washington University 
School of Medicine and Cincinnati Children’s Hospital. Polyarticular JIA was defined according 
to the International League Against Rheumatism criteria for classifying idiopathic arthritis of 








Samples from 17 treatment-naïve polyarticular JIA patients, 10 of the 17 JIA patients 
while in clinical remission on medication, and 19 controls were analyzed (Table 1). Patients who 
had either not achieved clinical remission at the time of the analysis or for whom follow-up 
samples were not available were not included in the assessment of samples in clinical remission 
on medication. The age of the patients and controls in the cohort was well matched with a mean 
patient age of 11.6 years and mean control age of 11.7 years.  52.9% of the patients were female 
while 73.7% of the controls were female.  
 
Immune cell percentages 
Mass cytometry was used to assess the distribution of distinct groups of immune cells in 
the peripheral blood of treatment-naïve polyarticular JIA patients and healthy controls as well as 
a subset of the polyarticular JIA patients in clinical remission on medication. Individual samples 
were debarcoded and gated for live immune cell singlets (Figure S1). Specific immune cell types 
were identified based on surface marker expression (Table S4).  No significant differences were 
identified in the distribution of any immune cell types when comparing treatment-naïve patients 
and controls (Figure 1A). There were also no differences in cell populations detected when 
treatment-naïve patients and remission patients were examined in aggregate or in paired 
treatment-naïve and remission patient samples (Figure 1B).  Of note, percentages of immune cell 
subtypes were compared rather than absolute cell counts because cell counts were not available 
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 After examining differences in immune cell frequency between treatment-naïve 
polyarticular JIA patients and matched controls, the baseline signaling state and signaling 
potential of immune cells from treatment-naïve polyarticular JIA patients and matched controls 
was assessed.  We first demonstrated that the basal and stimulated phosphorylation states of a 
panel of 14 signaling proteins following stimulation with five different cytokines were not 
significantly perturbed by cyropreservation during sample processing of a single donor (Figure 
S2).  To select appropriate stimuli for analysis of polyarticular JIA patients, a preliminary 
experiment was conducted with a single treatment-naive polyarticular JIA patient with eight 
different cytokines (Figure S3).  We saw expected patterns of phosphorylation with specific 
cytokine stimulation.  Given limitations in cell numbers, we elected to prioritize IFNγ and IL-6 
stimulation based on prior work demonstrating that IFNγ and IL-6 were the most significantly 
elevated cytokines in the serum of polyarticular JIA patients (21).  Due to cell number 
limitations, not all patient and control samples underwent stimulation with IL-6 or IFNγ (Table 
S3). 
Citrus was used to quantify stratifying differences (i.e., differences that distinguish 
patients from controls) in signaling phenotype between treatment-naïve patients and controls (or 
remission patients). Citrus is an analytical technique which combines hierarchical clustering of 
cells based on surface marker expression with an analysis of stratifying features (e.g., the 
signaling differences) that distinguish the two compared groups (i.e., patients and controls). As 
not all cells in a given population may be responding, Citrus allows for the analysis of subsets of 
cell populations (e.g., CD4 T cells) without the biases of manual gating. Citrus detected no 
distinguishing signaling differences at baseline or with IL-6 stimulation between treatment-naïve 
patients and controls or remission patients. Differences were detected with IFNγ stimulation 
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between treatment-naïve patients and controls as well as between treatment-naïve patients and 
remission patients (Figures 2, S4, S5, and S6). Specifically, treatment-naïve patients 
phosphorylated STAT3 in classical monocyte clusters (CD14+ CD16- HLA-DR+) and STAT1 
and STAT3 in naïve CD4 T cell clusters more strongly than controls (Figure 2). Stronger STAT3 
phosphorylation in treatment-naïve patients than controls was also detected on canonically gated 
classical monocytes via analysis with Significance Analysis of Microarrays (SAM) (Figure S7).   
Citrus utilizes unsupervised hierarchical clustering based on surface markers, allowing 
distinct immune cell types to be partitioned into different parts of a hierarchical tree, facilitating 
analysis of stratifying characteristics of the immune cell subsets between the two groups of 
interest (Figure 2A and S4). There was substantial heterogeneity within the naïve CD4 
population and to a lesser extent in the classical monocytes in subsets of cells with increased 
IFNγ responsiveness.  To investigate differences in surface marker expression that distinguished 
the subsets of cells with more robust responses to IFNγ in the patients compared to controls, trios 
of connected clusters in which two clusters were stratifying (between patients and controls for 
both p-STAT1 and p-STAT3 in CD4 T cells) and one non-stratifying were examined. 
Comparisons of these trios in proximal (larger clusters) and distal (smaller clusters) parts of the 
tree were performed (using ANOVA with a Dunnett’s post hoc test). When examining a larger, 
proximal CD4 cluster, the stratifying CD4 T cells were higher in CD11c, CD45RA (marker of 
naïve T cells), and CD38 than the nearest non-stratifying clusters (Figure 3A,B). When 
examining a smaller, more distal trio, CD45RA, CD38, and CD27 were higher in stratifying than 
non-stratifying clusters (Figure 3A,C). A global assessment of surface marker expression 
patterns of stratifying and non-stratifying naïve CD4 T cell clusters demonstrated that all 
stratifying clusters expressed CD3, CD4, and CD27 with variations in expression levels of CD4 
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and CD27 (Figure S4 and S8). All stratifying clusters were CD45RA positive and CD38 positive, 
with CD45RA intensity decreasing and CD38 intensity increasing as clusters were divided into 
smaller, more specific subsets from larger clusters (Figure S4 and S8).  All stratifying clusters 
were CD8 negative, CD45RO low or negative, and CD56 negative (Figure S4). Comparison of 
surface marker intensity of all stratifying to all non-stratifying naïve CD4 T cell clusters revealed 
a wide heterogeneity in expression of CD4, CD45RA, CD27, CD38, and HLA-DR (Figure S8).  
Heterogeneity was also observed in the stratifying classical monocyte clusters. Trios of 
two stratifying (between patients and controls for p-STAT3) and one non-stratifying monocyte 
clusters revealed distinct stratifying monocyte subsets on different branches of the monocyte 
portion of the tree (Figure 4). In one branch of the tree, stratifying monocyte subsets were higher 
in CD45RA and HLA-DR and lower in CD45RO than non-stratifying clusters (Figure 4A,B). On 
the other branch of the monocyte part of the tree, the non-stratifying cluster was lower in 
CD45RA, CD45RO, and CD11b than the largest stratifying monocyte clusters (Figure 4A,C). 
All monocyte clusters were CD14, CD11c, and CD38 positive, CD4 low, and lacked expression 
of CD8 and CD16 (Figure S4 and S9). Comparing all stratifying to all non-stratifying classical 
monocyte clusters for surface marker intensity revealed trends in higher levels of median CD4, 
CD45RA, and HLA-DR intensity and lower levels of CD45RO intensity in stratifying than non-
stratifying clusters (Figure S9).  
 Similar signaling differences with IFNγ stimulation were observed between treatment-
naïve patients and remission patients (Figure S5, S6). With IFNγ stimulation, STAT3 was more 
strongly phosphorylated in some CD4 T cell clusters, and STAT1 was more strongly 
phosphorylated in some classical monocyte clusters in treatment-naïve patients in comparison to 
remission patients (Figure S5A, B, C). Trends toward decreasing p-STAT1 in classical 
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monocytes and p-STAT3 in CD4 T cells were also observed paired treatment-naïve and 
remission patient samples (Figure S5D). 
 
Differences in expression of components of the IFNγ signaling cascade 
 Given the differences observed in patient and control CD4 T cell and classical monocyte 
signaling responses, further investigation into the mechanisms contributing to differences in 
IFNγ signaling was performed. Flow cytometry evaluation of targeted components of the IFNγ 
signaling pathway was performed on six treatment-naïve patients and four controls for whom 
samples were available. (Of note, half of these six patients had had only a modest response to 
IFNγ stimulation in the mass cytometry experiments). PBMCs were stained for naïve CD4 T cell 
or classical monocyte markers as well as p-STAT1, p-STAT3, JAK1, SOCS1, PIAS1, IFNGR1 
in four separate flow cytometry panels (Table S2). Both p-STAT1 and p-STAT3 were higher in 
patient than control naïve CD4 T cells at baseline and following IFNγ stimulation (Figure 5A). 
There was no difference in IFNGR1 expression between patient and control naïve CD4 T cells 
(Figure 5B); however, JAK1 expression was higher in treatment-naïve patient than control naïve 
CD4 T cells (Figure 5C), suggesting that increased JAK1 expression may contribute to increased 
IFNγ responsiveness.  There was also higher expression of the inhibitory protein SOCS1 (but not 
PIAS1) in treatment-naïve patient compared to control CD4 T cells (Figure 5D), consistent with 
its induction by IFNγ as a negative regulator (33).  No statistically significant differences were 
detected between patient and control classical monocytes in any of the examined IFNγ signaling 
cascade components, perhaps reflecting the small sample size evaluated (Figure S10).  
 
Function in relation to phenotype 
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 Further investigations were performed to determine whether the observed increased IFNγ 
responsiveness correlated with increased naïve CD4 T cell and classical monocyte proliferation 
in treatment-naïve JIA patients. Higher levels of proliferation (analyzed as Ki-67 expression) 
were observed in treatment-naïve patient classical monocytes and naïve CD4 T cells compared to 
controls (Figure S11A, B) supporting a potential association between IFNγ responsiveness and 
proliferation in treatment-naïve JIA patients.  Interestingly, both stratifying and non-stratifying 
patient classical monocytes and T cells were proliferating more than the same subsets from 
controls (Figure S11C, D). 
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Discussion 
Despite a large number of studies focused on polyarticular JIA, the pathogenesis of this 
disorder is still poorly understood. This study sought to delineate signaling differences in 
peripheral immune cells between treatment-naïve polyarticular JIA patients and controls using 
the high-dimensional capabilities of mass cytometry coupled with multiparameter phospho-
specific antibodies.  No significant differences were detected in basal signaling (unstimulated) or 
following IL-6 stimulation between treatment-naïve JIA patients and controls (or remission 
patients).  However, enhanced responsiveness to IFNγ stimulation was observed with increased 
STAT1 and/or STAT3 phosphorylation in subsets of CD4 T cells and classical monocytes from 
treatment-naïve JIA patients compared to controls.  This enhanced responsiveness to IFNγ  
correlated with increased expression of JAK1 and SOCS1 in CD4 T cells from treatment-naïve 
JIA patients compared to controls.  
No statistically significant perturbations in the percentages of different immune cells 
were observed between treatment-naïve patients and controls or paired treatment-naïve and 
remission patient samples. However, there was a trend toward an increase in the percentage of 
NK cells with cessation of active disease in the paired individual treatment-naïve and remission 
patient samples (Figure 1B; t=3.63, df=8, p=0.007).   
Unstimulated treatment-naïve patients and controls did not have significantly different 
basal phosphorylation patterns in the mass cytometry analysis despite reported elevated levels of 
IFNγ, IL-6, and IL-1 in polyarticular JIA patient serum (21).  This was unexpected given that 
baseline differences in gene expression profiles have been reported in treatment-naïve 
polyarticular JIA patients compared with healthy controls (16, 29).  However, other studies of 
unstimulated autoimmune patient PBMCs compared with controls have also not detected 
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baseline differences in phosphorylation of signaling molecules, including p-STAT1 and p-
STAT2 in Addison’s disease (34), p- ZAP70 in Type I Diabetes (35), and p-STAT1 in systemic 
JIA (36, 37). The lack of differences in basal phosphorylation may be due to sample processing. 
We evaluated parallel fresh and frozen samples from a single donor and demonstrated that 
cryopreservation did not affect phosphoprotein status in either unstimulated or cytokine-
stimulated conditions; however, it is possible that cell processing (and removal from the serum 
cytokine milieu) itself alters baseline phosphorylation.  The potential impact of sample 
processing on basal levels of phosphoproteins is consistent with previous work demonstrating 
differences in gene expression profiles of PBMCs after 4 hours of processing delay (38).   
 Signaling differences were detected between IFNγ stimulated treatment-naïve JIA 
patients and control PBMCs. Naïve CD4 T cells more strongly phosphorylated STAT1 and 
STAT3 while classical monocytes demonstrated enhanced phosphorylation of STAT3 following 
15 minutes of IFNγ stimulation of samples from treatment-naïve JIA patients compared to 
controls. The variation observed in p-STAT1 and p-STAT3 in the treatment-naïve patients was 
not correlated with rheumatoid factor status (Figure S12). Signaling differences were also 
detected in these cell types when comparing treatment-naïve and remission samples. These 
observations about enhanced responsiveness to IFNγ stimulation are supported by prior whole 
blood expression profiling studies of treatment-naïve polyarticular JIA patients, which found 
evidence of alterations in the STAT1-3/interferon response factor-mediated pathways using 
Ingenuity Pathway Analysis (29).  Aberrant STAT3 regulation has also been inferred from 
pathway analysis of CD4 T cells from patients with active rheumatoid arthritis, a disease with 
some similarities with polyarticular JIA (39). In contrast, monocytes from patients with active 
systemic JIA, a different subtype of JIA with an autoinflammatory phenotype, have been shown 
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to have defective STAT1 phosphorylation following IFNγ stimulation and elevated SOCS1 
transcript expression levels (37) as well as a restricted IFNγ-induced genetic signature and 
minimal upregulaton of IFNγ-induced chemokines (36). 
The stratifying naïve CD4 T cells and classical monocytes (i.e., subsets with increased p-
STAT1 and/or p-STAT3 in patients compared to controls) were heterogeneous with varying 
expression levels of different surface markers. This is reminiscent of recent work using mass 
cytometry that demonstrated that synovial T cell infiltrates in rheumatoid arthritis were highly 
heterogeneous and that characterization of the CD4 T cell diversity facilitated potential 
discrimination of pathogenic and non-pathogenic variants of known T cell subsets (40, 41).  
Similarly, NK cell heterogeneity identified with mass cytometry was shown to contribute to 
West Nile Virus susceptibility (42, 43). 
While STAT1 phosphorylation is the canonical response to IFNγ, STAT3 
phosphorylation can be coupled with STAT1 phosphorylation following IFNγ stimulation (44).  
The ability of  IFNγ stimulation to phosphorylate STAT3 is demonstrated by the more 
pronounced and prolonged STAT3 phosphorylation following IFNγ stimulation in murine 
STAT1-null cells compared with wild type cells (44). Flow cytometry studies in a subset of our 
patients found that both p-STAT1 and p-STAT3 basal levels were higher in JIA patient than 
control naïve CD4 T cells and confirmed the mass cytometry finding of increased p-STAT3 
following IFNγ stimulation. No changes in IFNGR1 or PIAS1 expression were detected via flow 
cytometry, but patient naïve CD4 T cells had higher levels of JAK1 and SOCS1 than control 
cells, although the magnitude of these differences was not large.  JAK1 is essential for 
phosphorylating STAT proteins, and elevated levels of JAK1 may contribute to a greater 
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phosphorylation of STAT1/STAT3 in response to IFNγ stimulation, while elevated levels of 
SOCS1 in patients may represent a compensatory feedback mechanism.  
The enhanced STAT1 and/or STAT3 phosphorylation following IFNγ stimulation 
correlated with increased CD4 T cell and classical monocyte proliferation (assessed by Ki-67 
expression) in treatment-naïve patients compared to controls, although CD4 T cell proliferation 
levels were very modest.  There is evidence in murine studies that IFNγ can enhance the 
proliferation and survival of CD4 T cells (45).  Interestingly, Ki-67 expression was higher in 
both stratifying and non-stratifying subsets of CD4 T cells and classical monocytes.  
While novel insights into IFNγ signaling differences in treatment-naïve polyarticular JIA 
patients were gained from this work, there were several limitations including the number of 
patients studied and the number of available PMBCs.  The study included 17 treatment-naïve 
samples from two centers and highlights the need for increased cooperation between centers to 
acquire large enough patient populations to allow new-onset, treatment-naïve polyarticular JIA 
patients to be interrogated in a statistically meaningful manner.  The number of stimulations and 
time points was also constrained by the sample size.  Mass cytometry helps mitigate this 
limitation by maximizing the data extracted from small biological samples, but subtler 
differences in signaling may be detectable with a larger cohort and more stimulation conditions 
and time points.  
This study highlights the utility of mass cytometry coupled with multiparameter phospho-
specific antibodies in analyzing signal differences in small volume patient samples.  Using this 
approach, differences in STAT1 and/or STAT3 phosphorylation in subsets of CD4 T cells and 
classical monocytes following IFNγ stimulation were identified in treatment-naïve polyarticular 
JIA patients compared to control samples.  The enhanced responsiveness of CD4 T cells to IFNγ 
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stimulation correlated with increased expression of JAK1 and SOCS1 in treatment-naïve JIA 
patients. These results suggest that drugs that attenuate IFNγ signaling (e.g., JAK-inhibitors) may 
be useful in treating polyarticular JIA patients and provide a potential mechanistic rationale for 
anecdotal observations regarding the effectiveness of JAK inhibitors in refractory polyarticular 
JIA patients (including the Case Series of 3 refractory polyarticular JIA patients treated with 
tofacitinib, a JAK inhibitor, in the Supplemental Appendix) and for an ongoing clinical trial 
(NCT02591434) of tofacitinib in polyarticular JIA patients.  Interestingly, one of patients in the 
Case Series (Case 2) was included in the mass cytometry analysis as a treatment-naïve sample 
(patient 7 in Table 1), and a follow up sample was subsequently obtained while the patient was in 
clinical remission on tofacitinib (after completion of the initial analysis).  Naïve CD4 T cell p-
STAT1 and p-STAT3 following IFNγ stimulation were lower in the remission sample while on 
tofacitinib (as well as leflunomide and hydroxychloroquine) compared to the paired treatment-
naïve sample (Figure S13). Future studies will focus on more detailed interrogation of specific 
CD45RA+ CD4 T cell subsets to help us further understand mechanistically the increased IFNγ 
responsiveness in subsets of CD4 T cells in this disease.  
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Figures
Figure 1. No differences were identified in the percentage of different cell types between 
treatment-naïve patients and matched controls or in paired patient samples with the cessation of 
disease. A) Treatment-naïve patient versus matched control peripheral blood mononuclear cells 
(PBMC) percentages (one-way ANOVA with Bonferroni’s multiple comparisons test: ANOVA: 
F=52.94, p<0.0001, pairwise comparisons: p>0.05 for all; n=17 treatment-naïve patients and 19 
controls). Data represent mean ± SEM. B) Differences for PBMC percentage in paired treatment-
naïve and remission patient samples (13 paired two-tailed t-tests with Benjamini Hochberg 
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Figure 2. Classical monocyte and CD4 T cell subsets respond more strongly to IFNγ stimulation 
in treatment-naïve patients than controls with STAT1 and STAT3 phosphorylation. (N=15 IFNγ 
stimulated treatment-naïve patients - patients 4 and 5 in Table 1 did not have enough cells for an 
IFNγ stimulated sample and were excluded here, and n=19 controls.) A) Hierarchical clustering 
for IFNγ stimulated treatment-naïve patient versus control PBMCs. Non-stratifying clusters are 
light blue for false discovery rate <0.05, p-STAT1 stratifying (different between patients and 
controls for a signaling molecule) clusters are purple, p-STAT3 stratifying clusters are orange, 
and clusters stratifying  for both p-STAT1 and p-STAT3 are red. Asterisks indicate clusters 
visualized in part C of figure, B) Heat map depicting surface marker intensities for stratifying 
and non-stratifying classical monocyte and CD4 T cell clusters  C) Arcsinh transformed median 
phosphoprotein intensities for largest stratifying CD4 T cell and classical monocyte clusters  
(classical monocyte p-STAT1: t=1.656, df=32, p=0.108; classical monocyte p-STAT3: t=2.72, 
df=32, p=0.011; CD4 T cell p-STAT1: t=3.04, df=21, p=0.006; CD4 T cell p-STAT3: t=3.40, 
df=32, p=0.002). Open circles denote treatment naïve patients and filled squares controls. Data 
represent mean ± SEM. 
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Figure 3. Heterogeneity in the naïve CD4 T cells with enhanced responsiveness to IFNγ 
stimulation in polyarticular JIA patients. (N=15 IFNγ stimulated treatment-naïve patients- 
patients 4 and 5 in Table 1 did not have enough cells for an IFNγ stimulated sample and were 
excluded here, and n=19 controls.)  A) Schematic of hierarchical clustering computed by Citrus 
with clusters analyzed in parts B and C in figure denoted by boxes. Non-stratifying clusters 
between patient and control samples are light blue for false discovery rate <0.05, p-STAT1 
stratifying (different between patient and control samples in regard to the phosphorylation of a 
specific signaling molecule) clusters are purple, p-STAT3 stratifying clusters are orange, and 
clusters stratifying for both p-STAT1 and p-STAT3 are red., B) CD11c, CD45RA, and CD38 
arcsinh transformed medians in three proximal nodes in the CD4 T cell branch of clustering tree 
(ANOVA with Dunnett’s post hoc p<0.05). Data represent mean ± SEM. C) CD27, CD45RA, 
and CD38 arcsinh transformed medians in three distal nodes in the CD4 T cell branch of 
clustering tree (ANOVA with Dunnett’s post hoc p<0.05). Data represent mean ± SEM. 
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Figure 4. Heterogeneity in the classical monocytes with enhanced responsiveness to IFNγ 
stimulation in polyarticular JIA patients. (N=15 IFNγ stimulated treatment-naïve patients- 
patients 4 and 5 in Table 1 did not have enough cells for an IFNγ stimulated sample and were 
excluded here, and n=19 controls.)  A) Schematic of hierarchical clustering computed by Citrus 
with clusters analyzed in parts B and C in figure denoted by boxes. Non-stratifying clusters 
between patient and control samples are light blue for false discovery rate <0.05, p-STAT1 
stratifying (different between patient and control samples in regard to the phosphorylation of a 
specific) clusters are purple, p-STAT3 stratifying clusters are orange, and clusters stratifying for 
both p-STAT1 and p-STAT3 are red, B) CD45RA, CD45RO, and HLA-DR arcsinh transformed 
medians in one branch of monocytes in hierarchical clustering tree (ANOVA with Dunnett’s post 
hoc p<0.05). Data represent mean ± SEM. C) CD45RA, CD45RO, and HLA-DR arcsinh 
transformed medians in other branch of monocytes in hierarchical clustering tree (ANOVA with 
Dunnett’s post hoc p<0.05). Data represent mean ± SEM. 
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Figure 5. Signaling differences between naive CD4 T cells from treatment-naïve patients and 
controls detected by mass cytometry are associated with higher levels of JAK1 and SOCS1 in 
patient naïve CD4 T cells. Open circles denote treatment naïve patients and filled squares 
controls. N=6 treatment naïve patients and 4 controls for which there were remaining samples 
available. Data represent mean ± SEM. A) Differences in STAT1 phosphorylation (left panel; 
unstimulated: 2-tailed t=2.71, df=8, p=0.027; stimulated: t=1.44, df=8, p=0.19) and STAT3 
phosphorylation (right panel; unstimulated: t=3.24, df=8, p=0.012; stimulated: t=3.91, df=8, 
p=0.005) in patient and control naïve CD4 T cells with and without 250ng/ml IFNγ stimulation 
for 15 minutes. B) Interferon Gamma Receptor 1 (IFNGR1) in unstimulated patient and control 
naïve CD4 T cells (t=1.40, df=8, p=0.20).  C) JAK1 in unstimulated patient and control naïve 
CD4 T cells (t=2.56, df=8, p=0.034). D) Inhibitory molecules SOCS1 (left) and Protein Inhibitor 
of Activated STAT 1 (PIAS1) (right) in unstimulated patient and control naïve CD4 T cells 
(SOCS1: t=2.78, df=8, p=0.024, PIAS1: t=1.89, df=8, p=0.096). 
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Tables 
Table 1. Patient demographics and medications.  
Pts Sex Age at Sample 
Collection 






Medications at 2nd 
draw 
 Control Research 
Site* 
1 F 13.9 + + 27 10.6 15 MTX, Plaquenil 15 yr F 1 
2 F 10.3 - - 85 138 12 MTX, Daypro 11.7 yr 
F 
1 
3 F 11.7 + - 9 4.5  12 MTX, Enbrel 11.7 yr 
F 
1 
4 M 15 + + 24 ND 16 MTX, Enbrel 17 yr M  1 
5 M 15 + + 14 12.2 16 MTX, Enbrel 17 yr M  1 
6 M 4 - nd 38 25.1 5 MTX, Enbrel 3 yr M 1 
7 F 16.9 + + 57 24.7   19 yr F 1 
8 F 7.2 + - 9 4   10.1 yr 
F  
1 
9 M 14.2 - - 18 ND   15.7 yr 
M 
1 
10 F 1.5 - nd NA NA 1.8 MTX 1.2 yr F 2 
11 F 14.6 - nd NA NA 15.3 MTX 15.4 yr 
F 
2 
12 F 11.3 - nd NA NA   11.1 yr 
F 
2 
13 M 15.2 - nd NA NA   9.4 yr F 2 
14 F 15.8 - nd NA NA 16.3 MTX, Adalimumab  12.8 yr 
F 
2 
15 M 8.8 - nd NA NA 9.3  MTX, Tocilizumab 8.2 yr F 2 
16 M 20.6 - nd NA NA   5.1 yr F 2 
17 M 1.4 - nd NA NA   4.7 yr M 2 
18         13.4 yr 
F 
1 
19         12.6 yr 
F 
1 
           
           
Abbreviations: MTX: methotrexate, RF: rheumatoid factor, CCP: anti-cyclic citrullinated 
peptide, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, ND: no data, NA: not 
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Supplemental Case Series 
Case Series of three refractory polyarticular JIA patients successfully treated with 
tofacitinib (a JAK inhibitor) 
 
Despite the efficacy of currently-available biologic therapies, polyarticular JIA remains difficult 
to control in a nontrivial subset of patients, underscoring the need for additional therapeutic 
approaches to the treatment of this disorder.  The identification of enhanced responsiveness to 
IFNγ stimulation in subsets of CD4 T cells and classical monocytes from treatment-naïve 
polyarticular JIA patients highlights the possibility that specifically targeting the IFNγ signaling 
pathway with a Janus Kinase (JAK) inhibitor (e.g., tofacitinib) may be beneficial in polyarticular 
JIA.   
 
Tofacitinib has been FDA approved for use in moderate to severe rheumatoid arthritis; however, 
we are not aware of any case reports or case series reporting the use of tofacitinib in polyarticular 
JIA patients other than a single case of its use in a 58 year old woman with a past history of 
polyarticular JIA and onset of refractory colitis in her thirties.  Below, we present three 
refractory polyarticular JIA patients who had positive responses to treatment with tofacitinib at 
our medical center.  All three were adolescent, RF+, Caucasian females who had failed to gain 
durable clinical remission with other biologic agents.    
 
Case 1 
A 7-year-old Caucasian female presented to an outside institution with a three month 
history of arthralgia and limitation in range of motion of her neck, ankles, knees, shoulders, and 
wrists.  She was diagnosed with RF+ polyarticular JIA.  Initial treatment by the outside provider 
  
     
41
included weekly intravenous steroid pulses and oral methotrexate (MTX), and she initially 
achieved prolonged clinical remission.  Etanercept was added after a flare in her disease at age 
12 but failed to induce a durable remission.  She transferred her care to our institution at age 13 
with active arthritis affecting her wrists, elbows, hips, knee, and ankles.  Laboratory evaluation at 
that time showed microcytic anemia (Hgb 9.9 g/dl;  MCV 74.4) and elevated inflammatory 
markers (ESR 106 mm/hr, CRP 54 mg/L).  Serologic testing revealed a positive anti-nuclear 
antibody (ANA) (1:320), rheumatoid factor (296 units/ml), and anti-CCP (>250 units).   
 
Her etanercept was replaced by adalimumab, and her MTX was converted to 
subcutaneous dosing with concomitant intra-articular steroid injections of multiple active joints.  
After six months she had not achieved clinical remission, so adalimumab was stopped, and she 
was given a course of rituximab with symptomatic improvement.   When her disease flared after 
five months with bilateral wrist arthritis, she was given a second course of rituximab (requiring 
four doses due to incomplete CD19 depletion) and continued on MTX.  She again had a good but 
not durable response to rituximbab. Within 9 months, she developed new-onset shoulder 
involvement and recurrence of arthritis in her fingers, wrists, elbows, hips, and ankles with 
numerous contractures.  Golimumab and hydroxychloroquine were added with an initial good 
response, but after six months, she had worsening hand symptoms with new erosions in her 
proximal interphalangeal (PIP) and metacarpeal (MCP) joints documented by x-ray.  Golimumab 
was replaced by weekly subcutaneous tocilizumab with modest improvement, and she 
subsequently developed severe erosive disease in her left shoulder that did not improve with 
intra-articular steroid injection.  Tocilizumab was then replaced with abatacept, which after three 
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months demonstrated no improvement in controlling her disease particularly of her left shoulder, 
which was severely limiting her activities of daily living.   
 
Therefore, abatacept was stopped and tofacitinib was started when she was 16 years old. 
She was also continued on hydroxychloroquine and leflunomide.  After two months she had 
significant improvement with near resolution of her morning stiffness and increased range of 
motion in her left shoulder, although she still had a number of swollen joints.  Therefore, low-
dose sulfasalazine was added, and her hydroxychloroquine was stopped.  After six months of 
tofacitinib, her left shoulder had regained approximately 80% of its normal range of motion with 
resolution of associated pain or stiffness, and she had only a single active joint (a PIP) that 
subsequently resolved over the next several months.  Nearly one year after starting tofacitinib, 
she remains in clinical remission and is tolerating the tofacitinib in combination with 
leflunomide and sulfasalazine. 
 
Case 2 
A 16-year-old Caucasian female presented with two years of progressively worsening 
and additive arthralgia/arthritis.  At presentation, she had involvement of her right knee, bilateral 
wrists, and multiple PIP and MCP joints as well as bilateral 1st-4th metatarsophalangeals (MTP), 
tibiotalar, subtalar and talonavicular synovitis and associated tenosynovitis (confirmed by MRI).  
Other features included livedo reticularis and Raynaud’s phenomenon.  Laboratory evaluation at 
presentation revealed normocytic anemia (Hgb 11 g/dl;  MCV 87.8) and elevated inflammatory 
markers (ESR 57 mm/hr; CRP 24.7 mg/L) with normal C3 and C4 complement levels. Serologic 
testing showed strongly positive rheumatoid factor (98 units/ml) and anti-CCP (>250 units) with 
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negative ANA, extractable nuclear antibodies (ENA), anti-double stranded DNA antibodies, and 
antiphospholipid antibodies. 
 
She was diagnosed with RF+ polyarticular JIA, and her initial treatment consisted of oral 
prednisone and subcutaneous methotrexate.  She had improvement with prednisone, but 
repeatedly worsened as it was weaned.  After 2 months, etanercept was added. Her symptoms did 
not improve, and after a three month trial, etanercept was replaced by adalimumab with the 
addition of hydroxychloroquine.  She had some symptomic improvement over a three-month 
period, but a repeat MRI demonstrated erosive synovitis and tenosynovitis in her right hand and 
wrist.  Adalimumab was replaced by weekly subcutaneous tocilizumab.  However, after three 
months, her symptoms had not improved, and an MRI showed progressive disease involving her 
right hand and wrist.  Tocilizumab was then stopped, and she was given a course of rituximab 
with complete CD19 depletion but only partial improvement of symptoms.  Abatacept was added 
several months later, and methotrexate was replaced with leflunomide for a period of six months 
with minimal improvement and continued MRI evidence of active synovitis in her right hand and 
wrist.   
 
At that point, abatacept was replaced with tofacitinib. Over a three-month period, she 
showed improvement in pain, morning stiffness, and function.  Repeat MRI of her hands after six 
months of therapy with tofacitinb showed resolved synovitis, no new erosions, and improved 
tenosynovitis.  She has now been maintained on tofacitinib in combination with leflunomide and 
hydroxychloroquine for 9 months without any adverse effects such as cytopenias, abnormal 
chemistries, or recurrent infections.   
  




A 14-year-old Caucasian female presented with two years of arthralgia and joint swelling 
(including hands, elbows, shoulders, hips, knees and feet).  She was initially diagnosed with RF+ 
polyarticularly JIA at another institution and prescribed methotrexate.  She did not start the 
methotrexate and was lost to follow-up for 11 months until she presented to our clinic.  Physical 
exam showed synovitis in her bilateral 1st-3rd MCPs, and MRI demonstrated synovitis and joint 
effusions involving her right shoulder and left hip.  Laboratory evaluation showed normal blood 
counts and negative inflammatory markers.  Serologic testing showed positive ANA (1:160), 
rheumatoid factor (65 units/ml), and anti-CCP (>250 units).   
 
Initial treatment including weekly oral methotrexate and etanercept induced sustained 
remission over a 12-month period.  However, withdrawal of etanercept resulted in rapid 
recrudescence of active arthritis.  Indeed, she experienced flares repeatedly when her injections 
were late or missed.  Her methotrexate was switched to leflunomide to minimize the number of 
injections and improve compliance. However, difficulty in consistency with weekly injections 
resulting in frequent disease recurrences lead us to change her therapy to tofacitinib and 
leflunomide as she was transitioning to college.  She has currently been using tofacitinib in 
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Figure S2. There is no difference in phosphorylation of signaling molecules in 13 cell types 
following 5 different stimulations between cell types of fresh and frozen samples collected from 
a single donor. Samples were stimulated 30 minutes with specified cytokines. Heat map of raw 
signaling molecule median intensity in different peripheral blood mononuclear cells (PBMCs) in 
response to different stimulations in fresh and frozen samples in shown cell populations. 
Columns for each signaling molecule correspond to the following cell types: basophils, pDCs, 
NK cells, NK T cells, naïve CD8 T cells, memory CD8 T cells, naïve CD4 T cells, memory CD4 
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Figure S3. Analysis of a preliminary polyarticular juvenile idiopathic arthritis (JIA) patient 
sample via CyTOF done with broad array of 8 cytokines. Samples were stimulated 30 minutes 
with specified cytokines. Heat map of raw signaling molecule median intensity in different cell 
types in response to different stimulations. Columns for each signaling molecule correspond to 
the following cell types: basophils, pDCs, NK cells, NK T cells, naïve CD8 T cells, memory 
CD8 T cells, naïve CD4 T cells, memory CD4 T cells, memory B cells, naïve B cells, mDCs, 
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Figure S4. Citrus hierarchical clustering for IFNγ stimulated treatment-naïve patients (n=15; Pt4 
and Pt5 were excluded due to lack of treatment-naïve IFNγ stimulated sample) versus controls 
(n=19) colored by arcsinh transform of median marker intensity, p-STAT1 and p-STAT3 false 
discovery rate comparing treatment naïve patient and control samples for each cluster for the 
bottom two plots. False discovery rate is an empirically calculated approximation for a p-value 
for the respective signaling molecules computed by permuting patient and control labels. Arrows 
indicate a child/children emanating from a parent cluster.  
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Figure S5. Classical monocyte subsets more strongly phosphorylate STAT1 in 16 treatment-
naïve patients than a subset of 10 of the 16 patients in remission with IFNγ stimulation, while 
CD4 T cells subsets have greater levels of STAT3 phosphorylation in treatment-naïve patients 
than remission patients after IFNγ stimulation. N=15 treatment naïve patients, N=10 remission 
patients. Pt4 and Pt5 were excluded due to lack of treatment-naïve IFNγ stimulated sample. A) 
Hierarchical clustering for IFNγ stimulated treatment-naïve patient versus remission patient 
PBMCs. Non-stratifying clusters are light blue for q<0.05, p-STAT3 stratifying (different 
between patients and controls for a signaling molecule) clusters are green, p-STAT1 stratifying 
clusters are yellow, B) Heat map depicting surface marker intensities for stratifying and non-
stratifying classical monocyte and CD4 T cell clusters, C) Arcsinh transformed median 
phosphoprotein intensities for largest stratifying CD4 T cell and classical monocyte clusters 
denoted with asterisks (classical monocyte p-STAT1: t=2.416, df=23, p=0.0240; CD4 T cell p-
STAT4: t=2.635, df=23, p=0.0148). Open circles denote treatment naïve patients and X’s denote 
remission patients, D) Arcsinh transformed median phosphoprotein intensities for largest 
stratifying CD4 T cell and classical monocyte clusters denoted with asterisks with paired 
treatment-naïve and remission patient samples. p-STAT1 (one-tailed paired t-test: t=0.394, df=7, 
p=0.705) in largest stratifying classical monocyte cluster and p-STAT3 (one-tailed paired t-test: 
t=1.718, df=7, p=0.130) in largest stratifying naïve CD4 T cell cluster with cessation of active 
disease (from IFNγ stimulated treatment-naïve versus remission patient Citrus) between paired 
treatment-naïve patient and remission patient IFNγ stimulated samples (n=8 paired treatment-
naïve and remission patient samples; n=15 treatment-naïve patients and n=10 remission patients; 
Pt 4 and Pt 5 were excluded, as they did not have IFNγ stimulated samples). Median intensity of 
p-STAT1 and p-STAT3 is visualized as the arcsinh transform of the raw median intensity. 
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Figure S6. Citrus hierarchical clustering for IFNγ stimulated treatment-naïve patients (n=15) 
versus remission patients (n=10) colored by arcsinh transform of median marker intensity, p-
STAT1 and p-STAT3 false discovery rate comparing treatment naïve patient and remission 
patient samples for each cluster for the bottom two plots. Pt4 and Pt5 were excluded due to lack 
of IFNγ stimulated sample. Arrows indicate a child/children emanating from a parent cluster. See 
Figure S5 for explanation of false discovery rate. 
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Figure S7. There are no signaling differences between treatment-naïve patient and matched 
control PBMC signaling at baseline or with IL-6 stimulation as assessed by significance analysis 
of microarrays (SAM), but there are statistically significant signaling differences in p-STAT3 
with IFNγ stimulation. Columns in the heat maps correspond to different cell types: basophils, 
pDCs, NK cells, NK T cells, naïve CD8 T cells, memory CD8 T cells, naïve CD4 T cells, 
memory CD4 T cells, memory B cells, naïve B cells, mDCs, classical monocytes, and 
intermediate monocytes. Color in heat maps represents intensity of p-STAT1 and p-STAT3 in 
these cell types for each specimen normalized to a run control using an arcsinh ratio. Patients and 
controls were excluded from certain stimulations due to low cell counts from these patients. A) 
Unstimulated signaling heat map (n=16 treatment-naïve patients, n=19 controls, n=10remission 
patients), B) IL-6 stimulated signaling heat map (n=10 treatment-naïve patients, n=15 controls, 
n=6 remission patients), C) IFNγ stimulated signaling heat map, D) Significant signaling 
differences between IFNγ stimulated treatment-naïve patient and control cells (classical 
monocyte p-STAT3: delta=4.18, q=0.030, two-tailed Student’s t-test: t=4.17, df=32, p=0.0002; 
n=15 treatment-naïve patients, n=19 controls, n=10 remission patients). 
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Figure S8. Arcsinh transformed median surface marker expression for all samples for stratifying 
(red) and non-stratifying (blue) naïve CD4 T cell clusters detected in Citrus comparing treatment 
naïve patient and controls with IFNγ stimulation for markers relevant to CD4 T cells (n=15 
treatment-naïve patients and n=19 controls; Pt4 and Pt5 were excluded due to lack of IFNγ 
stimulated sample). See Figure 3 for location of specific clusters in hierarchical clustering tree. 
Non-stratifying clusters are listed from the distal to proximal parts of the tree and stratifying 
from proximal to distal. 
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Figure S9. Arcsinh transformed median surface marker expression for all samples for stratifying 
(red) and non-stratifying (blue) classical monocyte clusters detected in Citrus comparing 
treatment naïve patient and controls with IFNγ stimulation for markers relevant to classical 
monocytes (n=15 treatment-naïve patients and n=19 controls; Pt4 and Pt5 were excluded due to 
lack of IFNγ stimulated sample). See Figure 4 for location of specific clusters in hierarchical 
clustering tree. Stratifying/non-stratifying nodes are listed from distal nodes on the left side 
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Figure S10. No signaling differences in IFNγ signaling cascade between treatment-naïve patients 
and controls in classical monocytes. N=6 treatment naïve patients and 4 controls. Not all patients 
had remaining samples and therefore were not included in flow cytometry analysis. A) STAT1 
phosphorylation in patient and control classical monocytes with and without 250ng/ml IFNγ 
stimulation for 15 minutes (left panel; unstimulated: 2 tailed t=1.32, df=8, p=0.22; stimulated: 
t=0.19, df=8, p=0.85) and STAT3 (right panel; unstimulated: t=1.17, df=8, p=0.28; stimulated: 
t=0.41, df=8, p=0.69), B) JAK1 in unstimulated patient and control classical monocytes (t=1.08, 
df=8, p=0.31), C) Interferon Gamma Receptor 1 (IFNGR1) in unstimulated patient and control 
classical monocytes (t=0.489, df=8, p=0.64), D) Inhibitory molecules SOCS1 (left) and Protein 
Inhibitor of Activated STAT 1 (PIAS1) (right) in unstimulated patient and control classical 
monocytes (SOCS1: t=0.57, df=8, p=0.59, PIAS1: t=0.15, df=8, p=0.89). 
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Figure S11. Signaling differences between treatment-naïve patients and controls in naïve CD4 T 
cells and classical monocytes correspond to higher levels of proliferation in manually gated 
populations and in populations clustered by Citrus. Open circles denote treatment naïve patients 
(n=16: Pt4 used in preliminary analyses was not analyzed using the same panel) and filled 
squares controls (n=19). A) Classical monocytes and B) naïve CD4 T cells are more actively 
proliferating in treatment-naïve patients than in controls, as suggested by levels of Ki-67. Ki-67 
expression in classical monocytes (t=2.14, df=24, p=0.043) and naïve CD4 T cells (t=3.22, 
df=24, p=0.004), C) Ki-67 median intensity in stratifying and non-stratifying classical monocyte 
clusters detected by Citrus compared between patients and controls (stratifying: t=3.28, df=8, 
p=0.011 ; non-stratifying: t=8.30, df=6, p=0.0002), D) Ki-67 median intensity in stratifying and 
non-stratifying naïve CD4 T cell clusters detected by Citrus compared between patients and 
controls (stratifying: t=2.61, df=30, p=0.014 ; non-stratifying: t=2.36, df=14, p=0.033). 
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Figure S12. There is not statistical difference in naïve CD4 T cell IFNγ responsiveness between 
rheumatoid factor (RF) positive and negative patients (n=19 healthy controls, n=11 RF- 
treatment-naïve patients, n=4 RF+ treatment-naïve patients; RF+ patients 4 and 5 were excluded 
because Pt4 was used for preliminary analyses, and Pt5 did not have IFNγ stimulated samples). 
Data for the largest stratifying naïve CD4 T cell cluster (33995) visualized as the arcsinh median 
intensity was analyzed between treatment-naïve patients that were RF+ and RF-. A) p-STAT1 
(two-tailed paired t-test: t=-1.12, df=3.98, p=0.325), B) p-STAT3 (two-tailed paired t-test: t=-
1.14, df=5.65, p=0.299). 
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Figure S13. P-STAT1 and p-STAT3 phosphorylation are decreased in single paired treatment-
naïve and remission patient treatment with tofacitinib (Pt 7 in Table1). A single patient discussed 
in the case studies had a treatment-naïve sample included in the study. A remission sample for 
the patient during tofacitib treatment was obtained at a later date and separately analyzed via 
mass cytometry with IFNγ stimulation along with the same matched control. The samples were 
gated on naïve CD4 T cells and assessed for p-STAT1 and p-STAT3. Data are displayed are 
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Supplemental Tables 
Table S1. Surface and intracellular antibodies for CyTOF. 





CD45 HI30 Fluidigm 89Y   0.3X 
CD19 HIB19 Fluidigm 142Nd 0.33x 
CD45RA HI100 Fluidigm 143Nd 0.1x 
CD4 RPA-T4 Fluidigm 145Nd 0.33x 
CD8a RPA-T8 Fluidigm 146Nd   1x 
CD7 CD7-6B7 Fluidigm 147Sm 0.33x 
CD16 3G8 Fluidigm 148Nd    1x 
CD66 CD66a-B1.1 Fluidigm 149Sm 0.33x 
CD123 (IL3r) 6H6 Fluidigm 151Eu  0.33x 
CD163 GHI/61 Fluidigm 154Sm   1X 
CD27 L128 Fluidigm 155Gd  0.1x 
CD11c Bu15 Fluidigm 159Tb   0.33x 
CD14 M5E2 Fluidigm 160Gd 1x 
CD69 FN50 Biolegend 163Dy 0.5ug/ml 
CD45RO UCHL1 Fluidigm 165Ho 0.33x 
CD25 (IL2Rα) 2A3 Fluidigm 169Tm    1x 
CD3 UCHT1 Fluidigm 170Er 0.33x 
CD38 HIT2 Fluidigm 172Yb    1x 
HLADR L243 Fluidigm 173Yb 0.1X 
CD56 NCAM16.2 Fluidigm 176Yb 0.03x 
CD11b ICRF44 Fluidigm 209Bi 1x 
pSHP2 D66F10 Fluidigm 141Pr 1x 
p-PLCγ2 K86-698.37 Fluidigm 144Nd   0.33 
p-STAT5 47 Fluidigm 150Nd 1x 
p-AKT D9E Fluidigm 152Sm 1x 
p-STAT1 58D6 Fluidigm 153Eu 1x 
p-p38 D3F9 Fluidigm 156Gd 1x 
p-STAT3 4/P-Stat3 Fluidigm 158Gd 1x 
Ki-67 B56 Fluidigm 161Dy 1x 
p-LCK  K86-689.37 Fluidigm 162Dy 0.1x 
IκB L35A5 Fluidigm 164Dy 1x 
p-p65-NFkB K10-895 Fluidigm 166 Er  0.1x 
p-ERK1/2 D13.14.4E Fluidigm 167Er 1x 
p-STAT6 18 Fluidigm 168Er 0.33x 
p-ZAP70/p-Syk 17a Fluidigm 171Yb 1x 
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pSTAT4 38 Fluidigm 174Yb 0.33x 
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SOCS1 Polyclonal Abcam FITC ab987
0 
19.2ng/ml X   X  
PIAS1 D33A7 CST PE #9272
5 
0.65ng/ml X   X  









10µg/ml X X X X 
p-STAT1 58D6 CST AF647 #8009
s 





20µg/ml X X   
CD16 3G8 BD V500 56139
4 
1:20 X X   
HLA-DR G46-6 BD BV786 56404
1 
1:20 X X   
CD3 UCHT1 BD BV395 56354
6 










37.5µg/ml   X  X 
JAK1 REA700 Miltenyi APC 130-
110-
550 
1:50   X  X 






10µg/ml     X X 









7.5µg/ml     X X 
CD27 L128 BD BV786 56332
7 







20µg/ml     
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Table S3. Number of patient and control samples for each stimulation condition. Of note, one of 
the 17 treatment-naïve patients (Pt 4) was used in preliminary experiments (including Figure S3) 






Unstimulated 16 10 19 
IL-6 Stimulated 11 6 15 
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Granulocytes neg neg   pos   neg                 neg 
Basophils neg neg   neg pos neg neg             pos neg 
NK cells neg neg pos   neg neg                   
Dim NK cells neg neg low   neg neg     high             
Bright NK cells neg neg high   neg neg     low             
NK T cells pos neg pos   neg neg                   
Effector CD8 T 
cells pos neg     neg neg neg neg   neg pos   pos     
Activated CD8 T 
cells pos neg     neg neg pos     neg pos     pos   
Memory CD8 T 
cells pos neg     neg neg neg pos   neg pos pos neg     
Naïve CD8 T cells pos neg     neg neg neg pos   neg pos neg pos     
Effector CD4 T 
cells pos neg     neg neg neg neg   pos neg   pos     
Activated CD4 T 
cells pos neg     neg neg pos     pos neg     pos   
Memory CD4 T 
cells pos neg     neg neg neg pos   pos neg pos neg     
Naïve CD4 T cells pos neg     neg neg neg pos   pos neg neg pos     
Memory B cells neg pos     neg neg pos pos               
Naïve B cells neg pos     neg neg pos neg               
 Plasma B cells neg pos     neg neg neg             pos   
B cells neg pos     neg neg                   
pDCs neg neg   neg pos neg pos             pos neg 
mDCs neg neg     neg neg pos             pos pos 
Non-classical 
monocytes neg neg neg   neg neg pos   pos             
Classical 
monocytes neg neg neg   neg pos pos   neg             
Intermediate 
monocytes neg neg neg   neg pos pos   pos             
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Chapter 3: Dysregulation of PLC2 signaling in juvenile 
dermatomyositis patient NK cells 
Abstract 
Juvenile dermatomyositis (JDM) is a debilitating pediatric autoimmune disease 
manifesting with characteristic rash and muscle weakness. To delineate signaling abnormalities 
in JDM, mass cytometry was performed with PBMCs from treatment-naïve JDM patients and 
controls.  NK cell percentages were lower while frequencies of naïve B cells and naïve CD4 T 
cells were higher in JDM patients than controls. These cell frequency differences were attenuated 
with cessation of active disease. A large number of signaling differences were identified in 
treatment-naïve JDM patients compared to controls.  Classification models incorporating feature 
selection demonstrated that differences in PLC2 phosphorylation comprised 10 of 12 features 
(i.e., phosphoprotein in a specific immune cell subset) distinguishing the two groups.  As NK 
cells represented 5 of these 12 features, further studies focused on the PLC2 pathway in NK 
cells, which is responsible for stimulating calcium flux and cytotoxic granule movement. No 
differences were detected in upstream signaling or total PLC2 protein levels.  
Hypophosphorylation of PLC2 and downstream MAPKAPK2 were partially attenuated with 
cessation of active disease.  PLC2 hypophosphorylation in treatment-naïve JDM patients 
resulted in decreased calcium flux.  The novel identification of dysregulation of PLC2 
phosphorylation and decreased calcium flux in NK cells provides potential mechanistic insight 
into JDM pathogenesis. 
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Introduction 
 Juvenile dermatomyositis (JDM) is an inflammatory myopathy/vasculopathy that results 
in inflammation of striated muscle, skin, and the gastrointestinal tract.  It presents with 
characteristic skin findings (including heliotrope rash, Gottron’s papules, and periungual 
erythema and telangiectasias) and proximal muscle weakness in childhood with an incidence of 
2-3 cases per million children (1). Before the advent of steroid therapy, JDM had a mortality rate 
of forty percent (1). Even with treatment, the disease inflicts significant morbidity on children 
with over 25% of JDM patients experiencing persistent symptoms for over 36 months (2) and 
approximately 20% of patients experiencing an even more protracted, refractory disease course 
(1).  
The etiology of JDM is not well characterized, but both adaptive and innate immune 
responses have been associated with JDM pathogenesis.  Myositis-specific and myositis-
associated antibodies (against extractable nuclear antigens) have been identified in 
approximately 65% of JDM patients (3, 4).  Furthermore, B cell depletion with rituximab (a 
chimeric monoclonal antibody against CD20) leads to clinical improvement in some JDM 
patients (5-7).  T cells are implicated by the association of JDM with HLA-B08 and HLA-DRB1 
(8-10). Furthermore, JDM patients exhibit increased skewing toward Th2 and Th17 T cell 
subsets, which correlates with disease activity and blood plasmablasts (11).  The innate immune 
system also appears to play a role in JDM. Plasmacytoid dendritic cells (pDCs) and macrophage 
secreted proteins are present in inflamed JDM patient muscles (12, 13), and chemokines eotaxin, 
monocyte chemoattractant protein 1 (MCP-1), and interferon gamma-induced protein 10 (IP-10) 
are elevated in JDM patient serum in comparison to healthy controls (14). In addition, specific 
TNF and IL-1 alleles as well as a type I interferon stimulated gene signature are associated with 
JDM disease risk (15, 16). 
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 Several studies have implicated NK cells in the pathogenesis of JDM.  NK cells are 
innate lymphocytes (identified as CD3- CD56+) with germ-line encoded receptors that play a 
critical role in antiviral defense and tumor surveillance (17).  NK cells perform this critical 
function by secreting immunomodulatory cytokines and releasing cytotoxic granules to lyse 
target cells (18).  The movement of cytotoxic granules within NK cells is regulated by the 
phosphorylation of PLC2 and subsequent generation of calcium flux (19, 20).  There is 
accumulating evidence that human NK cells play an immunoregulatory role and that NK cell 
dysfunction may contribute to the onset of human autoimmunity (21, 22).  In JDM, lower 
percentages of NK cells have been found in the blood of treatment-naïve patients than in healthy 
controls (23), and there is some evidence that NK cells infiltrate the affected muscle (15).  
Furthermore, decreased NK cell cytotoxicity has been reported in a small cohort of JDM patients 
(24). 
Despite these insights, the etiology of JDM is not well understood, and the dysregulation 
of immune cell signaling in JDM has not been systematically investigated. Therefore, to 
delineate potential immune cell signaling abnormalities in JDM, we performed mass cytometry 
on peripheral blood mononuclear cells (PBMCs) from treatment-naïve JDM patients and 
controls.  By pairing the deep profiling facilitated by mass cytometry with phospho-specific 
antibodies, we were able to probe the activation state of 14 signaling molecules in 23 distinct 
leukocyte subsets within single patient samples, both at baseline and over a time-course 
following stimulation with a cocktail of cytokines and cross-linking antibodies.  This approach 
identified dysregulated PLC2 phosphorylation in several different immune cell types, with 
defective PLC2 phosphorylation in NK cells comprising the primary signaling difference 
between treatment-naive JDM patients and controls. 
  
     
73
Materials and Methods 
Patients 
JDM was defined according to modified Bohan and Peter’s criteria (1).  JDM patients 
diagnosed in our pediatric rheumatology clinics at St. Louis Children’s Hospital (site 1) or Ann 
and Robert H. Lurie Children’s Hospital of Chicago (site 2) were eligible for enrollment if they 
were new-onset and treatment-naïve. The definition of clinical inactive disease varied slightly 
between the two sites.  Site 1 defined clinical inactive disease as no proximal muscle weakness, 
no difficulty swallowing, and only residual Gottron’s papules or rash.  Site 2 defined apparent 
inactive disease as a disease activity score (DAS) (25) of 2 or less. 
Reagents 
Antibodies conjugated to heavy metals were purchased from Fluidigm (San Fransisco, 
CA) with the exception of CD69 (Table S1).  
Sample preparation and collection 
Blood samples were collected from 17 treatment-naïve, new-onset JDM patients, 11 of 
these 17 JDM patients after achieving clinical inactive disease, and 17 healthy controls (Table 1), 
and peripheral blood mononuclear cells (PBMCs) were isolated using a Ficoll gradient (GE 
Healthcare, Uppsala, Sweden) and cryopreserved. 
Mass cytometry 
PBMCs were thawed and labeled with cisplatin to distinguish live cells (Fluidigm, San 
Francisco, CA). Cells were aliquoted (1.7-3.3 x 106 cells per tube) into polypropylene tubes with 
80 µl volume.  Cells were stained with all surface marker antibodies except CD45, CD45RA, 
and CD45RO for 30 min at 37°C, washed with warm media, and rested for 30 min at 37°C prior 
to stimulation.  To maximize insights gained from limited samples, a combination of stimuli to 
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activate different signaling pathways were chosen to stimulate the samples. Cells were left 
unstimulated or stimulated with 500 U/ml IL-2 (R&D Systems, Minneapolis, MN), 50 ng/ml IL-
12 (R&D Systems), 500 ng/ml LPS (InvivoGen, San Diego, CA), 500 U/ml IFN-⍺4 (PBL 
Interferons Source, Piscataway, NJ), and 1µl/ml anti-mouse IgG (Biolegend, San Diego, CA) for 
3 or 15 min in RPMI1640 medium supplemented with 10% fetal calf serum at 37°C then fixed 
with MaxPar Fix I Buffer, permeabilized with MaxPar Barcode Perm Buffer, and barcoded with 
the Cell-ID 20-Plex Barcoding Kit (Fluidigm, San Francisco, CA). Barcoded samples were 
pooled and stained with antibodies for CD45, CD45RA, and CD45RO (Table S1). After staining 
for surface markers, the pooled samples were methanol permeabilized and stained with 
antibodies for intracellular markers (Table S1). Samples were put in Cell-ID Intercalator-Ir 
(Fluidigm, San Francisco, CA) overnight to facilitate detection of debris and doublets, and then 
run on a CyTOF2/Helios instrument (Fluidigm, San Francisco, CA). Samples were debarcoded 
using the Single Cell Debarcoder, a standalone MATLAB application (26). Data were analyzed 
using Cytobank and R (Santa Clara, CA).  A run control from the same normal donor was used 
in each experiment to normalize the phosphoprotein data as follows: 
 :  ℎ(!3#$%&'/5) − ℎ(!2-. 40.120&/5) 
Citrus 
Citrus, a computational technique combining hierarchical clustering with an analysis of 
stratifying differences in cluster features (i.e., phosphorylation signaling proteins in immune 
subsets) between two groups of samples, was performed with the R “citrus” package on flow 
cytometry standard (fcs) files gated on live immune cells to compare treatment-naïve patients 
with healthy controls for each stimulation time point (27).  Surface markers were clustering 
parameters. Minimum cluster size was set as 2% of the total population with 10,000 events 
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sampled per file. Cluster characterization features were signaling molecules. All clustering and 
characterization features were arcsinh transformed.  Differences in cluster features were 
calculated using least absolute shrinkage and selection operator (LASSO) feature selection, as 
the number of stratifying features with Significance Analysis of Microarrays (SAM) was too 
large to manually interpret. LASSO model cross validation-error rates were acceptably low for 
model interpretation (Figure S2). 
To aid in interpretation of cluster cell type, all surface marker transformed medians 
(Table S1) were visualized in a heat map. A partial least-squares discriminant analysis (PLS-DA) 
model to classify treatment-naïve patients from controls was constructed with LASSO selected 
features in Citrus combining all three stimulation time points into a single Z-score transformed 
matrix for analysis. 
Flow cytometry to assess total PLC2 and SHIP1 protein levels in NK cells 
Flow cytometry was performed on a subset of 3 treatment-naïve patients (for which 
samples were available) and 3 matched controls collected at the host site to assess total PLC2 
and SHIP1 levels. Samples (2 x 105 cells per sample) were stained with surface marker 
antibodies and fixed with BD Cytofix/Cytoperm buffer (BD Biosciences, San Jose, CA). 
Samples were stained with CD16 (3G8) V500, CD3 (UCHT1) PerCP-Cy5.5, CD19 (SJ25C1) 
BV786, total PLC2 (K86-1161) PE (BD Biosciences, San Jose, CA) as well as  CD56 Pac Blue 
(NCAM1), CD45RA (HI100) PE-Cy7, and SHIP1 (P1C1-A5) AF647 (Biolegend, San Diego, 
CA).  Flow cytometry was performed on a 12-color LRSFortessa X-20 Flow Cytometer (BD) 
and analyzed with FlowJo (FlowJo, Ashland, OR).  NK cells were gated as CD56+ CD3- 
lymphocytes and analyzed for differences in PLC2 and SHIP1 between patient and control 
samples.    
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Analysis of NK cell calcium flux via flow cytometry 
To assess if differences in NK cell PLC2 phosphorylation led to functional alterations, 
flow cytometry-based calcium flux assays were performed on two treatment-naïve patients and a 
control sample.  NK cells were enriched using an EasySep Human NK Cell Isolation Kit (>86% 
purity), then loaded with Indo-1 dye (Invitrogen), and labelled with mouse IgG antibodies 
against the NK cell receptors 2B4 (clone C1.7, Biolegend) and NKG2D (clone 1D11, BD). 
Kinetic measurements of calcium flux were obtained using a BD LRSFortessa X-20 Flow 
Cytometer at baseline and then upon antibody crosslinking using anti-mouse IgG. 
Statistics 
An alpha value of 0.05 was set to determine significance, incorporating multiple 
hypothesis correction as appropriate. Error bars in figures represent the mean plus or minus the 
standard error of the mean. Differences in immune cell proportions were assessed by one-way 
ANOVA with Bonferroni’s correction for multiple comparisons. Signaling differences in 
canonically gated cell types were confirmed with two-tailed Welch’s t-tests with a Bonferroni 
adjustment to account for testing 897 hypotheses (3 time points with 299 signals in different cell 
types per each time point). Differences in PLC2, Itk/Btk, Syk/ZAP70, and MAPKAPK2 
signaling time courses between treatment-naïve patients and controls were compared using a 
two-tailed Welch’s t-test with Benjamini-Hochberg multiple hypothesis correction (n=3 time 
points*4 signaling molecules=12 hypotheses).  Differences in NK cell activation and 
proliferation (assessed by CD69 and Ki-67, respectively) between treatment-naïve patients and 
controls were assessed using two-tailed student’s t-tests with Benjamini-Hochberg multiple 
hypothesis correction.  PLC2 flow cytometry panel data were analyzed using two-tailed 
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student’s t-tests with Benjamini-Hochberg multiple hypothesis correction to account for testing 2 
hypotheses. 
Study Approval 
The study was approved by the institutional review boards at Washington University 
School of Medicine, St Louis (IRB ID# 201109216) and at Ann and Robert H. Lurie Children’s 
Hospital of Chicago (IRB ID# 2008-13457 and 2001-11715).    
 
  




 Samples from 17 treatment-naïve JDM patients, 11 of these 17 JDM patients after 
achieving clinical inactive disease, and 17 healthy controls were analyzed (Table 1). The mean 
age of the patients and controls in the cohort were 7.4 years and 9.3 years, respectively, with 
similar sex distributions (76% and 70.6% females in patients and controls, respectively).  82% of 
the patients were Caucasian (compared with 70.6 % of the controls).  The median duration of 
untreated disease (DUD) in the patients was 3.6 months (average 5.6 months with a standard 
deviation of 5 months). 
Cell percentages 
 Mass cytometry was used to quantify the distribution of 23 distinct leukocyte subsets in 
samples from treatment-naïve JDM patients, healthy controls, and a subset of the JDM patients 
after achieving clinical inactive disease. Samples were gated on live immune cell singlets and 
then into 23 distinct immune cell types, based on distribution of surface markers (Figure S1). NK 
cells were present at a lower frequency while the percentages of naïve B cells and naïve CD4 T 
cells were higher in treatment-naïve JDM patients than in controls (Figure 1A).  Frequency of 
PBMC subsets was also examined between in 11 paired treatment-naïve and clinical inactive 
disease JDM patient samples. Naïve B cell frequency normalized in paired samples with 
cessation of active disease (Figure 1B). While there was a trend toward increased NK cell 
percentage with cessation of active disease in paired samples, the difference was not statistically 
significant after multiple hypothesis correction (Figure 1B; t=2.37, df=10, p=0.039).  
Signaling phenotype 
 Differences in signaling between treatment-naïve JDM patients and controls (or patients 
with clinical inactive disease) were also examined. To simultaneously gain insights about 
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multiple signaling pathways, samples were stimulated concurrently with IL-2, IL-12, LPS, and 
IFN-⍺4 as well as IgM, CD3, and CD16 crosslinking for 0, 3, or 15 minutes and then subjected 
to mass cytometry to quantify phosphorylation of a panel of 14 intracellular signaling molecules 
(Table S1).  As 292 stratifying (i.e., distinguishing) features were detected when Significance 
Analysis of Microarrays (SAM) was used to compare JDM patients and controls (data not 
shown), a method incorporating feature selection was necessary to aid in interpreting the results. 
Feature selection techniques (such as LASSO - least absolute shrinkage and selection operator) 
enhance generalization by reducing overfitting and removing redundant or irrelevant features 
(e.g., features that are redundant in the presence of another correlated feature (28)).  Citrus 
(cluster identification, characterization, and regression), a technique that combines unsupervised 
hierarchical clustering with a regularized supervised learning algorithm to predict the class of the 
samples (e.g., patients vs. controls) from the features of a data set (e.g., phosphorylation of a 
signaling molecule in an immune subset/cluster), with LASSO regression was used to determine 
which features were stratifying between treatment-naïve JDM patients and controls (29). This 
approach identified NK cell subsets as stratifying for each stimulation time point as well as 
unstimulated classical monocytes and T cells (Figure 2A).  The 12 stratifying features identified 
by Citrus (unstimulated as well as 3 and 15 minute stimulated p-PLC2 in NK cells, 
unstimulated p-STAT3 in a NK cells, unstimulated classical monocyte subset p-PLC2, 
unstimulated as well as 3 and 15 minute stimulated p-PLC2 in CD4 and CD8 T cell subsets, 
and 3 minute stimulated non-classical monocytes p-STAT3) were sufficient to completely 
segregate treatment-naïve JDM patient from control samples by hierarchical clustering (Figure 
2B).  
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A partial least-squares discriminant analysis (PLS-DA) model was constructed from the 
selected features to visualize the stratifying signaling features in relation to classification as 
patient or control (Figure 2C, D). PLS-DA was used to decompose matrices of signaling data and 
disease state into scores and loadings matrices, with the hypothesis that the classification of a 
sample as a treatment-naïve patient or control is dependent upon the signaling profile of the 
sample. The scores plot describes the relationship of the samples to one another (Figure 2C), and 
the loadings plot describes the relationships of the variables (signaling protein phosphorylation in 
specific immune cell clusters) to one another (Figure 2D). The PLS-DA model was able to 
completely distinguish patients and controls (Figure 2C). Furthermore, the loadings plot 
demonstrated that treatment-naïve JDM patient samples were associated with lower levels of NK 
cell p-PLC2 for all stimulation time points (and unstimulated classical monocyte p-PLC2) in 
comparison to control samples, while p-PLC2 in stratifying T cell and p-STAT3 in NK cell and 
non-classical monocyte clusters were higher in JDM treatment-naïve patient samples than 
controls (Figure 2D). 
 Given that many of the detected stratifying differences were in NK cells (5 of 12 Citrus 
features) and PLC2 (10 of 12 Citrus features), we confirmed the significance of NK cell PLC2 
phosphorylation using two-tailed Welch’s t-tests with stringent Bonferroni correction to account 
for 897 comparisons (299 features examined across for each of the three time points).  This 
statistical test specified that the 3 most significant features (phosphoprotein in a specific immune 
cell subset) were NK cell p-PLC2 at 0, 3, and 15 minutes (Table S2) and that 7 of the 9 features 
involved p-PLC2 and one involved p-MAPKAPK2, a downstream kinase in the PLC2 
signaling cascade (Table S2), clearly highlighting the importance of dysregulated NK cell p-
PLC2 in JDM.  Therefore, subsequent studies focused on NK cell PLC2 signaling.  
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NK cell PLC2 signaling cascade  
The NK cell signaling time course was examined for phosphorylation of PLC2 as well 
as of 2 kinases upstream of PLC2 (spleen tyrosine kinase (Syk)/zeta-chain-associated protein 
kinase 70 (ZAP70), interleukin-2-inducible T-cell kinase (Itk)/ Bruton’s tyrosine kinase (Btk)) 
and a downstream kinase (MAPKAPK2) in the PLC2 signaling cascade. NK cell PLC2 
phosphorylation was lower in treatment-naïve JDM patients than controls for all time points 
(Figure 3A, manually gated on NK cells). Interestingly, available samples for a subset of (n=11) 
of these JDM patients while in clinical inactive disease (note that 5 of the 11 patients in clinical 
inactive disease were on medications) displayed an intermediate time course between treatment-
naïve JDM patients and controls (Figure S3A), suggesting that the observed phosphorylation 
differences are not likely due to germline mutations in PLC2. No differences were observed in 
the phosphorylation of upstream signaling molecules Syk/ZAP70 or Itk/Btk in NK cells between 
treatment-naïve JDM patients and controls (Figure 3B,C). Phosphorylation of the downstream 
kinase MAPKAPK2 was lower in treatment-naïve JDM patients, similar to what was seen with 
p-PLC2 (Figure 3D).  
 Given that differences were detected in NK cell PLC2 phosphorylation kinetics, we 
examined several potential mechanisms for this hypophosphorylation. Flow cytometry was 
performed with available remaining samples from three treatment-naïve JDM patients and 
controls to assess NK cell levels of PLC2 protein as well as total phosphatidylinositol-3,4,5-
trisphosphate 5-phosphatase 1 (SHIP1) protein, an inhibitory molecule in the PLC2 signaling 
cascade (Figure 4). No significant difference was detected in total protein levels of PLC2 
(Figure 4A) suggesting that PLC2 hypophosphorylation in JDM patient NK cells was not 
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simply due to lower PLC2 expression levels. Unexpectedly, SHIP1 protein levels were lower in 
treatment-naïve JDM patients than in controls (Figure 4B).   
 PLC2 is a key signaling component downstream of many NK cell receptors, including 
CD16, 2B4, and NKG2D.  CD16 cross-linking in our stimulation cocktail was upstream of the 
observed phosphorylation of PLC2 in NK cells; therefore, it was of interest to determine if 
CD16 receptor expression levels differed between treatment-naïve patients and controls.  CD16 
expression was indeed significantly lower in treatment-naïve JDM patients in comparison to 
controls (Figure 4C). Given the observed variation in treatment-naïve patient NK cell CD16 
expression, p-PLC2 integrated over time (i.e., area under the p-PLC2 signal-versus-time plot,  
a metric that captures the duration and magnitude of p-PLC2 signaling (30)) was plotted versus 
CD16 expression levels (arcsinh MFI of CD16),  demonstrating a significantly positive 
correlation with the p-PLC2 integrated time course in treatment-naïve patients but not healthy 
controls or patients in clinical inactive disease (Figure 4D, S4). Patients in clinical inactive 
disease displayed an intermediate slope between treatment-naïve patients and controls. The 
positive correlation of CD16 expression levels with PLC2 signaling over time in treatment-
naïve patient NK cells could suggest that lower p-PLC2 signaling was due to decreased CD16 
receptor expression levels; however, the normal phosphorylation of the two upstream kinases 
(Syk/Zap70 and ITK/BTK) that lie between CD16 and PLC2 suggests that the lower CD16 
levels are correlative but not causative.  
Impact of lower NK cell p-PLC2 
As an assessment of the functional consequences of lower p-PLC2 levels, calcium flux 
was evaluated by flow cytometry in enriched NK cells from available samples from two 
treatment-naïve JDM patients and one healthy control. The treatment-naïve JDM patients 
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displayed suppressed calcium flux following 2B4 and NKG2D receptor crosslinking in 
comparison to the healthy control (Figure 5A).  Expression levels of 2B4 and NKG2D did not 
differ between the treatment-naïve JDM patients and control (Figure 5B,C), verifying that the 
diminished calcium flux was not due to decreased NK cell activating receptor levels.  The 
reduced calcium flux demonstrated that the hypophosphorylation of PLC2 has functional 
consequences and strongly suggests that NK cell granule movement and cytotoxicity would be 
impaired in the treatment-naïve JDM patients. 
Finally, median signaling intensities of CD69 and Ki-67 (normalized to the run control by 
the arcsinh ratio) were also evaluated in samples as surrogates for cellular activation and 
proliferation. Treatment-naïve JDM patient NK cells were more activated than control cells, as 
assessed by median levels of normalized CD69 intensity (Figure S5A). Furthermore, treatment-
naïve JDM patient NK cells were actively proliferating more than control NK cells, as 
demonstrated by normalized median intensity of Ki-67 (Figure S5B). 
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Discussion 
Based on the hypothesis that cell signaling differences (particularly in innate leukocytes) 
may contribute to early disease in JDM, this study was designed to delineate signaling 
differences in peripheral immune cell subsets between treatment-naïve JDM patients and 
controls using the high-dimensional capabilities of mass cytometry coupled with phospho-
specific antibodies. Many differences were detected; however, using several different analysis 
approaches (including Citrus with LASSO feature selection), signaling differences that were 
sufficient to differentiate between JDM patients and controls were found to primarily involve the 
phosphorylation of PLC2 in NK cells as well as in classical monocytes, CD4 T cells, and CD8 
T cells.  Given (i) the prominence of the decreased NK cell p-PLC2 in the identified stratifying 
features (4 of 12) in the Citrus analysis and (ii) the fact that NK cell PLC2 phosphorylation 
comprised the top 3 out of 9 significant differences identified in 897 features using two-tailed 
Welch’s t-tests with stringent Bonferroni correction, hypophosphorylation of  PLC2 in NK cells 
appears to be the most important signaling difference distinguishing treatment-naïve JDM 
patients compared to controls.  Dysregulation of PLC2 in JDM has not been previously 
reported.  
NK cell percentages in the blood were decreased in treatment-naïve JDM patients in 
comparison to controls with a trend to normalization with the cessation of active disease.  
Previous work suggested that NK cells may be enriched in affected muscles of JDM patients 
with short disease duration at diagnosis in comparison to patients with longer disease duration 
(15), raising the possibility that NK cells may migrate from the blood to affected muscles early 
in the JDM disease course.  Despite the paucity of NK cells in the peripheral blood, NK cells 
from treatment-naïve JDM patients were more highly activated and proliferating to a greater 
extent than NK cells from healthy controls, as assessed by CD69 and Ki-67, respectively. 
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Interestingly, decreased NK cell frequencies observed in treatment-naïve JDM patients 
correlated with lower levels of PLC2 phosphorylation (Figure S4).  In contrast, NK cell 
frequency was not correlated with PLC2 phosphorylation in JDM patients in clinical inactive 
disease or in healthy controls  (Figure S4). 
Treatment-naïve JDM patient NK cells exhibited lower levels of PLC2 phosphorylation 
than healthy controls over all stimulation timepoints.  Phosphorylation of the upstream kinases 
Syk/ZAP70 and Itk/Btk in the PLC2 signaling cascade was not different between JDM patients 
and controls, suggesting that PLC2 hypophosphorylation is due to other factors (e.g., inhibitory 
molecules), although the dynamic range of Syk/ZAP70 and Itk/Btk signaling necessary for 
normal phosphorylation of PLC2 is not well established.  Minimal differences were seen in 
PLC2 phosphorylation based on the presence of myositis-specific antibodies (Figure S3).  
Interestingly, the 3 patients with no myositis-specific antibodies had the lowest levels of p-
PLC2, although we did not have enough statistical power to detect a significant difference.   
PLC2 hypophosphorylation after receptor crosslinking resulted in substantially 
suppressed calcium flux in treatment-naïve patients compared to controls.  Crosslinking of 2B4 
and NKG2D receptors leads to synergistic, selective PLC2 phosphorylation and calcium 
mobilization (31).  No differences were observed in expression levels of 2B4 and NKG2D 
receptors between treatment-naïve JDM patients and controls.  PLC2 phosphorylation results in 
a conformational change in PLC2, facilitating the hydrolysis of the membrane phospholipid 
phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol triphosphate (IP3) and diacylglycerol 
(DAG).  IP3 subsequently binds to its receptor on the endoplasmic reticulum and releases 
cellular stores of calcium.  Decreased calcium flux is associated with altered cytotoxic granule 
movement and localization to the immune synapse resulting in poor NK cell-mediated killing 
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(32).  Therefore, the PLC2 hypophosphorylation and decreased calcium flux observed in the 
JDM patients suggests that NK cells from treatment-naïve JDM patients would have decreased 
NK cell cytotoxicity.  This is supported by prior observations of decreased NK cell cytotoxicity 
in small cohort of five JDM patients (24) and a second small study with five untreated patients 
with dermatomyositis (2 of whom were adolescents with JDM) who were found to have low NK 
cell cytotoxicity compared to controls (33). 
After our analysis was completed, we determined that patient 7 had been consented 
during his initial hospitalization but his study blood sample was not drawn until his first clinic 
visit 5 weeks later.  He was inadvertently included in our analysis as a treatment-naïve patient 
despite having received methylprednisolone (2 mg/kg IV for 3 days) followed by oral 
prednisolone (0.8 mg/kg titrated down to 0.4 mg/kg over 5 weeks) and subcutaneous 
methotrexate (12 mg/m2/wk).   Surprisingly, his PLC2 phosphorylation at all three timepoints 
was not substantially different than the 16 treatment-naïve patients (Figure S6A) and looked very 
similar to the other eight other p155/140 antibody-positive JDM patients (Figure S3B).  In 
contrast, for reasons that are not yet clear, his p-MAPKAPK2 had normalized.  This finding will 
be investigated in future studies and may provide insight into JDM response to therapy.  To 
assess whether the inclusion of patient 7 in the treatment-naïve cohort had skewed our results, we 
repeated individual two-tailed Welch’s t-tests with Bonferroni correction (accounting for 897 
comparisons between the two groups) without patient 7.  This stringent statistical test identified 
that 3 of the top 4 most significant features (phosphoprotein in a specific immune cell subset) 
between the JDM and control groups were NK cell p-PLC2 at 0, 3, and 15 minutes and that 7 of 
the 8 features that were significantly different between the groups involved p-PLC2 (including 
all three timepoints in non-classical monocytes) with the other significant feature involving p-
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MAPKAPK2 in non-classical monocytes (data not shown) - nearly identical to our findings in 
the initial cohort (which included patient 7; Table S2).  Therefore, the inclusion of this new-onset 
patient (who had started therapy) did not substantially alter our results, and his results suggest 
that early therapy with corticosteroids and methotrexate is insufficient to attenuate the 
dysregulated NK cell p-PLC2 seen in treatment-naive JDM.    
Interestingly, several of the immune cell percentages or signaling differences in JDM 
patients (e.g., NK cell percentages in JDM patients) were partially attenuated with cessation of 
active disease.  Indeed, PLC2 and downstream MAPKAPK2 phosphorylation were largely 
normalized in NK cells patients in clinical inactive disease in comparison to those from 
treatment-naïve patients. For 7 of 11 paired treatment-naïve and clinical inactive disease patient 
samples, CD16 receptor expression levels also increased with the cessation of active disease 
(Figure 4E). The attenuation of NK cell defects in patients in clinical inactive disease strongly 
suggests that the PLC2 hypophosphorylation is not due to mutations in PLC2. 
The mechanism(s) underlying the NK cell PLC2 hypophosphorylation in treatment-
naïve JDM patients is not yet clear. No differences were detected in total PLC2 protein level (in 
a small subset of available patient samples).  SHIP1, a negative regulator of p- PLC2, was also 
assessed, and SHIP1 levels were actually lower in NK cells from treatment-naïve JDM patients 
compared to controls, which would not explain the the hypophosphorylation of PLC2 in NK 
cells observed in these patients. CD16 expression was lower in JDM patients, but this appears to 
be correlative rather than causative, since signaling through other NK cell receptors (2B4 and 
NKG2D) manifested with decreased calcium flux.  Future work will leverage RNA-Seq on 
sorted NK cells (from treatment-naïve JDM patients and controls) to further delineate potential 
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inhibitors and other PLC2 signaling cascade components that contribute to differences in NK 
cell PLC2 in the early, active JDM environment.  
PLC2 phosphorylation was also lower in treatment-naïve JDM unstimulated classical 
monocytes.  Macrophage colony-stimulating factor-induced monocyte differentiation is mediated 
through PLC2 phosphorylation (34, 35).  However, we did not observe perturbations in the 
percentage of circulating monocytes in treatment-naïve JDM patients compared to controls, and 
future work will evaluate monocyte function to determine if hypophosphorylation of PLC2 in 
classical monocytes has functional significance in these patients. 
While new insights into NK cell PLC2 signaling defects in JDM were gained in this 
study, there were several limitations in this work, including the size of the treatment-naïve 
patient cohort and the number of available PBMCs. The study included 17 treatment-naïve 
patient samples from two medical centers and highlights the need for increased collaboration 
among pediatric centers to obtain enough patients to study new-onset, treatment-naïve JDM 
patients in a statistically meaningful way.  To maximize insights from small volume patient 
samples, the mass cytometry samples were stimulated with a combination of different stimuli at 
three timepoints.  However, the limited patient samples coupled with a paucity of NK cells in 
many of the JDM samples restricted the potential follow-up experiments to assess the functional 
impact of hypophosphorylation of NK cells PLC2.  
A better understanding of the etiology of JDM may inform new targeted therapeutic 
interventions (e.g., small molecules or biologics that target specific signaling pathways).  This 
study highlighted the utility of mass cytometry coupled with multiparameter phospho-specific 
antibodies in identifying differences in signaling phenotype in small biological samples from 
treatment-naïve JDM patients and controls.  Treatment-naïve JDM patient NK cells hypo-
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phosphorylated PLC2 which resulted in decreased calcium flux, providing a mechanistic 
explanation for previous reports of poor NK cell killing in JDM patients.  Future studies will 
focus on mechanisms underlying the NK cell PLC2 signaling defects in new-onset, treatment-
naïve JDM patients and on potential strategies to mitigate this signaling defect. 
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Figures
Figure 1. PBMC percentages in JDM patients and healthy controls. Open circles denote 
treatment-naïve patients (n=17). Filled squares denote healthy controls (n=17). X’s in Figure 1B 
denote patients after achieving clinical inactive disease (n=11). A) Percentage of PBMC 
population in treatment-naïve patients and controls for higher (left panel) and lower frequency 
(right panel) immune cell types (1-way ANOVA: F=7.429; p<0.001; naïve B cells: t=7.459, 
p<0.05; naïve CD4 T cells: t=6.561, p<0.05; NK cells: t=4.415, p<0.05). B) Percentage of 
PBMC populations in paired treatment-naïve and clinical inactive disease patient samples for 
higher frequency (left panel) and lower (right panel) frequency immune cell types (ANOVA: 
F=36.15; p<0.005; naïve B cells: t= 6.986, p<0.05, n=11 paired patient samples). 
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Figure 2. Signaling molecules in several immune cell subsets were stratifying between treatment-
naïve JDM patients and healthy controls for unstimulated as well as three and fifteen minute 
stimulated samples, as indentified by Citrus (n=17 treatment-naïve patients, n=17 matched 
controls in all subpanels in figure 2). A) Heat map of arcsinh median intensity for surface 
markers used for Citrus clustering for stratifying clusters detected by Citrus at all time points 
(cluster numbers are denoted on right side of the figure). B) Heat map of arcsinh transformed 
median signaling molecule intensity of stratifying signaling molecules in the respective clusters 
for all time points retained by LASSO feature selection with the minimum cross validation error 
as the threshold. Rows correspond to signaling features, and columns correspond to samples with 
red denoting treatment-naïve patients and black representing healthy controls. Abbreviations: 
classical monocytes (CM), CD4 T cells (CD4T), CD8 T cells (CD8T), non-classical monocytes 
(NCM). C) Partial least squares discriminant analysis (PLS-DA) scores plot for classification of 
treatment-naïve patients and controls developed using LASSO selected features from Citrus in B. 
Red points correspond to treatment-naïve patients and black to controls. D) PLS-DA loadings 
plot (depiction of relationship of variables to one another in dimensionally reduced variable 
space) for classification of treatment-naïve patients and controls developed using LASSO 
selected features from Citrus in panel B.   
  
     
92
Figure 3. Treatment-naïve JDM patient NK cells hypophosphorylate PLC2 and MAPKAPK2 
but not Syk/ZAP70 and Itk/Btk in comparison to controls over stimulation time course (tested 
with 2-way Welch’s t-tests with Benjamini-Hochberg multiple hypothesis correction for 12 
tests). Open circles denote treatment-naïve patients (n=17). Filled squares denote healthy 
controls (n=17).  Data are displayed as the arcsinh ratio of the median intensity of the sample 
normalized to the run control.  A) NK cell PLC2 (0 min p=6.88e-8, 3 min p=1.62e-6, 15 min 
p=1.47e-6) phosphorylation differs between treatment-naïve JDM patients and controls, B) NK 
cell Syk/ZAP70 and C) Itk/Btk phosphorylation are not different between treatment-naïve JDM 
patients and controls, D) MAPKAPK2 (0 min p=0.003, 3 min p=0.002, 15 min p=0.0008) 
phosphorylation differs over the time course between 17 treatment-naïve JDM patients and 17 
controls. 
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Figure 4. Evaulation of total PLC2, SHIP1, and CD16 levels.  Open circles denote treatment-
naïve patients. Filled squares denote healthy controls. X’s denote JDM patients after achieving 
clinical inactive disease. A) Total PLC2 protein levels determined with flow cytometry (n=3 
treatment-naïve patients, n=3 controls; two-way Welch’s t-test: t=1.662, df=4, p=0.1719), B) 
total SHIP protein levels determined with flow cytometry (n=3 treatment-naïve patients, n=3 
controls; two-way Welch’s t-test: t=3.701, df=4, p=0.0208), C) Arcsinh transform of CD16 in 
treatment-naïve JDM patient (open circles) and control (filled squares) NK cells assessed with 
mass cytometry (one-way Welch’s t-test: t=1.968, df=25, p=0.0301, n=17 patients and n=17 
controls), D) Correlation of integrated p-PLC2 time course versus arcsinh MFI CD16 for 
patients and controls (treatment-naïve patients: y=-2.78+0.80x, R=0.66, p=0.0039, n=17; patients 
with clinical inactive disease: y=-0.44+0.568x, R=0.38, p=0.254, n=11; controls: y=2.12+0.15x, 
R=0.17, p=0.51, n=17), E) Arcsinh transform of CD16 in treatment-naïve JDM patients (open 
circles) and paired JDM patients in clinical inactive disease (X’s) NK cells (one-way paired 
Welch’s t-test: t=1.343, df=10, p=0.209, n=11 treatment-naïve  patients and n=11 patients in 
clinical inactive disease). 
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Figure 5. Enriched NK cells from treatment-naïve JDM patients exhibit decreased Ca2+ flux 
compared to NK cells from healthy controls upon stimulation by 2B4 and NKG2D receptor 
cross-linking . A) Calcium flux in treatment-naïve patient and control NK cells (n=2 treatment-
naïve patients, n=1 matched control).   B & C) The cell surface expression of 2B4 (B) and 
NKG2D (C) was similar on the treatment-naïve JDM patients and controls. 
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Tables 
Table 1. Patient demographics. Research site 1 denotes St. Louis Children’s Hospital, and 
research site 2 denotes Lurie Children’s Hospital. Medication abbreviations: myositis specific 
autoantibody (MSA), myositis associated autoantibody (MAA), duration of untreated disease 
(DUD), anti-SUMO activating enzyme (SAE), oral prednisone (PO), methotrexate (MTX), IV 
gammaglobulin (IVIG), plaquenil (PLQ), cyclosporine (CSA), mycophenolate mofetil (MMF). 
Abbreviations for race: Caucasian (W), African-American (B), Hispanic (H), and Asian (A).  If 
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Supplemental Figures 
Figure S1. Gating schemes for A) live singlet lymphocytes and B) immune cell subsets. 
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Figure S2. Citrus error plots for LASSO classification models between treatment naïve JDM 
patients and controls for A) unstimulated samples, B) 3 minute stimulated samples, and C) 15 
minute stimulated samples. 
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Figure S3. Assessment of p-PLC2 and p-MAPKAPK2 in JDM patients with clinical inactive 
disease and in relationship to MSA autoantibody status. Data are displayed as the arcsinh ratio of 
the median intensity of the sample normalized to the run control. A) PLC2 phsophorylation 
time course in NK cells from JDM treatment-naïve patients (n=17), JDM patients with clinical 
inactive disease (n=11), and healthy controls (n=17). PLC2 phosphorylaton in NK cells from 
JDM patients with clinical inactive disease is intermediate between that observed in NK cells 
from JDM treatment-naïve patients and controls. B), MAPKAPK2 phosphorylation time course 
in NK cells for treatment-naïve patients (n=17), patients with clinical inactive disease (n=11), 
and controls (n=17). MAPKAPK2 phsophorylation in NK cells from from JDM patients with 
clinical inactive disease is intermediate between that observed in NK cells from JDM treatment-
naïve patients and controls, C) PLC2 phosphorylation in NK cells from treatment-naïve JDM 
patients (n=17) is compared with two subsets of treatment-naïve JDM patients with p155/140 
autoantibodies (n=9) or no MAS antibodies (n=3).   
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Figure S4. NK cell frequency correlates with PLC2 phosphorylation intensity in treatment-
naïve JDM patient NK cells. Correlation of integrated p- PLC2 time course versus NK cell 
percentage for JDM patients and controls (treatment naïve patients: y=-2.39+0.42x, R=0.55, 
p=0.0235, n=17; clinical inactive disease patients: y=1.05-0.039x, R=-0.051, p=0.88, n=11; 
controls: y=2.12+0.059x, R=0.35, p=0.167, n=17). 
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Figure S5. Treatment-naïve JDM patient and control NK cells differ in activation and 
proliferation, as assessed by CD69 and Ki67 expression levels. Data are displayed as the arcsinh 
ratio of the median intensity of the sample normalized to the run control. A) Signal intensity of 
CD69 in treatment naïve JDM patient (n=17) and control (n=17) NK cells (t=3.327, df=32, 
p=0.0022), B) Signal intensity of Ki-67 in treatment naïve JDM patient (n=17) and control 
(n=17) NK cells (t=5.463, df=32, p<0.0001). 
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Figure S6. NK cell phosphorylation time courses with patient 7 mapped separately from n=16 
other treatment-naïve patients and n=17 matched controls. Data are displayed as the arcsinh ratio 
of the median intensity of the sample to the run control. A) NK cells PLC2 phosphorylation, B) 
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Supplemental Tables 






CD45 089Y HI30 
CCR6 141Pr G034E3 
CD19 142Nd  HIB19 
CD45RA 143Nd HI100 
p-PLC2 144Nd K86-689.37 
CD4 145Nd RPA-T4 
IgD 146Nd IA6-2 
CD11c 147Sm Bu15 
CD14 148Nd RMO52 
CD127 149Sm A019D5 
p-STAT5 150Nd 47 
CD123 151Eu 6H6 
p-AKT 152Sm D9E 
p-STAT1 153Eu 58D6 
p-Itk/Btk 154Sm 24a/BTK  
CD27 155Gd L128 
CXCR3 156Gd G025H7 
p-STAT3 158Gd 4/P-Stat3 
p-MAPKAPK2 159Tb 27B7 
CD69 160Gd FN50 
Ki-67 161Dy B56 
p-LCK 162Dy  4/LCK-Y505 
p-JAK21 163Dy D4A8 
IkBa 164Dy L35A5 
CD45RO 165Ho UCHL1 
p-NFKB 166Er  K10-95.12.50 
p-ERK 167Er D13.14.4E 
CD8 168Er SK1 
CD25 169Tm 2A3 
CD3 170Er UCHT1 
p-Syk/ZAP70 171Yb 17a 
IgM 172Yb MHM-88 
HLA-DR 173Yb L243 
p-STAT4 174Yb 38/p-Stat4 
PD-1 175Lu EH12.2H7 
CD56 176Yb NCAM16.2 
CD16 209Bi 3G8 
 
1 p-JAK2 was not included in some specimens due to issues with reagent availability
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Table S2. Significant p-values using 2 tailed Welch’s t-test and MHC. *Denotes significant by 
Bonferroni correction (5adj=0.05/897). All others are significant by Benjamini-Hochberg FDR 
multiple hypothesis correction. 
name tval pval FDRthresh 
NK cells p-PLC2 unst* -7.852986436 2.42584E-08 5.57414E-05 
NK cells p-PLC2 15 min* -7.498464205 1.50352E-07 0.000111483 
NK cells p-PLC2 3 min* -7.260336613 1.81878E-07 0.000167224 
Non-classical monocytes p-PLC2 unst* -6.475463858 3.28929E-07 0.000222965 
Non-classical monocytes p-PLC2 3 min* -5.907332717 1.76436E-06 0.000278707 
mDCs p-PLC2 unst* -5.534029597 4.55974E-06 0.000334448 
Non-classical monocytes pMAPKAPK2 15 min* -5.093395629 1.55108E-05 0.00039019 
Non-classical monocytes p-PLC2 15 min* -4.931659373 2.50224E-05 0.000445931 
Classical monocytes p-ERK 15 min* -4.771229485 3.86315E-05 0.000501672 
Naive B cells p-STAT3 unst -4.581093204 0.000114761 0.000557414 
Non-classical monocytes p-NFkB 15 min -4.402050767 0.000115162 0.000613155 
Unswitched memory B cells p-PLC2 15 min -4.60841832 0.000134452 0.000668896 
Naive B cells p-AKT 15 min -4.324920957 0.000140748 0.000724638 
Naive B cells p- PLC2 unst -4.465519349 0.000155212 0.000780379 
Classical monocytes p-NFkB 15 min -4.385934405 0.000182175 0.00083612 
Naive B cells p-AKT 3 min -4.18625037 0.000216521 0.000891862 
Non-classical monocytes p-AKT 15 min -4.319755417 0.000216603 0.000947603 
Classical monocytes p- PLC2 3 min -4.175200378 0.000216783 0.001003344 
Naive B cells p-AKT unst -4.165542806 0.00022982 0.001059086 
Classical monocytes IkBa unst -4.216688736 0.000242932 0.001114827 
NK cells pMAPKAPK2 15 min -4.432499128 0.000246073 0.001170569 
Classical monocytes p-AKT 15 min -4.221088834 0.000261133 0.00122631 
Classical monocytes IkBa 3 min -4.128551449 0.000291522 0.001282051 
Classical monocytes p- PLC2 unst -4.051880176 0.00030337 0.001337793 
Classical monocytes p-AKT 3 min -4.017485092 0.000401034 0.001393534 
Classical monocytes p-ZAP70/SYK unst -4.052172809 0.000413522 0.001449275 
Class-switched memory B cells p-STAT3 unst -4.021879424 0.000429642 0.001505017 
NK cells pMAPKAPK2 3 min -4.177410213 0.000446839 0.001560758 
Classical monocytes p-STAT5 3 min -3.91696179 0.000463162 0.001616499 
IgM memory B cells p- PLC2 unst -4.081576067 0.000497738 0.001672241 
CD8 CM T cells p-AKT 15 min -3.898795411 0.000532513 0.001727982 
mDCs p-AKT 15 min -4.00689282 0.000553302 0.001783724 
Classical monocytes p-STAT5 unst -3.869090839 0.000581397 0.001839465 
pDCs p-PLC2 15 min -4.033481198 0.000608125 0.001895206 
IgM memory B cells p-PLC2 15 min -4.031382903 0.000643085 0.001950948 
CD8 CM T cells p-AKT 3 min -3.848868811 0.000664293 0.002006689 
mDCs p-PLC2 15 min -3.727960689 0.00075426 0.00206243 
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Non-classical monocytes p-AKT 3 min -3.790249617 0.00077987 0.002118172 
Non-classical monocytes p-STAT1 3 min -3.713451586 0.000806289 0.002173913 
Non-classical monocytes pMAPKAPK2 3 min -3.772895964 0.000843054 0.002229654 
Non-classical monocytes p-ERK 15 min -3.693105014 0.000893942 0.002285396 
NK cells pMAPKAPK2 unst -3.824242602 0.000897015 0.002341137 
Classical monocytes p-AKT unst -3.725288925 0.00094697 0.002396878 
IgM memory B cells p-PLC2 3 min -3.859116855 0.001001104 0.00245262 
pDCs p-PLC2 unst -3.751242004 0.001023663 0.002508361 
mDCs p-PLC2 3 min -3.570848826 0.001149672 0.002564103 
Naive B cells p-PLC2 3 min -3.642749714 0.001229433 0.002619844 
Naive CD8 T cells p-ERK 15 min -3.675820485 0.001271397 0.002675585 
mDCs p-AKT unst -3.654776711 0.00128198 0.002731327 
Unswitched memory B cells p-PLC2 unst -3.743624532 0.00129909 0.002787068 
CD8 EM T cells IkBa unst -3.633263879 0.001311013 0.002842809 
CD8 CM T cells p-AKT unst -3.594127595 0.001362115 0.002898551 
Non-classical monocytes pMAPKAPK2 unst -3.657639336 0.001391583 0.002954292 
Non-classical monocytes p-ZAP70/SYK 3 min -3.573470136 0.001414836 0.003010033 
CD8 CM T cells p-NFkB 3 min -3.603965427 0.001436343 0.003065775 
Class-switched memory B cells p-AKT unst -3.508707981 0.001445751 0.003121516 
Class-switched memory B cells p-AKT 3 min -3.476047577 0.00148754 0.003177258 
CD8 TEMRA p-AKT 15 min -3.503207678 0.001498708 0.003232999 
Classical monocytes p-NFkB unst -3.55602452 0.001503956 0.00328874 
Non-classical monocytes p-NFkB unst -3.600974645 0.001597665 0.003344482 
Classical monocytes p-NFkB 3 min -3.534940025 0.001623767 0.003400223 
NK cells p-AKT 15 min -3.522490015 0.001749898 0.003455964 
Naive B cells p-PLC2 15 min -3.463834188 0.001795491 0.003511706 
Class-switched memory B cells p-PLC2 unst -3.622862181 0.001817119 0.003567447 
Non-classical monocytes p-NFkB 3 min -3.430234587 0.001982258 0.003623188 
TH17/22 p-PLC2 3 min -3.380269726 0.002049574 0.00367893 
Naive CD8 T cells p-AKT 15 min -3.388441856 0.002100108 0.003734671 
Classical monocytes pMAPKAPK2 15 min -3.343633827 0.00219741 0.003790412 
TFH p-AKT unst -3.3742471 0.002297207 0.003846154 
Naive CD8 T cells p-ERK 3 min -3.374354435 0.002386375 0.003901895 
mDCs p-AKT 3 min -3.398881571 0.002403988 0.003957637 
NK cells p-AKT 3 min -3.387935699 0.002427461 0.004013378 
Class-switched memory B cells p-AKT 15 min -3.288670837 0.002478457 0.004069119 
CD4 CM p-AKT 3 min -3.336454037 0.002524976 0.004124861 
CD8 EM T cells IkBa 3 min -3.316517198 0.002576971 0.004180602 
mDCs p-STAT5 unst -3.283645486 0.002616175 0.004236343 
NK cells p-STAT3 unst 3.332834793 0.002716647 0.004292085 
CD4 EM p-PLC2 3 min -3.279326492 0.002748886 0.004347826 
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CD4 CM p-AKT unst -3.291346836 0.002836356 0.004403567 
IgM memory B cells p-AKT unst -3.231259371 0.002856454 0.004459309 
Naive CD8 T cells p-ERK unst -3.332624156 0.002857043 0.00451505 
Unswitched memory B cells p-PLC2 3 min -3.348006256 0.00291983 0.004570792 
Naive CD8 T cells p-PLC2 unst -3.2931526 0.002921574 0.004626533 
pDCs p-PLC2 3 min -3.376797972 0.003049141 0.004682274 
IgM memory B cells p-AKT 3 min -3.204208034 0.003070744 0.004738016 
Class-switched memory B cells p-PLC2 15 min -3.395494296 0.003085244 0.004793757 
Naive CD8 T cells p-AKT 3 min -3.239428869 0.003107065 0.004849498 
pDCs p-NFkB unst -3.292382589 0.003177485 0.00490524 
CD8 CM T cells p-NFkB 15 min -3.221865275 0.003218725 0.004960981 
Unswitched memory B cells pMAPKAPK2 15 min -3.404283166 0.003294037 0.005016722 
Naive CD8 T cells p-PLC2 15 min -3.262248851 0.003343216 0.005072464 
Tregs p-AKT 3 min -3.199021407 0.003370795 0.005128205 
Class-switched memory B cells p-PLC2 3 min -3.342794512 0.003400203 0.005183946 
CD8 CM T cells p-NFkB unst -3.295327918 0.003463346 0.005239688 
IgM memory B cells p-ZAP70/SYK unst -3.155224622 0.003500603 0.005295429 
Naive CD8 T cells p-PLC2 3 min -3.244108017 0.003511206 0.005351171 
Naive CD4 T cells p-PLC2 3 min -3.257447901 0.003535796 0.005406912 
CD4 CM p-PLC2 3 min -3.191298426 0.00355494 0.005462653 
Naive CD8 T cells p-STAT4 3 min -3.16759611 0.003749432 0.005518395 
CD4 CM p-AKT 15 min -3.155078427 0.003778482 0.005574136 
Naive CD4 T cells p-AKT 3 min -3.173456488 0.003883861 0.005629877 
Naive CD8 T cells p-LCK 15 min -3.107778253 0.004005701 0.005685619 
IgM memory B cells p-AKT 15 min -3.104200254 0.004063048 0.00574136 
CD4 CM IkBa 3 min -3.179637231 0.004126611 0.005797101 
TH1 p-AKT 3 min -3.133980329 0.004170055 0.005852843 
CD4 TEMRA p-ZAP70/SYK 3 min -3.084840822 0.004209115 0.005908584 
CD8 CM T cells IkBa 3 min -3.172215067 0.004265661 0.005964326 
Class-switched memory B cells p-STAT3 15 min -3.079361952 0.004288836 0.006020067 
NK cells p-AKT unst -3.136855295 0.004559049 0.006075808 
CD4 TEMRA pMAPKAPK2 unst -3.066632579 0.004562753 0.00613155 
CD4 TEMRA p-ERK 3 min -3.050840446 0.00456971 0.006187291 
Naive CD8 T cells IkBa 3 min -3.161824418 0.004774268 0.006243032 
TFH p-AKT 15 min -3.063074407 0.004842181 0.006298774 
TH2 p-PLC2 3 min -3.083410753 0.004848321 0.006354515 
TFH p-AKT 3 min -3.076026225 0.004898365 0.006410256 
CD8 CM T cells IkBa unst -3.141189278 0.004912292 0.006465998 
Tregs p-AKT unst -3.041373313 0.005080226 0.006521739 
Non-classical monocytes p-STAT1 15 min -3.015180288 0.005368756 0.00657748 
Naive CD8 T cells p-AKT unst -3.015932582 0.005409759 0.006633222 
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CD8 TEMRA p-AKT 3 min -2.985277009 0.005494042 0.006688963 
CD4 EM p-AKT unst -3.056428529 0.005533822 0.006744705 
mDCs p-ERK 15 min -3.044660179 0.005613143 0.006800446 
TH1 p-AKT 15 min -3.000354694 0.005903431 0.006856187 
TH1 p-AKT unst -2.978988325 0.005996179 0.006911929 
CD8 CM T cells p-ERK 3 min -2.998182731 0.006206259 0.00696767 
CD8 EM T cells p-AKT 15 min -2.936492295 0.006240829 0.007023411 
Tregs p-AKT 15 min -2.958468378 0.006240873 0.007079153 
TH1 IkBa 3 min -3.02117059 0.00639121 0.007134894 
NK T cells p-ZAP70/SYK 15 min 3.024677793 0.006412514 0.007190635 
CD4 EM p-AKT 3 min -2.955508607 0.006447829 0.007246377 
IgM memory B cells p-STAT3 unst -2.910286202 0.006523654 0.007302118 
CD4 CM IkBa unst -2.99732679 0.006607945 0.00735786 
Naive CD4 T cells p-PLC2 15 min -2.948283458 0.006625331 0.007413601 
CD8 TEMRA IkBa 3 min -2.979820568 0.007080528 0.007469342 
Class-switched memory B cells p-STAT3 3 min -2.913304778 0.007088316 0.007525084 
Naive CD8 T cells p-STAT4 15 min -2.89216144 0.007203813 0.007580825 
Unswitched memory B cells p-AKT 3 min -2.868796619 0.007238945 0.007636566 
Naive CD8 T cells IkBa 15 min -2.973565525 0.007443768 0.007692308 
IgM memory B cells pMAPKAPK2 15 min -3.013202668 0.007472737 0.007748049 
TH2 p-AKT 3 min -2.904080312 0.007529999 0.00780379 
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Chapter 4: Examining mechanisms of NK cell PLC2 
hypophosphorylation in JDM  
Abstract 
Juvenile dermatomyositis (JDM) is a debilitating pediatric autoimmune disease 
manifesting with characteristic rash and muscle weakness. To determine defects in NK cell gene 
expression leading to aberrant NK cell PLC2 phosphorylation and other potential signaling 
defects in NK cells in JDM, NK cells, B cells, and T cells were sorted from PBMCs from 4 JDM 
patients and 4 controls, and RNA-Seq was performed with RNA isolated from each of these 
three cell types. Differences in a manually curated set of PLC2 cascade components and NK 
cell receptors that use PLC2 for signaling were analyzed on an individual gene level and total 
pathway level. Expression levels of LCK, MAPK1, SIGLEC7, and CD160, as well as the total 
manually curated NK cell PLCG2 pathway were lower in JDM patient NK cells than control NK 
cells. JDM patient NK cells, T cells, and B cells had IFN5 and IFN signatures. JDM patient NK 
cells had a transcriptional profile suggesting that they were more actively proliferating than 
control NK cells. JDM patient T cells had defective protein translation and localization in 
comparison to T cells from healthy controls. The defects in LCK and MAPK1 expression 
provide insight into potential mechanisms contributing to NK cell PLC2 hypophosphorylation 
in JDM. NK cell exposure to an abnormal cytokine milieu in JDM may contribute to NK cell 
functional defects. 
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Introduction 
 Juvenile dermatomyositis (JDM) is an inflammatory vasculopathy and myopathy 
resulting in inflammation of striated muscle, the gastrointestinal tract, and skin. The etiology of 
JDM is not well characterized, but both adaptive and innate immune responses have been 
associated with JDM pathogenesis. Using mass cytometry and flow cytometry, we have shown 
that JDM patient NK cells had lower levels of PLC2 phosphorylation and defects in calcium 
flux upon NKG2D and 2B4 crosslinking (Chapter 3; Under review). 
The etiology of JDM is not well understood, but it has been demonstrated that NK cells 
but not B cells hypophosphorylate PLC2 in JDM. This study employed RNA-Seq on sorted NK 
cells, B cells, and T cells from 4 JDM patients and 4 healthy controls to explore potential 
mechanisms in JDM NK cell hypophosphorylation. JDM NK cell gene expression patterns were 
compared and contrasted with those in B cells, which also utilize PLC2 but did not exhibit 
PLC2 phosphorylation defects in JDM in our initial mass cytometry study, as well as T cells, 
which primarily utilize PLC1 but demonstrated defects in PLC2 phosphorylation in prior mass 
cytometry experiments. Using RNA-Seq, we found that JDM patients had lower levels of LCK 
expression, which may contribute to PLC2 phosphorylation defects, and MAPK1, which is 
downstream of PLC2 in the signaling cascade. In addition, pathway analysis revealed that NK 
cells were more actively proliferating and all three cell types (NK cells, B cells, and T cells) and 
had enhanced IFN and IFN5 stimulated gene expression in JDM, suggesting that these 
cytokines may be modulating the immune response in JDM.  IFN signatures and lower LCK and 
MAPK1 expression levels appear to be associated with the PLC2 hypophosphorylation 
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Methods 
RNA-Seq data acquisition, quality control, and processing  
NK cell, T cell, and B cell gene expression was analyzed using RNA-Seq for a subset of 
4 JDM patients and 4 matched controls for which there were available samples remaining from 
the initial JDM study. Immune cells were stained with CD56 (NCAM-1) BV421, CD3 (UCHT1) 
PerCP-Cy5.5, CD14 (M5E2) APC-Fire750, and CD19 (SJ25C1) FITC (Biolegend, San Diego, 
CA) and sorted using a FACSAria sorter (BD, Franklin Lakes, NJ).  Purity ranged from 93-99 
percent for all three cell types. RNA was isolated with an RNeasy Micro Kit Plus (Qiagen, 
Germantown, MD). A cDNA library of mRNA was constructed using a Clontech SMARTer 
cDNA Synthesis Kit (Takara Bio USA, Mountain View, CA). RNA sequencing was performed 
using a HiSeq3000 instrument (Illumina, San Diego, CA) with 50bp single-end reads, targeting 
25-30 million reads per sample. Library construction and sequencing was performed by the 
Genome Technology Access Center (GTAC) at Washington University in St. Louis. 
RNA-Seq reads were aligned to the Ensembl release 76 top-level assembly with STAR 
version 2.0.4b. Gene counts were derived from the number of uniquely aligned unambiguous 
reads by Subread:featureCount version 1.4.5. Transcript counts were determined by Sailfish 
version 0.6.3. Sequencing performance was assessed for total number of aligned reads, total 
number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known 
junction saturation, and read distribution over known gene models with RSeQC version 2.3. 
All gene-level and transcript counts were then imported into the online Phantasus 
software package (https://artyomovlab.wustl.edu/phantasus/). Data were log2-transformed and 
quantile normalized to account for variations between samples. Duplicate genes were collapsed 
into a single representation by the mean. To assess quality of data, expression of surface markers 
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specific for NK cells, B cells, and T cells was manually assessed to ensure that the three cell 
populations expressed appropriate surface marker gene transcripts. Data quality was also 
assessed by k-means clustering of genes and hierarchical clustering of samples as well as with 
principal component analysis (PCA). Data were filtered to contain the top 12000 genes according 
to ranking by mean expression prior to analysis of differential expression. Limma, linear analysis 
models of differential expression, was performed to detect differential expression between 
patients and controls in NK cells, B cells, and T cells.  
Limma calculations were exported to Excel files and imported into R for gene set 
enrichment analysis (GSEA). Pathways were analyzed using the “fgsea” package available for R 
from Bioconductor on ranked gene lists with the t statistic of differences between JDM patients 
and controls using limma models. Differences in NK cell PLCG2 cascade gene expression as 
well as other signaling cascades were analyzed between patients and controls.  Hallmark and C5 
gene sets from MsigDb were used as sets for GSEA as well as a manually curated set of genes 
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Results 
To determine potential mechanisms and functional consequences of NK cell 
hypophosphorylation of PLC2 in JDM, RNA-Seq was performed on sorted NK cells, T cells, 
and B cells from four treatment-naïve JDM patients and four healthy controls (Tables 1, 2, 3). 
Before downstream analysis, data quality was assessed. Characteristic marker expression was 
examined for each of the cell types. NCAM1 (CD56) and CD244 were expressed at high levels 
in NK cells, and not in B or T cells (Data not shown). CD19 was expressed in B cells but not NK 
cells or T cells (Data not show). CD3, CD4, and CD8 were expressed in T cells but NK or B 
cells (Data not shown). In addition, separation of the samples by cell type and status as a patient 
or control was analyzed by principal component analysis (PCA) on the data matrix of log2 
transformed, quantile normalized gene expression counts (Figure S1). Indeed, the distinct cell 
populations were separated from one another. PC1 separated B cells from NK cells and T cells. 
NK cells and T cells were separated along PC2. There were smaller separations between patient 
and control samples of the same cell type along PC1. Furthermore, clustering was performed to 
assess data quality. Genes were clustered by k-means clustering with k=16, and samples were 
clustered using hierarchical clustering (Figure S2). Clustering of genes revealed several groups 
that had different expression patterns varying with cell type and/or status as a patient or control. 
Patient and control samples for all three cells types were segregated by hierarchical clustering. 
As our previous mass cytometry studies demonstrated that NK cells have defective 
PLC2 phosphorylation in JDM, it was of interest to study a curated gene set of PLCG2 and NK 
cell receptor related components in JDM NK cell gene expression (Table 4). Gene count data 
was weighted, and log2, quantile normalized and then analyzed for differences between patients 
and controls using limma-generated linear models. NK cell differential gene expression models 
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detected lower levels of NK cell LCK, MAPK1, CD160, and SIGLEC7 expression in JDM 
patients compared to controls (Figure 1A). To determine if there were global differences in the 
expression of PLCG2 NK cell pathway components, gene set enrichment analysis (GSEA) was 
performed using the limma t-test as a ranking metric to assess the curated NK cell PLCG2 set 
(Table 4, Figure 1B). Indeed, the global expression of the curated NK cell PLCG2 set was lower 
in JDM patient NK cells than in control NK cells (Figure 1B). Several other NK cell receptors, 
including KLRC4 (NKG2F), KLRC3 (NKG2E), KLRC2 (NKG2C), and FCGR3A (CD16), and 
signaling molecules, including FYN, were in the leading edge set, the genes in the gene set of 
interest that contribute to the maximum enrichment score (Figure 1C). There were no differences 
detected between JDM patient and control PLCG2 transcript expression levels (Figure 1D) in 
agreement with previous flow cytometry data assessing total PLC2 protein levels.  
It was also of interest to determine if there were gene expression differences in other 
signaling cascades beyond those directly associated with PLCG2 in NK cells. Samples were 
normalized as before and again analyzed for differences between treatment-naïve patients and 
controls using limma-generated linear models. Using this analysis method, 302 genes were 
differentially expressed between JDM patients and controls in NK cells (Table S1), many of 
them appearing to be interferon stimulated genes (ISGs). To aid in interpreting the biological 
significance of these differences, gene set enrichment analysis (GSEA) was performed with the 
Hallmark and C5 gene sets from MSigDB (a total of 5967 gene sets). The t-scores comparing 
patient and control cells for each respective cell type from the limma analysis were used as 
ranking metrics (Figure 2A; Table S4). 598 gene sets were differentially expressed between JDM 
patient and control NK cells. In NK cells, 113 gene sets were tied for the highest adjusted p-
value. IFN and IFN5 related gene sets as well as proliferation gene sets were upregulated in 
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JDM patient NK cells in comparison to controls (Figure S3). Because a large number of 
pathways were differentially expressed between patient and control NK cells, leading edge 
analysis was performed for the pathways deemed significantly different after multiple hypothesis 
correction. Counts for each gene in the leading edges of these pathways were analyzed (Table 
S4). In NK cells PML, PLK1, CCNB1, CDK1, AURKA, SNCA, IL1B, BRCA1, LRRK2, 
AURKB, JAK2, and TP53 were each found in the leading edge of over 100 differentially 
expressed gene sets. Most of these genes are involved in cell cycle regulation (Figure 2B, C). 
In addition to analyzing NK cells, B cells were analyzed, as they also primarily employ 
PLC2 for B cell receptor signaling but did not have observed PLC2 signaling defects via mass 
cytometry in JDM patients. With limma differential expression analysis, 10 genes were 
differentially expressed between JDM patients and controls below a Benjamini-Hochberg p-
value of 0.05 in B cells (Table S2). In addition, GSEA was employed to examine differences in 
gene sets in B cells and detected significant differences in 302 gene sets between patients and 
controls below a false discovery rate threshold of 5%, with 41 sets being tied for the lowest 
adjusted p-value (Figure 3A; Table S5).  IFN and IFN5 related gene sets were upregulated in 
JDM patient B cells in comparison to controls. Leading edge analysis was performed to gain 
insight about the most common genes in differentially expressed gene sets.  ITGB1, TGFB1, 
ICAM1, ANXA1, ITGAV, ADRB2, IL1B, SYK, FCER1G, THBS1, LRRK2, and TGFBR1 
were the top twelve most frequent genes in the leading edge of differentially expressed gene sets 
for B cells (Figure 3B, C). 
Furthermore, gene expression differences in T cells were analyzed since JDM T cells had 
defects in PLC2 phosphorylation in a mass cytometry experiment, but primarily rely on PLC1 
for T cell receptor signaling with PLC2 being redundant. With limma analysis, 13 genes were 
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differentially expressed between patient and control T cells (Table S3). GSEA was also used to 
compare differences in T cell gene expression sets (Figure 4A). With GSEA 156 gene sets were 
differentially expressed between T cell patient and control samples with a FDR threshold of 5% 
with 51 sets tied for the lowest adjusted p-value (Table S6). IFN and IFN5 related gene sets in 
addition to protein translation and localization related gene sets were upregulated in JDM patient 
T cells in comparison to control T cells. Leading edge set analysis was performed to determine 
which genes were shared among differentially expressed gene sets.  PML, TRIM25, RPL38, 
RPS3, RPL10A, RPL13A, RPL18, RPL19, RPL27, RPL3, RPL31, and RPL4 were the top 
twelve most frequent genes in the leading edge of differentially expressed gene sets for T cells 
(Figure 4B, C). Most of these are genes for ribosomal proteins. 
While analyzing signaling differences in NK cells was the primary goal in this study, T 
cells (which signal primarily using PLC1 but had PLC2 signaling defects in cytometry 
studies) and B cells (which signal primarily using PLC2 but did not have signaling defects in 
cytometry studies) were also analyzed to compare and contrast with findings in NK cells. 
Overall, 302 genes were differentially expressed in NK cells (Table S1), with 13 for T cells 
(Table S2), and 10 for B cells (Table S3) below a Benjamini-Hochberg p-value of 0.05. Of these 
differentially expressed genes, 2 were shared by all three cells (IFIT1 and MX1), 5 between NK 
cells and B cells (IFIT1, RSAD2, DDX60, IFI44L, and MX1), 6 between NK cells and T cells 
(IFIT1, EPSTI1, IFIT3, OAS2, OAS1, and MX1), and 2 between T cells and B cells (IFIT1 and 
MX1). IFIT1 and MX1, both interferon stimulated genes, were differentially expressed in all 
three cell populations. In addition, GSEA was performed comparing JDM patient and control 
samples for each of the three cell types. For NK cells 598 gene sets were differentially expressed 
between JDM patients and controls, along with 302 in B cells and 156 in T cells. Nineteen of 
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these pathways were differentially expressed between patients and controls in NK cells, B cells, 


















GO_CHROMOSOMAL_REGION, and GO_DNA_REPAIR were differentially expressed only 
in NK and B cells. GO_INTERFERON_GAMMA_MEDIATED_SIGNALING_PATHWAY, 
GO_RESPONSE_TO_CYTOKINE, and  GO_RESPONSE_TO_INTERFERON_GAMMA were 
differentially expressed only in NK and T cells. GO_CHROMOSOME, 
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GO_DEFENSE_RESPONSE, GO_RECEPTOR_ACTIVITY, 
_RESPONSE_TO_BIOTIC_STIMULUS, and GO_SIGNALING_RECEPTOR_ACTIVITY 
were differentially expressed only in B and T cells. For pathways only differentially expressed in 
NK cells, many were involved in mitosis and proliferation. For pathways only differentially 
expressed in T cells, many were involved in protein translation and localization. There was no 
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Discussion 
The etiology of JDM is not well understood, but we have demonstrated that JDM patient 
NK cells have defective PLC2 phosphorylation, which is the primary signaling difference 
distinguishing JDM patients from controls. This study sought to delineate potential mechanisms 
of defective NK cell PLC2 phosphorylation in JDM and compare and contrast these differences 
with expression patterns in B and T cells. JDM patient NK cells expressed lower levels of LCK, 
MAPK1, SIGLEC7, and CD160, which may be contributing to lower levels of JDM patient NK 
cell PLC2 phosphorylation. Total PLCG2 transcript levels were not different between JDM 
patients and controls, in agreement with flow cytometry analysis of total PLC2 protein levels in 
prior studies. NK cells had more or more robust differences in gene expression between JDM 
patients and controls than T cells and B cells. There were IFN, IFN5, and cytokine associated 
signatures in all three cell types in JDM. NK cells appeared to be more actively proliferating in 
JDM patients, in agreement with Ki-67 data in mass cytometry, and T cells had differences in 
translation/protein localization in JDM.  This manuscript provides potential insight into 
mechanisms for NK cell PLC2 hypophosphorylation in JDM. 
NK cells had lower transcript levels of LCK, MAPK1, CD160, and SIGLEC7 in JDM 
patients than controls, as well as lower levels of a manually curated NK cell PLCG2 gene set. 
Lck is important for lymphocyte signal transduction (20) and is upstream of PLC2 in NK cell 
signal transduction (21). The expression of LCK is controlled by two distinct promoters, one 
primarily used in mature lymphocytes and the other primarily used by immature lymphocytes; 
which promoter is used is controlled by promoter acetylation (22). In prior mass cytometry 
studies, Lck phosphorylation was not detectable in NK cells. However, Lck is a receptor-
proximal signaling molecule and likely should be assayed at an earlier time point. Previous 
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studies on autoimmune mouse models have detected Lck inactivation in autoimmunity (23), 
providing further support for lower levels of LCK expression in JDM NK cell phenotype. 
MAPK1 (ERK2) is also downstream of NK cell receptor activation distal to PI3K activation 
(21). ERK activation defects have been detected in NOD mouse autoimmunity models 
downstream of T cell receptor activation in T cells (24), and it has been demonstrated that ERK1 
deficient mice are prone to experimental autoimmune encephalitis (25). Defects in PLC2 
phosphorylation may lead to defects in MAPK1 levels, as MAPK1 is downstream of PLC2 
signaling. SIGLEC7 is an inhibitory receptor expressed on NK cells, particularly mature NK 
cells in the peripheral blood; SIGLEC7 positive NK cells have more degranulation and IFN 
production than SIGLEC7 negative cells after stimulation with K562 cells and PMA+ionomycin 
(26). Thus, reduced levels of JDM patient NK cell SIGLEC7 expression may be indicate that 
JDM NK cells are less mature, potentially contributing to functional defects. SIGLEC7 has also 
been shown to be involved in other autoimmune diseases. SIGLEC7 expression is elevated in 
classical monocytes in the blood during multiple sclerosis flares (27). Additionally, SIGLEC7 
negative NK cells have been shown to act as a dysfunctional subpopulation with an association 
with severe liver disease in chronic HCV infection (28). CD160 is expressed on activated human 
NK and T cells that produce IFN (28). CD160 has been previously suggested as a target for 
treating autoimmunity (29), as its receptor HVEM has been shown to be involved in the 
pathogenesis of several autoimmune diseases (30). As LCK, SIGLEC7, CD160, and MAPK1 
have all been linked to autoimmunity or NK cell effector function, defects in these genes could 
be contributing to the JDM phenotype. Lower levels of NK cell PLC2 phosphorylation must be 
due to a factor other than lower levels of total PLC2 protein in JDM, as there was no significant 
difference; LCK may be contributing to NK cell PLC2 hypophosphorylation.  
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NK cells appear to upregulate gene sets related to proliferation in JDM patients in 
comparison to controls. Similarly, previous mass cytometry experiments also detected elevated 
proliferation levels in JDM patient NK cells in comparison to controls as measured by Ki-67 
protein levels.  Previous work has provided preliminary data that NK cells may be enriched in 
JDM patient affected muscles (31), raising the possibility that NK cells may migrate from the 
blood to affected muscles early in the JDM disease course. Alternatively, NK cells may be dying 
and proliferating at higher levels in JDM in an attempt to maintain homeostasis in the blood; 
future experiments should test for differences in NK cell death in JDM to distinguish between 
hypotheses. 
B and T cells were analyzed as controls in comparison to NK cells. In B cells there are 
few distinctive differences in comparison to NK and T cells. B cells did not have defects in 
PLC2 phosphorylation in prior mass cytometry experiments, potentially explaining the minimal 
overlap. T cells had aberrant translation and protein localization in JDM as suggested by GSEA. 
Aberrant protein translation and localization may contribute to T cell dysfunction in disease, as 
peptide processing and presentation are important for normal T cell function. 
All three cell types, NK cells, B cells, and T cells had IFN5 and IFN expression 
signatures. Specific TNF and IL-1 alleles as well as a type I interferon stimulated gene signature 
are associated with JDM disease risk (31, 32). IFNs have been implicated in the pathogenesis of 
other autoimmune diseases. Type I IFNs, in particular IFN5, have been shown to be a dominant 
mediators of pathogenesis in lupus (33). Classical monocytes and naïve CD4 T cells 
preferentially respond to IFN stimulation with STAT3 phosphorylation in polyarticular juvenile 
idiopathic arthritis (Throm in press). Furthermore, a clinical trial has demonstrated the 
effectiveness of an IFN5 antibody in treating dermatomyositis and polymyositis patients (34). 
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While new insights into NK cell PLC2 defects in JDM were gained in this study, there 
were several limitations in this work, including the size of the patient cohort. The study included 
4 patient and control samples. Although negative binomial models allowed for sample number 
limitations to be overcome, the limited number patient samples coupled with a paucity of NK 
cells in many of the JDM samples restricted the RNA-Seq experiments to a single unstimulated 
condition to assess gene expression; it would be of interest to analyze gene expression patterns 
under a wider variety of stimulation conditions and for more JDM patients and healthy controls, 
particularly with IFN5 or IFN.  
A better understanding of the etiology of JDM may inform new targeted therapeutic 
interventions (e.g., small molecules or biologics that target specific signaling pathways).  This 
study highlighted the utility of exploring findings from the high dimensional mass cytometry 
technique with high dimensional RNA-Seq to explore gene expression differences between JDM 
patients and controls contributing to NK cell PLC2 hypophosphorylation. JDM patient NK cells 
had lower expression levels of PLCG2 related components, including LCK and MAPK1, 
potentially providing insights into a mechanistic explanation for hypophosphorylation of PLC2 
in JDM patient NK cells, which resulted in decreased calcium flux.  Future studies will focus on 
verifying protein levels of LCK and MAPK1 (ERK2) and exploring the functional consequences 
of differential gene expression on NK cell PLC2 signaling and killing in JDM patients and on 










Figure 1. Differences in NK cell PLCG2 related components between JDM patients and healthy 
controls. A) LCK, CD160, SIGLEC7, and MAPK1 (ERK2) gene expression depicted as heat 
map. These four genes were lower in patient than control NK cells with limma analysis (LCK: 
t=7.40, p=0.015, CD160: t=5.71, p=0.032, SIGLEC7: t=8.30, p=0.01, MAPK1: t=5.58, 
p=0.034). B) There is a difference between patients and controls in the manually curated NK cell 
PLCG2 pathway as determined by gene set enrichment analysis (GSEA) (ES=0.376, p=0.00068). 
A heatmap of sorted results by the t-value scoring metric is depicted with the running score of 
the enrichment statistic (ES) along the ranked genes. C) Heatmap of genes in the leading edge of 
the GSEA analysis on the manually curated NK cell PLCG2 pathway. D) Transcript counts of 
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Figure 2. Genes most frequently found in leading edge subset for the 598 pathways detected as 
differentially expressed between JDM patient and control NK cell samples by GSEA with a false 
discovery rate (FDR) threshold of 5%. A) Heatmap of all genes sorted by NK cell limma t-test. 
B) Frequency of genes in leading edge subsets for significantly different genes subsets detected 
by GSEA comparing NK cells with an FDR threshold of 5% for the top 12 most frequent genes. 
C) Heatmap of log2-transformed, quantile normalized NK cells gene expression for the 100 most 
frequent genes in the leading edge subsets detected by GSEA with an FDR threshold of 5%. 
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Figure 3. Genes most frequently found in leading edge subset for the 302 pathways detected as 
differentially expressed between JDM patient and control B cell samples by GSEA with a false 
discovery rate (FDR) threshold of 5%. A) Heatmap of all genes sorted by B cell limma t-test. B) 
Frequency of genes in leading edge subsets for significantly different genes subsets detected by 
GSEA comparing B cells with an FDR threshold of 5% for the top 12 most frequent genes. C) 
Heatmap of log2-transformed, quantile normalized B cells gene expression for the 100 most 
frequent genes in the leading edge subsets detected by GSEA with an FDR threshold of 5%. 
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Figure 4. Genes most frequently found in leading edge subset for the 156 pathways detected as 
differentially expressed between JDM patient and control T cell samples by GSEA with a false 
discovery rate (FDR) threshold of 5%. A) Heatmap of all genes sorted by T cell limma t-test. B) 
Frequency of genes in leading edge subsets for significantly different genes subsets detected by 
GSEA comparing T cells with an FDR threshold of 5% for the top 12 most frequent genes. C) 
Heatmap of log2-transformed, quantile normalized T cell gene expression for the 100 most 
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Tables 
Table 1. Patient demographics. Medication abbreviations: myositis specific autoantibody (MSA), 
myositis associated autoantibody (MAA), duration of untreated disease (DUD), anti-SUMO 
activating enzyme (SAE), Abbreviations for race: Caucasian (W), African-American (B). 
 




Age at sample collection 
(yrs) 
MSA MAA Healthy controls 
2 M W 3 3.2 negative negative 7.5 you W M 
5 F W <1 12.8 MJ negative 13.4 yo W F 
6 F W <3 8.2 p155/140 negative 9.4 yo F 
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Table 2. Cell counts after sorting cells 
Sample NK cells Classical 
monocytes 
B cells T cells 
Pt144 17529 212284 372462 640975 
Pt172 44291 232750 171152 1302225 
Pt173 33578 86684 44381 1393891 
Pt168 12171 467844 251790 1646992 
AMC170 216704 86708 142059 1562679 
AMC012 130526 205504 32110 817965 
AMC013 315106 139143 54173 1131190 
AMC016 182157 44919 59378 1473443 
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Table 3. Mass of RNA used in RNA-Seq analysis in ng 
Sample NK cells B cells T cells 
Pt144 10.71 237.6  401.4  
Pt172 12.06 104.4  631.8  
Pt173 10.98 14.4  619.2  
Pt168 41.4 157.5  918.0  
AMC170 91.8 77.22  878.4  
AMC012 51.66 9.0  622.8  
AMC013 121.5 19.8  478.8  
AMC016 61.74 50.04  784.8 
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Table 4. Manually curated NK cell PLCG2 pathways 
Protein Name Gene Name Class Source 
NKp46 NCR1 Receptor 1 
NKp44 NCR2 Receptor 1 
NKp30 NCR3 Receptor 1 
CD56 NCAM1 Receptor 1 
NKG2D KLRK1 Receptor 1 
2B4 CD244 Receptor 1 
NKp80 KLRF1 Receptor 1 
CD16 FCGR3A Receptor 1 
LAIR1 LAIR2 Receptor 1 
SIGLEC-3 CD33 Receptor 1 
SIGLEC-7 SIGLEC7 Receptor 1 
SIGLEC-9 SIGLEC9 Receptor 1 
KLRG1 KLRG2 Receptor 1 
NKR-P1A KLRB1 Receptor 1 
CD94 KLRD1 Receptor 1 
NKG2A KLRC1 Receptor 1 
LILRB1 LILRB1 Receptor 1 
KIR2DL1 KIR2DL1 Receptor 1 
KIR2DL2 KIR2DL2 Receptor 1 
KIR2DL3 KIR2DL3 Receptor 1 
KIR2DL5A KIR2DL5A Receptor 1 
KIR2DL5B KIR2DL5B Receptor 1 
KIR2DS2 KIR2DS2 Receptor 1 
KIR2DS3 KIR2DS3 Receptor 1 
KIR2DS4 KIR2DS4 Receptor 1 
KIR2DS5 KIR2DS5 Receptor 1 
KIR3DS1 KIR3DS1 Receptor 1 
DAP12 TYROBP Adaptor 1 
NKG2C KLRC2 Receptor 1 
NKG2E KLRC3 Receptor 1 
DAP10 HCST Adaptor 1 
CD160 CD160 Receptor 1 
CD3z CD247 Adaptor 1 
FGRg FCERG1 Adaptor 1 
KIR2DS1 KIR2DS1 Receptor 1 
DNAM1 CD226 Receptor 1 
CRTAM CRTAM Receptor 1 
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CD27 CD27 Receptor 1 
PSGL1 SELPLG Receptor 1 
CD96 CD96 Receptor 1 
CD100 SEMA4D Receptor 1 
CEACAM1 CEACAM1 Receptor 1 
NTB-A SLAMF6 Receptor 1 
SLAMF7 SLAMF7 Receptor 1 
NKG2F KLRC4 Receptor 1 
TIGIT TIGIT Receptor 1 
PLCG2 PLCG2 Signaling molecule 2 
Lyn LYN Signaling molecule 2 
Syk SYK Signaling molecule 2 
ZAP70 ZAP70 Signaling molecule 2 
Btk BTK Signaling molecule 2 
Itk ITK Signaling molecule 2 
BLNK BLNK Scaffold 2 
LAT LAT Scaffold 2 
SLP76 LCP2 Scaffold 2 
Src SRC Signaling molecule 2 
VAV1 VAV1 Signaling molecule 2 
Gads GRAP2 Scaffold 2 
Lck LCK Signaling molecule 2 
Fyn FYN Signaling molecule 2 
CD45 PTPRC Signaling molecule 2 
MIST CLNK Scaffold 2 
SHIP-1 INPP5D Signaling molecule 2 
CDC42 CDC42 Cell division 2 
WASP WAS Signaling molecule 2 
ARF6 ARF6 Signaling molecule 2 
PIP5Ka PIP5K1A Signaling molecule 2 
PLD PLD Signaling molecule 2 
PYK-2 PTK2B Signaling molecule 2 
RAC RAC1 Signaling molecule 2 
PAK1 PAK1 Signaling molecule 2 
MEK1/2 MAP2K1 Signaling molecule 2 
ERK MAPK1 Signaling molecule 2 
MEK3/6 MAP2K3 Signaling molecule 2 
p38 MAPK14 Signaling molecule 2 
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P160 MYBBP1A Transcription factor 2 
ROCK ROCK1 Signaling molecule 2 
LIMK LIMK1 Signaling molecule 2 
PIK3CA PIK3CA Signaling molecule 2 
PIK3CB PIK3CB Signaling molecule 2 
PIK3CG PIK3CG Signaling molecule 2 
PIK3CD PIK3CD Signaling molecule 2 
PIK3R2 PIK3R2 Signaling molecule 2 
PIK3R3 PIK3R3 Signaling molecule 2 
PIK3R4 PIK3R4 Signaling molecule 2 
PIK3R5 PIK3R5 Signaling molecule 2 
PIK3R6 PIK3R6 Signaling molecule 2 
PIK3C2B PIK3C2B Signaling molecule 2 
PIK3C2G PIK3C2G Signaling molecule 2 
IP3R ITPR1 Calcium flux 3 
TnC TNNC2 Calcium flux 3 
MLCK MYLK Calcium flux 3 
PHK PHKA1 Signaling molecule 3 
CAMK CAMK4 Calcium flux 3 
NOS NOS1 Enzyme 3 
ADCY ADCY1 Enzyme 3 
PDE1 PDE1A PDE1A 3 
FAK2 PTK2B Signaling molecule 3 
IPS3K ITPKA Signaling molecule 3 
CALM CALM1 Calcium flux 3 
CCN1 CCNA2 Cell division 3 
CNA1 CNA1 Regulatory element 3 
 IECEE PPP3CA Signaling molecule 3 
PPP2B PPP2B Signaling molecule 3 
SHP-1 PTPN6 Signaling molecule 4 
SHP-2 PTPN11 Signaling molecule 4 
SAP SH2D1A Scaffold 4 
EAT-2 SH2D1B Scaffold 4 
NFAT NFATC1 Transcription factor 4 
TNFa TNF Cytokine product 4 
IFNg IFNG Cytokine product 4 
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3BP2 SH3BP2 Scaffold 4 
Shc SHC2 Scaffold 4 
Grb GRB2 Receptor 4 
Sos SOS1 Signaling molecule 4 
Ras HRAS Signaling molecule 4 
Raf ARAF Signaling molecule 4 
PAK1 PAK1 Signaling molecule 4 
GMCSF CSF2 Cytokine product 4 
Calcineurin B PPP3CA Calcium flux 4 
Itpkb ITPKB Enzyme 4 
Orai ORAI1 Calcium flux 4 
STIM1 STIM1 Calcium flux 4 
Arp2/3 ACTR2 Actin polymerization 4 
Arp2/3 ARPC3 Actin polymerization 4 
FASL FASLG Ligand 4 
IL-3 IL3 Cytokine product 4 
IL-4 IL4 Cytokine product 4 
IL-2 IL2 Cytokine product 4 
AP1 JUN Transcription factor 4 
c-FOS FOS Transcription factor 4 
PLD1 PLD1 Signaling molecule 4 




2: https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-065X.2006.00463.x,  

















Figure S1. Principal component analysis (PCA) scores plot confirming that different cells and 
JDM patients and controls have distinct gene expression signatures. 
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Table S1. Differentially expressed genes in NK cells from JDM patients versus controls using 




expression clusters logFC AveExpr t p.value adj.p.val B 
AC083798.1 3.2409 15 1.3385 2.8244 4.9471 0.001064 0.047367 -0.48655 
GBP1P1 3.2598 4 -4.5081 4.5341 -4.906 0.001121 0.048056 -0.53964 
SALL2 3.3381 10 3.2588 2.3423 5.5859 0.000485 0.034332 0.3048 
AL031316.1 3.43 16 2.022 4.4412 6.0257 0.000292 0.027332 0.81313 
DEPDC1 3.4464 13 -4.885 3.2743 -9.3509 1.23E-05 0.006622 3.8434 
AC018450.1 3.4687 16 1.7818 5.216 5.93 0.000325 0.028933 0.70503 
CYP2F1 3.4738 9 1.8718 4.9959 4.8521 0.001202 0.049329 -0.60968 
LY6E 3.4881 4 -1.8412 4.1864 -5.3273 0.000662 0.038391 -0.00782 
ODF3B 3.4987 13 -4.0177 3.3548 -5.5998 0.000477 0.034332 0.32135 
KIF20A 3.5195 4 -2.7228 4.8944 -5.124 0.000851 0.043504 -0.26096 
CD70 3.5399 15 -2.6267 1.7615 -6.7463 0.000133 0.020646 1.5854 
AC079922.2 3.5473 9 1.6218 4.4541 5.016 0.000975 0.04701 -0.39811 
ZNF213 3.5935 4 -1.553 4.3512 -5.1266 0.000848 0.043504 -0.25769 
DIAPH3 3.6041 4 -2.6679 4.5936 -6.5563 0.000163 0.021497 1.3888 
FEZ1 3.6826 16 3.1433 6.9591 7.9564 4.08E-05 0.01189 2.7288 
UTS2 3.7803 9 3.1752 6.2399 5.6915 0.000428 0.032517 0.42957 
EXO1 3.7966 4 -2.6552 5.4397 -4.8258 0.001243 0.04973 -0.64408 
RPL7AP6 3.8002 12 1.284 3.3876 8.2949 3.01E-05 0.010303 3.0178 
ETV7 3.8676 4 -4.1816 5.3528 -5.8778 0.000345 0.029571 0.64537 
EEF1A1P14 3.8902 8 1.2633 3.7488 5.463 0.000562 0.035656 0.15751 
RPS29P5 3.9894 11 0.99026 3.0861 5.0213 0.000968 0.04701 -0.39136 
AC012615.1 4.0111 9 2.5321 4.942 5.8216 0.000368 0.030451 0.58078 
RND1 4.0159 6 3.0592 2.7414 4.9506 0.001059 0.047367 -0.48201 
GTSE1 4.0352 1 -1.9059 5.913 -5.9282 0.000326 0.028933 0.70292 
AF196972.1 4.0709 10 1.6734 3.838 6.524 0.000169 0.021497 1.3548 
AC069213.1 4.0725 9 2.3081 4.4394 6.1351 0.000258 0.02582 0.93508 
STIL 4.079 4 -2.2913 5.6383 -5.7951 0.000379 0.030451 0.55019 
LINC00239 4.092 9 1.7593 5.5858 5.3763 0.000624 0.037048 0.052159 
SDC4 4.2034 9 -2.3218 6.0037 -6.0581 0.000281 0.027029 0.84946 
HJURP 4.2328 4 -2.6196 5.5167 -6.134 0.000258 0.02582 0.93385 
KIF23 4.2907 4 -3.1034 5.8071 -6.5059 0.000172 0.021497 1.3358 
LINC01534 4.3217 11 2.104 3.6245 6.4345 0.000186 0.022185 1.2601 
ORC6 4.3268 1 -2.0444 5.2155 -5.1823 0.000791 0.042778 -0.18774 
DEPDC1B 4.3519 4 -3.0511 5.7176 -7.7415 4.98E-05 0.012827 2.5387 
KLRA1P 4.4048 9 3.6819 4.6557 4.9914 0.001006 0.04714 -0.42961 
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CTSF 4.4143 9 1.9073 4.7445 5.1377 0.000837 0.043504 -0.24376 
PRSS30P 4.4248 16 1.6876 8.2057 5.1925 0.000781 0.042429 -0.17492 
RLN1 4.4324 9 1.9628 4.9628 4.9922 0.001005 0.04714 -0.42856 
AL121658.1 4.4975 12 1.8579 3.9951 5.146 0.000828 0.043504 -0.23329 
AC068152.1 4.547 9 1.0272 4.8992 6.336 0.000207 0.022185 1.1546 
KIF2C 4.5991 4 -2.6962 6.1196 -5.5254 0.000521 0.035014 0.23256 
ESCO2 4.6114 4 -2.6073 6.4065 -7.3439 7.3E-05 0.01536 2.1726 
AL161909.1 4.6234 11 1.2536 3.7133 5.7004 0.000424 0.032386 0.43999 
AC245407.1 4.6382 9 1.3803 5.0465 5.1379 0.000836 0.043504 -0.24346 
BX284668.5 4.6502 12 1.712 4.6755 5.2687 0.000711 0.040261 -0.08018 
EID2B 4.6954 12 2.0584 4.6904 6.678 0.000143 0.020646 1.5152 
CDC20 4.6967 4 -2.3829 5.8529 -5.1427 0.000831 0.043504 -0.23738 
C15orf61 4.7024 9 1.3947 5.264 5.3073 0.000678 0.038949 -0.03246 
MKI67 4.7661 4 -2.3961 5.2965 -5.5979 0.000478 0.034332 0.3191 
MTFR2 4.7771 4 -2.4814 5.6492 -7.2321 8.14E-05 0.016022 2.0662 
FO393401.1 4.8097 5 2.1637 5.3933 7.1083 9.21E-05 0.016619 1.9465 
AC245297.3 4.8361 5 2.2903 5.7161 4.83 0.001236 0.04973 -0.63854 
EEF1A1P38 4.8552 8 1.0366 4.3052 6.3381 0.000206 0.022185 1.1569 
AC241585.2 4.893 9 1.4881 5.5877 5.0739 0.000906 0.044912 -0.3243 
SKA3 4.9175 4 -2.6359 6.3203 -6.394 0.000194 0.022185 1.217 
ORC1 4.9176 4 -1.5851 6.0086 -5.0949 0.000882 0.044179 -0.29772 
SHCBP1 4.9302 1 -2.2012 5.8599 -7.1114 9.18E-05 0.016619 1.9496 
AC121761.1 4.9834 10 1.5887 4.9149 5.4114 0.000598 0.036912 0.094968 
CLSPN 4.9839 4 -2.2281 6.6599 -5.6014 0.000476 0.034332 0.32324 
CDC6 5.0062 4 -1.3992 6.7974 -5.0397 0.000946 0.046524 -0.3678 
HMMR 5.0124 4 -2.3484 6.1886 -8.7538 2.02E-05 0.008659 3.3901 
BEX5 5.0149 9 2.3884 5.5154 6.6976 0.00014 0.020646 1.5354 
AL135818.1 5.0229 16 1.697 7.8134 7.2372 8.1E-05 0.016022 2.0711 
LINC02482 5.0533 12 1.8917 4.6701 8.4938 2.52E-05 0.009461 3.1819 
MHENCR 5.0643 11 2.1828 3.8126 5.3781 0.000622 0.037048 0.054355 
ZNF554 5.1391 10 1.5607 4.9338 8.2255 3.2E-05 0.010303 2.9596 
TYMP 5.1412 1 -3.4913 5.4061 -7.6893 5.23E-05 0.012827 2.4916 
RPL5P1 5.1552 11 1.0603 4.4722 6.2422 0.000229 0.024105 1.0529 
CYP2J2 5.22 13 -5.193 4.5809 -4.8805 0.001159 0.04821 -0.57275 
FAM111B 5.2786 1 -2.4807 5.8234 -6.2284 0.000233 0.024263 1.0377 
SNHG21 5.3257 12 1.826 4.7197 5.271 0.000709 0.040261 -0.07729 
KIF11 5.3507 4 -1.7158 6.4043 -4.8788 0.001161 0.04821 -0.57489 
ITPKB-IT1 5.3706 1 1.5374 5.6933 5.2295 0.000746 0.04147 -0.12882 
CENPF 5.3744 7 -1.9333 5.5859 -5.8049 0.000375 0.030451 0.56152 
AURKB 5.4005 4 -3.2233 6.5715 -9.3213 1.26E-05 0.006622 3.8217 
IQCH-AS1 5.4032 9 1.4799 5.7685 5.379 0.000622 0.037048 0.05552 
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SCOC-AS1 5.408 11 1.574 4.5205 4.8418 0.001218 0.049369 -0.62313 
DLGAP5 5.4366 4 -2.6339 6.0973 -5.6142 0.000469 0.034332 0.33835 
TYMS 5.4405 4 -1.9212 7.015 -8.9399 1.72E-05 0.007957 3.535 
SOBP 5.471 13 -4.7059 3.3115 -5.2213 0.000754 0.041551 -0.13905 
HOOK1 5.481 11 -1.3684 3.5167 -4.9238 0.001096 0.047828 -0.5166 
MINCR 5.4912 8 1.6584 4.6963 6.3684 0.000199 0.022185 1.1895 
AL136454.1 5.4976 11 1.3768 4.7844 4.8973 0.001134 0.048129 -0.55086 
RPL3P7 5.5037 8 1.2988 4.8929 5.1277 0.000847 0.043504 -0.25637 
AC127521.1 5.5204 9 1.0335 5.9149 4.8287 0.001239 0.04973 -0.64027 
RTKN2 5.5514 8 -2.6096 3.9967 -4.9294 0.001088 0.047828 -0.50933 
ASF1B 5.574 4 -1.771 7.0413 -7.0721 9.55E-05 0.016862 1.9112 
STAG3 5.6134 15 -1.5175 4.4316 -6.8976 0.000114 0.018756 1.7384 
DDIAS 5.6525 4 -1.9719 5.8605 -6.0386 0.000287 0.027148 0.82762 
HCG11 5.6688 6 1.4879 5.3207 7.3594 7.19E-05 0.01536 2.1872 
C1DP5 5.6704 16 1.4188 6.461 5.5042 0.000534 0.035143 0.20712 
TMEM62 5.6888 1 -1.1545 6.0275 -5.0091 0.000983 0.04701 -0.40688 
E2F2 5.7598 4 -3.1577 6.2033 -7.9098 4.26E-05 0.01189 2.688 
ZNF540 5.7882 8 1.1974 5.284 5.5348 0.000515 0.035014 0.24383 
LAMP3 5.8042 13 -3.6939 4.6972 -5.1405 0.000834 0.043504 -0.24017 
SLC1A5 5.8321 1 -1.8323 6.8123 -8.7106 2.09E-05 0.008659 3.356 
SIGLEC7 5.9038 16 2.3988 10.683 8.2975 3E-05 0.010303 3.0199 
HELZ2 5.925 13 -1.8329 5.9984 -5.1329 0.000842 0.043504 -0.2498 
SNHG9 5.926 12 2.8114 5.7743 8.6347 2.23E-05 0.008804 3.2956 
SLC29A1 5.9688 4 -1.5239 6.8164 -5.5623 0.000499 0.034395 0.27667 
EEF1A1P11 6.0307 8 0.84377 5.4561 5.4883 0.000545 0.03515 0.18795 
CISH 6.0916 2 -1.7915 6.6859 -4.8631 0.001185 0.048855 -0.59531 
SIGLEC17P 6.2065 16 3.0227 9.7869 6.3539 0.000203 0.022185 1.1739 
AC012146.1 6.2075 11 1.7016 5.6014 9.5844 1.02E-05 0.006622 4.0116 
PRMT3 6.2098 13 -1.4807 6.0888 -6.3749 0.000198 0.022185 1.1965 
CCNB2 6.2252 4 -2.499 6.9369 -4.979 0.001022 0.047177 -0.44548 
BUB1 6.2738 4 -3.1304 6.2693 -8.7159 2.08E-05 0.008659 3.3602 
HIST1H2BC 6.329 4 -1.1963 6.9767 -5.824 0.000367 0.030451 0.58362 
AL451165.2 6.3484 8 0.95672 6.1241 5.4574 0.000565 0.03571 0.15071 
ASH1L-AS1 6.3516 12 0.87939 6.3024 6.1132 0.000264 0.02599 0.91088 
DTL 6.3836 4 -2.0747 7.8123 -6.3416 0.000205 0.022185 1.1607 
LINC00869 6.4174 9 1.4471 7.2441 6.3771 0.000198 0.022185 1.1989 
LINC02328 6.4949 9 1.8292 6.6964 8.203 3.26E-05 0.010303 2.9406 
PAXIP1-AS1 6.5009 11 1.3906 5.5397 4.9712 0.001032 0.047177 -0.45555 
C6orf226 6.5144 12 1.0081 6.4263 4.8831 0.001155 0.04821 -0.56935 
ZNF582-AS1 6.5752 11 1.7767 5.5946 6.3505 0.000203 0.022185 1.1702 
CDKN3 6.5899 4 -2.0576 6.9399 -7.626 5.56E-05 0.012827 2.4342 
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ZNF821 6.6026 6 1.0601 6.384 5.6805 0.000434 0.032643 0.41664 
FAR2 6.6695 2 -3.7427 6.9995 -11.839 2.03E-06 0.002432 5.4122 
ZNF514 6.706 11 0.79779 6.3528 5.5 0.000537 0.035143 0.20206 
SLC1A4 6.7076 1 -0.9374 7.862 -5.416 0.000594 0.036912 0.1005 
CDCA7 6.7187 4 -2.3333 7.4194 -7.6312 5.53E-05 0.012827 2.4389 
GINS2 6.7202 4 -2.094 7.6 -7.0175 0.000101 0.017559 1.8575 
CENPW 6.725 4 -1.9805 7.03 -10.212 6.32E-06 0.00519 4.4402 
TIAM1 6.7339 9 -1.9738 7.6327 -4.9248 0.001095 0.047828 -0.51536 
PSMG1 6.7592 2 -1.0338 6.9721 -6.2064 0.000238 0.024644 1.0137 
AC018521.5 6.7628 12 0.7368 6.8688 4.8452 0.001212 0.049369 -0.61867 
YRDC 6.7642 12 1.229 6.36 5.8112 0.000372 0.030451 0.56889 
C3orf14 6.7714 13 -2.8191 6.5173 -5.6775 0.000435 0.032643 0.41312 
LDOC1 6.8259 10 1.9247 6.5101 6.9824 0.000105 0.017937 1.8228 
CCR1 6.8447 4 -3.6966 9.1357 -5.3134 0.000673 0.038846 -0.02498 
IQCG 6.8449 12 1.0493 6.9242 4.8269 0.001241 0.04973 -0.64257 
CHEK1 6.8646 4 -1.5752 7.6288 -6.1712 0.000248 0.025192 0.97495 
CCDC65 6.9293 9 2.116 8.5437 6.5302 0.000168 0.021497 1.3613 
NDC80 7.001 4 -1.4224 7.4757 -5.3898 0.000613 0.037048 0.068696 
PML 7.0015 4 -1.6305 7.2977 -9.1239 1.48E-05 0.007105 3.675 
FAM210B 7.0237 8 1.0426 6.7674 4.9077 0.001119 0.048056 -0.53745 
AC021054.1 7.0404 5 1.1233 7.1529 5.4929 0.000542 0.035143 0.19356 
TRMT5 7.055 13 -1.3994 6.3646 -5.0119 0.00098 0.04701 -0.40338 
UBE2T 7.0642 4 -1.8916 7.2163 -5.3879 0.000615 0.037048 0.066392 
MYL6B 7.0785 13 -1.0765 6.9583 -4.9477 0.001063 0.047367 -0.4857 
ZWINT 7.0895 4 -2.0141 7.8613 -7.6474 5.45E-05 0.012827 2.4537 
ZNF665 7.0996 6 1.2625 6.5947 5.961 0.000314 0.028519 0.74016 
AP002360.1 7.1186 11 1.3367 6.5276 6.0869 0.000272 0.02655 0.8816 
SPATS2L 7.1418 2 -3.5564 7.8126 -15.162 2.92E-07 0.001753 6.912 
AC004656.1 7.1842 10 1.9377 7.1403 5.5668 0.000496 0.034395 0.28207 
B4GALT5 7.2403 16 -0.85955 8.7402 -4.8695 0.001175 0.048622 -0.58698 
JAK2 7.2497 4 -1.5151 7.8869 -5.5768 0.00049 0.034332 0.29396 
ERN1 7.2709 9 1.5518 8.1327 4.8977 0.001133 0.048129 -0.55034 
SCARNA9 7.293 1 -2.1122 7.2087 -9.3044 1.28E-05 0.006622 3.8092 
AC145207.5 7.2953 10 1.8577 7.3671 5.4747 0.000554 0.035403 0.17158 
ZNF433-AS1 7.3137 11 1.6526 6.5228 5.3884 0.000615 0.037048 0.066907 
PSAT1 7.3194 13 -1.8429 6.6827 -5.0286 0.000959 0.046989 -0.38199 
CDK1 7.3204 4 -2.6029 8.4311 -7.3044 7.58E-05 0.015424 2.1352 
MT1X 7.3295 9 -0.85251 7.5861 -4.9695 0.001034 0.047177 -0.45765 
PAIP2B 7.3413 11 0.98132 6.3425 4.8855 0.001151 0.04821 -0.56621 
ADRB2 7.3497 16 0.98856 9.4998 4.9326 0.001084 0.04782 -0.50518 
PANK2 7.3619 14 -1.0261 7.5124 -5.5318 0.000517 0.035014 0.24023 
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TK1 7.3635 4 -2.0802 8.8625 -5.7436 0.000403 0.031394 0.49041 
ARIH2OS 7.4079 12 1.0301 7.4319 4.8927 0.001141 0.048194 -0.55689 
KRT10 7.4089 6 1.3119 6.9866 6.7316 0.000135 0.020646 1.5703 
TOP2A 7.4148 4 -2.1537 8.7836 -6.6946 0.000141 0.020646 1.5323 
RAB11FIP4 7.4518 3 1.1021 7.5855 5.815 0.000371 0.030451 0.57319 
IGF1R 7.4571 8 1.9232 7.2938 6.825 0.000123 0.019414 1.6653 
AIMP2 7.5266 4 -1.116 7.8855 -5.64 0.000455 0.033695 0.36892 
RASGRP3 7.5758 15 -2.023 6.1602 -4.9109 0.001114 0.048056 -0.53328 
GALNT11 7.5885 9 1.1337 8.4281 5.4358 0.00058 0.036309 0.12461 
MCM4 7.6075 4 -1.7843 8.3733 -6.8941 0.000114 0.018756 1.7349 
FAM98A 7.6291 4 -1.2323 7.685 -6.3448 0.000205 0.022185 1.1641 
ARHGAP26 7.6567 16 0.80629 8.8743 4.971 0.001032 0.047177 -0.45582 
HELLS 7.6674 13 -1.6285 7.5522 -5.7808 0.000386 0.030663 0.53364 
ATAD2 7.6891 1 -1.2634 7.9992 -5.0907 0.000887 0.044179 -0.3031 
DHX58 7.7354 13 -2.7571 7.9123 -7.1022 9.27E-05 0.016619 1.9406 
NOP16 7.7584 4 -1.1969 7.8567 -7.8442 4.53E-05 0.012348 2.6302 
NUSAP1 7.7672 4 -1.9564 8.8721 -6.6654 0.000145 0.020646 1.5022 
AC108673.3 7.7755 11 0.93731 6.9747 5.1707 0.000803 0.042819 -0.20223 
CMPK2 7.8215 13 -4.1902 7.9968 -11.633 2.32E-06 0.002533 5.2992 
RRM2 7.8293 4 -2.8876 8.9427 -7.3451 7.29E-05 0.01536 2.1737 
ACVR2A 7.8597 9 1.4335 8.4809 5.496 0.00054 0.035143 0.19724 
RPL3P4 7.8769 11 1.1845 7.1927 5.9221 0.000328 0.028933 0.69603 
UBE4B 7.9 12 1.1099 7.7976 6.6414 0.000149 0.02078 1.4774 
PARP12 7.903 13 -2.177 7.8437 -9.683 9.46E-06 0.006622 4.0812 
ZNF844 7.9078 11 1.6004 6.8357 5.1231 0.000852 0.043504 -0.26211 
WDR12 7.9381 13 -0.88843 7.8661 -4.9828 0.001017 0.047177 -0.44064 
ZNF480 8.021 10 1.0555 7.9351 6.5694 0.000161 0.021497 1.4025 
IFIH1 8.0637 13 -2.3007 7.8795 -5.5884 0.000483 0.034332 0.30776 
ZNF32 8.0804 12 1.0951 8.2673 4.9635 0.001042 0.047363 -0.46547 
NAALADL1 8.0848 16 0.86935 9.1643 4.9701 0.001033 0.047177 -0.45688 
PCLAF 8.0951 4 -1.7907 9.1245 -4.9592 0.001048 0.047367 -0.47091 
SLC25A24 8.102 15 -1.632 8.0247 -4.8853 0.001151 0.04821 -0.56654 
AC024075.2 8.1323 10 1.6246 7.7532 5.8396 0.00036 0.030451 0.60155 
TFDP1 8.1957 13 -0.95144 8.0506 -5.2126 0.000762 0.041765 -0.14987 
LGALS3BP 8.211 13 -4.6014 6.7391 -6.8843 0.000116 0.018756 1.725 
HERC5 8.2213 4 -2.5752 8.4843 -6.1795 0.000245 0.025173 0.98414 
CD160 8.2345 16 2.6565 11.975 5.7127 0.000418 0.032128 0.45438 
TMEM161B-
AS1 8.2516 12 1.3348 7.8344 7.1013 9.28E-05 0.016619 1.9397 
TRIM25 8.2559 13 -1.4469 8.2446 -7.1094 9.2E-05 0.016619 1.9476 
SERTAD1 8.2789 16 1.7207 8.9221 5.1989 0.000775 0.042285 -0.16693 
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CD9 8.3213 15 -3.6086 6.6885 -5.335 0.000656 0.038386 0.00165 
LTV1 8.3973 13 -1.0417 8.2869 -5.5189 0.000525 0.035014 0.22476 
AC008555.5 8.4182 8 1.5186 7.6735 5.4349 0.000581 0.036309 0.12347 
ZYG11B 8.4724 11 1.2909 7.5365 5.5047 0.000534 0.035143 0.20772 
PTTG1 8.4999 4 -1.7145 8.6017 -6.6847 0.000142 0.020646 1.5221 
BICRAL 8.5461 10 1.1948 8.2486 5.9236 0.000327 0.028933 0.69771 
CASP3 8.6124 4 -1.4781 9.1058 -5.7723 0.00039 0.030762 0.5238 
HERC6 8.6143 13 -2.31 8.5368 -10.197 6.38E-06 0.00519 4.4307 
TMA7 8.6812 12 1.0366 8.4701 4.9085 0.001118 0.048056 -0.53637 
OAS3 8.7118 13 -3.8473 8.7031 -9.26 1.32E-05 0.006622 3.7765 
CASP7 8.771 4 -0.83396 9.236 -5.255 0.000723 0.040693 -0.09712 
IFIT1 8.8094 13 -6.0138 9.0327 -10.176 6.49E-06 0.00519 4.4168 
FAM168B 8.8194 12 0.96806 8.6241 5.0153 0.000976 0.04701 -0.39903 
TSC22D2 8.8936 6 0.89794 8.3682 4.9325 0.001084 0.04782 -0.50536 
CHMP7 8.986 11 -1.203 7.5295 -5.3545 0.00064 0.03767 0.025503 
MAD2L1 9.015 2 -1.2001 8.9636 -5.8028 0.000376 0.030451 0.55914 
ZBTB1 9.0282 10 1.3375 8.9841 4.8503 0.001204 0.049329 -0.612 
EPSTI1 9.0498 4 -3.1351 9.2675 -11.852 2.01E-06 0.002432 5.4195 
PCYOX1 9.0704 9 1.6131 9.4152 7.9106 4.26E-05 0.01189 2.6887 
TXNDC17 9.1235 4 -1.1365 9.4801 -4.8965 0.001135 0.048129 -0.55196 
KTN1 9.1417 6 0.85044 8.8154 4.9955 0.001 0.04714 -0.42436 
USP18 9.1658 4 -3.5355 9.704 -12.451 1.37E-06 0.002432 5.7325 
BARD1 9.1764 4 -1.0776 9.5519 -5.9849 0.000305 0.027968 0.76715 
HIST1H2AC 9.247 14 -1.8266 9.1949 -5.1013 0.000875 0.044179 -0.28966 
PAICS 9.2534 13 -1.3125 8.6389 -6.524 0.000169 0.021497 1.3549 
LINC02001 9.2782 11 0.94508 8.8972 4.8432 0.001216 0.049369 -0.62129 
OASL 9.3111 4 -3.1954 10.824 -9.4926 1.1E-05 0.006622 3.946 
RSAD2 9.3148 4 -6.1645 10.044 -11.84 2.03E-06 0.002432 5.4127 
KLRG1 9.3369 9 2.4982 10.652 5.5736 0.000492 0.034332 0.29011 
OSER1-AS1 9.3426 10 1.3612 9.1516 6.6026 0.000155 0.0214 1.4372 
DANCR 9.39 11 1.7144 7.9402 5.0193 0.000971 0.04701 -0.39388 
CSNK1G3 9.4271 15 0.97857 8.9775 4.9951 0.001001 0.04714 -0.42483 
LINC00861 9.4353 9 1.4889 10.646 6.2658 0.000223 0.023694 1.0786 
PARP11 9.4503 13 -0.89415 9.44 -5.6107 0.000471 0.034332 0.33425 
CDCA7L 9.5078 15 -1.6193 7.3591 -5.3643 0.000633 0.037409 0.03745 
MTHFD2 9.5719 4 -0.98143 10.032 -5.4084 0.0006 0.036912 0.091323 
SPOCK2 9.5735 8 1.2322 9.1328 6.4201 0.000189 0.022185 1.2448 
DDX58 9.5921 4 -1.7449 9.7809 -5.2456 0.000732 0.040843 -0.10879 
IL24 9.6194 6 0.98139 8.3175 5.0933 0.000884 0.044179 -0.29978 
IFI44 9.6433 4 -3.6456 10.086 -11.956 1.88E-06 0.002432 5.4752 
RC3H1 9.7076 10 0.93314 9.425 5.2908 0.000692 0.039554 -0.05279 
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ITGAE 9.7541 6 1.6178 9.2644 4.9511 0.001058 0.047367 -0.48135 
TRIM21 9.849 4 -1.0973 10.443 -6.0184 0.000294 0.027344 0.80492 
MYLIP 9.8621 6 1.038 9.4099 6.7237 0.000137 0.020646 1.5622 
SNHG3 9.9805 11 1.79 8.8077 6.4849 0.000176 0.021759 1.3137 
PCNA 10.009 4 -1.2851 10.811 -5.1738 0.0008 0.042819 -0.19842 
MGAT4A 10.029 9 1.2386 10.425 7.4356 6.67E-05 0.015107 2.2587 
MX2 10.067 13 -3.0551 9.982 -8.6134 2.27E-05 0.008804 3.2785 
FCRL3 10.103 1 2.2677 10.109 7.3088 7.55E-05 0.015424 2.1393 
SFPQ 10.146 15 -0.79722 10.052 -5.5489 0.000507 0.03475 0.26064 
IFI6 10.252 4 -3.4947 10.826 -5.7925 0.000381 0.030451 0.5472 
DDX60 10.284 13 -1.5638 10.459 -6.123 0.000261 0.025922 0.92166 
MAPK1 10.316 16 1.1886 11.133 5.5808 0.000488 0.034332 0.29879 
ZNF652 10.327 6 1.2253 9.9571 6.5359 0.000167 0.021497 1.3673 
TIMM17A 10.329 4 -0.84272 10.591 -4.916 0.001107 0.048056 -0.52666 
GBP1 10.347 2 -1.9226 10.905 -5.071 0.000909 0.044912 -0.32806 
LY9 10.461 11 2.5511 8.6429 6.0566 0.000282 0.027029 0.8478 
INTS6 10.518 6 0.77362 10.212 4.9917 0.001005 0.04714 -0.42914 
ISG15 10.583 4 -3.4858 10.97 -7.743 4.98E-05 0.012827 2.54 
DNAJB9 10.605 11 1.2205 10.009 4.9457 0.001066 0.047367 -0.48828 
MYD88 10.618 4 -1.2712 11.18 -5.854 0.000355 0.030173 0.61817 
ZBTB44 10.627 10 1.3588 10.558 5.327 0.000662 0.038391 -0.00825 
IFI35 10.63 4 -1.7704 11.335 -5.7565 0.000397 0.031128 0.50543 
SAMD9L 10.641 4 -1.3404 10.859 -6.5148 0.00017 0.021497 1.3452 
PARP9 10.713 4 -2.4569 11.092 -13.191 8.73E-07 0.002096 6.0902 
AL035071.1 10.814 10 1.7558 10.365 8.2608 3.1E-05 0.010303 2.9892 
EIF2AK2 10.822 13 -2.0911 10.768 -10.347 5.71E-06 0.00519 4.5283 
LAP3 10.928 4 -2.1753 11.268 -6.3625 0.000201 0.022185 1.1832 
ILF3-AS1 10.93 12 1.0546 10.402 5.5224 0.000523 0.035014 0.22895 
IFIT3 10.958 13 -4.3764 11.348 -7.7112 5.13E-05 0.012827 2.5114 
XAF1 10.986 7 -1.5303 11.141 -6.9541 0.000108 0.018199 1.7948 
PNRC1 11.012 11 1.0106 10.296 4.9839 0.001015 0.047177 -0.43918 
RBL2 11.096 8 1.2102 11.061 4.8182 0.001255 0.049887 -0.654 
OAS2 11.128 4 -2.7271 11.536 -9.91 7.93E-06 0.005951 4.2382 
FCMR 11.216 6 1.0794 10.007 6.6587 0.000146 0.020646 1.4953 
S100A11 11.304 4 -2.0162 12.347 -6.3341 0.000207 0.022185 1.1526 
PLSCR1 11.384 4 -3.3109 12.139 -9.416 1.17E-05 0.006622 3.8907 
OAS1 11.421 4 -4.3798 11.604 -13.482 7.36E-07 0.002096 6.2233 
DNAJA1 11.47 4 -1.336 11.773 -6.0036 0.000299 0.02759 0.78833 
IFI44L 11.498 13 -6.3929 11.132 -19.645 3.72E-08 0.000446 8.2521 
DTX3L 11.507 4 -1.5075 11.803 -5.4734 0.000555 0.035403 0.16999 
LCK 11.534 9 1.4382 12.127 7.4 6.91E-05 0.015349 2.2254 
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IFI16 11.598 4 -0.97607 11.891 -5.0976 0.00088 0.044179 -0.29437 
ANXA2 11.609 14 -1.2503 12.407 -5.8798 0.000344 0.029571 0.64768 
SP100 11.621 13 -1.0831 11.271 -6.5263 0.000168 0.021497 1.3573 
LGALS1 11.66 4 -1.8288 13.479 -6.8288 0.000122 0.019414 1.6692 
HMGB2 11.753 4 -1.0432 12.087 -5.9019 0.000336 0.029394 0.67296 
STAT1 11.764 13 -2.2915 11.667 -7.6688 5.34E-05 0.012827 2.4731 
PPM1K 11.796 15 -1.149 11.064 -7.1797 8.58E-05 0.016604 2.0158 
BST2 11.836 4 -1.4749 12.508 -8.2098 3.24E-05 0.010303 2.9463 
MX1 11.849 13 -4.708 11.904 -14.128 5.1E-07 0.002039 6.5032 
EIF4B 12.003 10 1.4759 11.421 8.0101 3.89E-05 0.011657 2.7754 
TNRC6B 12.081 6 1.3982 11.318 4.8208 0.001251 0.049884 -0.65058 
STAT2 12.117 13 -1.1265 12.018 -5.1007 0.000876 0.044179 -0.29044 
TRIM22 12.452 4 -1.7192 12.761 -8.1609 3.39E-05 0.010426 2.9049 
SP110 12.583 15 -0.91558 12.21 -6.0443 0.000285 0.027148 0.83399 
PSMA4 12.588 4 -1.0449 13.086 -5.2524 0.000726 0.040693 -0.10038 
EEF2 12.719 11 0.99633 12.106 5.6451 0.000452 0.033695 0.3749 
ISG20 12.797 13 -2.0343 12.226 -6.3524 0.000203 0.022185 1.1723 
PSME2 13.028 4 -1.0446 13.544 -5.3886 0.000614 0.037048 0.067244 
PPP2R5C 13.055 16 1.5884 13.737 5.7319 0.000408 0.03162 0.47675 
UBE2L6 13.26 4 -1.2891 13.735 -5.8907 0.00034 0.029558 0.66016 
EIF1 14.493 12 0.89394 14.362 5.1749 0.000799 0.042819 -0.19699 
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Table S2. Differentially expressed genes in B cells from JDM patients versus controls using the 




n clusters logFC AveExpr t p.value adj.p.val B 
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Table S3. Differentially expressed genes in T cells from JDM patients versus controls using the 






n clusters logFC AveExpr t p.value adj.p.val B 
OAS1 11.421 4 -3.2458 10.518 -10.088 8.81E-06 0.035253 3.7118 
PNOC 4.4327 15 -1.3 0.64998 -9.2875 1.62E-05 0.043582 3.2593 
TLR7 6.1971 15 -4.2399 2.5367 -8.7598 2.47E-05 0.043582 2.9297 
IFIT1 8.8094 13 -4.8043 8.8375 -8.662 2.68E-05 0.043582 2.8657 
ST3GAL
6 3.2848 14 -4.0562 2.0281 -8.6349 2.74E-05 0.043582 2.8477 
OAS2 11.128 4 -2.3002 11.021 -8.5656 2.91E-05 0.043582 2.8015 
IFIT3 10.958 13 -5.7857 10.401 -8.209 3.94E-05 0.046799 2.556 
EPSTI1 9.0498 4 -2.5695 8.5669 -8.0371 4.58E-05 0.046799 2.4327 
MX1 11.849 13 -3.0986 11.629 -8.0134 4.68E-05 0.046799 2.4154 
LYAR 9.4334 9 1.7291 10.023 7.853 5.4E-05 0.049862 2.2969 
KLRB1 10.84 16 2.9717 11.201 8.1707 4.07E-05 0.046799 2.5288 
P2RY14 4.6037 15 4.9534 2.4767 12.744 1.54E-06 0.009224 4.8821 
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Table S4. Differentially expressed gene sets as determined by gene set enrichment analysis 
(GSEA) in NK cells from JDM patients versus controls using the limma computed t-value as a 
ranking metric with a false discovery rate (FDR) cutoff of 5%. 
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GO_PROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 6.01 0.00 - - 0 99
  







































































































































































































































































































2.12 2 62 
  


















































































































































































































































































































































































































































































































































































2.10 12 43 
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963 234 51 
GO_REGULATION_OF_DENDRITIC_CELL_DIFFERENTIATION 0.00 0.00 - - 272 5 
  










































































































































































































































































1.91 341 38 
  








































































































































































































































































1.78 395 67 
  










































































































































































































































































693 470 82 
GO_REGULATION_OF_FIBROBLAST_PROLIFERATION 0.00 0.01 - - 496 47 
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318 1230 8 
  






















































































































































































































































































1.89 1407 12 
  






































































































































































































































































1.62 1477 83 
  









































































































































































































































































269 1906 29 
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Table S5. Differentially expressed gene sets as determined by gene set enrichment analysis 
(GSEA) in B cells from JDM patients versus controls using the limma computed t-value as a 
ranking metric with a false discovery rate (FDR) cutoff of 5%. 




































































































































































































































































































































































































































































































































































































2.27 1 45 
  


















































































































































































































































































































GO_CONDENSED_NUCLEAR_CHROMOSOME 5.14 0.00 - - 24 51 
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Table S6. Differentially expressed gene sets as determined by gene set enrichment analysis 
(GSEA) in T cells from JDM patients versus controls using the limma computed t-value as a 
ranking metric with a false discovery rate (FDR) cutoff of 5%. 
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1.6596 310 123 
  






















































































































































































































































1 455 790 
GO_POSITIVE_REGULATION_OF_CELLULAR_EXTRAVASATION 0.0012 0.0479 0.8145 1.8704 634 8 
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Chapter 5: Summary and Future Directions 
We exploited the high dimensionality of mass cytometry to delineate signaling in two 
pediatric autoimmune diseases: polyarticular juvenile idiopathic arthritis (JIA) and juvenile 
dermatomyositis (JDM). 
Polyarticular Juvenile Idiopathic Arthritis (JIA) 
 Prior to our studies, immune cell signaling cascades had not been systematically 
examined in polyarticular JIA. We examined immune cell signaling responses to single 
cytokines after fifteen minutes of stimulation using a mass cytometry panel of surface marker 
and intracellular signaling molecule antibodies. We demonstrated that both naïve CD4 T cells 
and classical monocytes differed in IFN signaling potential with more pronounced STAT1 and 
STAT3 phosphorylation. Differentially responding naïve CD4 T cells and classical monocytes 
were heterogeneous for expression levels of different surface markers. Further work should 
elucidate which surface markers differentiate responsive versus non-responsive naïve CD4 T cell 
clusters and classical monocyte clusters. This may be studied by leveraging mass cytometry with 
panels designed to more deeply probe T cell and monocyte markers.  
Elevated levels of naïve CD4 T cell STAT1/3 phosphorylation in response to IFN 
stimulation were associated with higher levels of JAK1 and SOCS1 protein levels in patients in 
comparison to controls. It would be interesting to more deeply probe mechanisms contributing to 
increased signaling potential in response to IFN stimulation, in particular if there are 
differences in total protein levels of STAT1 and STAT3 between treatment-naïve polyarticular 
JIA patients and controls. This could be studied using a series of flow cytometry panels, so that 
more signaling molecules can be incorporated, or potentially Western blotting sorted classical 
monocytes and naïve CD4 T cells. As differences were detected in response to IFN stimulation, 
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determining if there was a pattern of interferon stimulated gene expression in treatment-naïve 
polyarticular JIA patients using either qPCR or RNA-Seq analysis could provide further insight 
into potential differences in disease. 
Furthermore, since polyarticular JIA immune cell response was only examined with two 
individual cytokines, observing signaling patterns over a time course using a combination of 
different stimulations could ascertain if there are defects in other cell types or signaling cascades. 
These experiments could be performed using mass cytometry or flow cytometry. 
Juvenile Dermatomyositis (JDM) 
Based on our experience with polyarticular JIA mass cytometry experiments, we 
modified our experimental approach to incorporate a combination of stimuli over multiple 
timepoints rather than individual stimuli at a single timepoint. We elucidated potential immune 
cell signaling differences between treatment-naïve JDM patients and healthy controls by 
stimulating cells over three time points with a combinatorial cocktail of multiple stimuli and 
analyzing surface markers and intracellular signaling molecules with mass cytometry. Many 
significant differences were detected between treatment-naïve patients and controls, necessitating 
the use of feature selection for data interpretation. Feature selection revealed that PLC2 
phosphorylation in several different cell types distinguished treatment-naïve JDM patients and 
controls. In particular, treatment-naïve JDM patient NK cells hypophosphorylated PLC2 in 
comparison to healthy controls over all three examined time points and had defects in calcium 
flux in response to receptor crosslinking. As NK cells had the most striking differences in this 
study, future studies should be performed to assess NK cell function. Future work should include 
studies of NK cell degranulation and killing assays to demonstrate that defective NK cell PLC2 
phosphorylation and calcium flux are associated with degranulation and killing defects. 
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Furthermore, our pilot RNA-Seq analysis was promising and a more thorough RNA-Seq and 
proteomic analysis may provide insights in mechanisms contributing to differential treatment-
naïve JDM patient NK cell PLC2 phosphorylation. Additionally, it would be interesting to 
examine NK cell calcium flux in remission patients to determine if they display intermediate 
levels of calcium flux, as they had intermediate PLC2 phosphorylation between treatment-naïve 
patients and controls. This approach may allow us to determine the time course of the impact of 
our current therapies on dysregulated signaling. 
Not only were differences detected in treatment-naïve JDM patient NK cell signaling, but 
also T cells and monocytes. In addition to NK cells, differences in PLC2 signaling were 
detected in monocytes and T cells. Further experiments should be performed with flow 
cytometry and RNA-Seq to examine mechanisms contributing to differences in monocytes.  
Additionally, B cells utilize PLC2 signaling downstream of the B cell receptor but did not 
exhibit differences in PLC2 signaling in our studies. Comparing transcripts, protein levels, and 
protein phosphorylation between NK cells and B cells may provide further mechanistic insights 
into NK cell PLC2 signaling defects. 
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Appendix A: Documentation for CytobankAPIstats R 
library to process mass cytomery data from Cytobank 
 
Cytobank is a convenient platform for analyzing cytometry data. However, export of 
statistics from the online platform manually is labor intensive and time consuming. The 
“CytobankAPI” package in R allows a user to connect to their Cytobank account and access 
statistics. General statistics about markers and populations can be exported, but they must still be 
filtered to contain populations/markers of interest and formatted to a suitable matrix for 
downstream analysis. To format data in a convenient matrix for downstream applications 
containing data for only cell populations and markers of interest with connection to Cytobank 
API, the “CytobankAPIstats” R package was developed. 
 
To install the package, use the following command: 
install.packages("CytobankAPIstats",dep=T) 
 
For documentation and examples of how to use the package, see: 
 https://CRAN.R-project.org/package=CytobankAPIstats 
 
To view source code, see https:/github.com/athrom/CytobankAPIstats 
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Appendix B: R code for extracting extra data from Citrus 
analysis 
 
 Citrus allows for the analysis of signaling differences between clusters in different 
conditions (1). A deeper examination of the surface marker expression between stratifying and 
non-stratifying clusters can provide insights into which specific cell populations have differences 
in signaling between a healthy and diseased state.  The “mineCitrus” package allows users to 
extract marker expression data from Citrus analysis, as done in Figures 2.3 and 2.4. 
 
To install the package, use the following command: 
install.packages("mineCitrus",dep=T) 
 
For documentation and examples of how to use the package, see: 
 https://cran.r-project.org/web/packages/mineCitrus/index.html 
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Appendix C: R code for examining validity of Citrus division 
into clusters 
 
The first step of Citrus is performing hierarchical clustering on aggregated events 
sampled from each specimen (1). The user determines a threshold for clusters to retain in the 
final analysis based on prior knowledge about cell subsets of the data in a population of interest. 
In our characterization of specific subsets for IFN stimulated treatment-naïve polyarticular JIA 
patients and controls we characterized differences in surface marker expression between 
stratifying and non-stratifying clusters for p-STAT1 and p-STAT3 to learn characteristics of 
differentially responding cells. However, due to the nature of hierarchical clustering, large cell 
populations are naturally divided into smaller subsets, so it is necessary to ensure that comparing 
clusters at a cutoff of 2% of the total population (selected to allow for analysis of NK cell 
subsets) does not spuriously subdivide clusters. 
 To determine if nearly identical cells were separated into clusters, the Euclidean distances 
between all IFN stimulated treatment-naïve polyarticular JIA patients and control Citrus 
clusters meeting the 2% threshold criterion were computed and visualized as a heat map (Figure 
1). As expected, more distinct immune cell types (i.e. B cells vs T cells, classical monocytes 
versus B cells, etc) were larger Euclidean distances from one another; these differences are 
apparent further away from the diagonal. CD4 and CD8 T cells were closer as dictated by 
Euclidean distance than to less related cell types. However, even within distinct cell populations, 
(e.g. comparing all B cell clusters to one another), these clusters were still distinct from one 
another, having distances greater than one. These differences are present near the diagonal. 
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The CheckingClustDist.R (Below) was designed to test for the validity separating subsets 
of immune cells in the Citrus hierarchical clustering tree into clusters representing 2% of pooled 
events:  
#The goal of this script is to determine the Euclidean distances between each split in the tree to 
ascertain if observed cluster heterogeneity is valid 
#Loading data set of interest 
load("/Volumes/Research/PB Science/French Lab/00_Lab 
Members_Current/Allison/Documents/CyTOF/Citrus results for updated pooled data/Citrus Live 
IFNg pre v ctrl pooled/citrusClustering.rData") 
library(citrus) 
#Function to get Medians for each cluster 
clustermeds<-function(citrus.foldFeatureSet,citrus.foldClustering,medsofinterest){ 




  rownames(clusterMedians) = citrus.foldFeatureSet$allLargeEnoughClusters 
  return(clusterMedians) 
} 





                                                        featureType=c('medians'), 
                                                        minimumClusterSizePercent=0.02, 
                                                        conditions=conditions, 
                                                        
medianColumns=c("Nd144Di","Nd150Di","Sm152Di","Eu153Di","Gd156Di","Gd158Di","Dy1
62Di","Dy164Di","Er166Di","Er167Di","Er168Di","Yb171Di","Yb174Di","Lu175Di") 












#Getting Euclidean distances between clusters 
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  xind<-grep(clust1,rownames(distmat)) 
  yind<-grep(clust2,colnames(distmat)) 

















save.image('/Volumes/Research/PB Science/French Lab/00_Lab 
Members_Current/Allison/Documents/CyTOF/Citrus results for updated pooled 
data/clustDistAnalysis.RData') 
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Figure 1. Heat map depicting Euclidean distance in 15-dimensional space between Citrus 
clusters meeting the 2% size threshold criterion for IFN stimulated treatment-naïve 




     
210
References for Appendix 
 
1. Bruggner RV, Bodenmiller B, Dill DL, Tibshirani RJ, and Nolan GP. Automated 
identification of stratifying signatures in cellular subpopulations. Proc Natl Acad Sci U S 
A. 2014;111(26):E2770-7. 
 
